bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Estrogen receptor concentration, social factors, natural killer cell activity, early - stage breast cancer patients	100587_task2	Sentence: Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "O", "O", "O", "O", "O", "O" ]	Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model.	[ "Estrogen", "receptor", "concentration", "and", "social", "factors", "as", "predictors", "of", "natural", "killer", "cell", "activity", "in", "early", "-", "stage", "breast", "cancer", "patients", ".", "Confirmation", "of", "a", "model", "." ]	[ "other_name", "(AND multi_cell multi_cell)", "multi_cell", "", "protein_family_or_group", "cell_type", "tissue" ]
Kindern is an umlsterm, Patientenkollektiv is an umlsterm, Atemwegsreflexe is an umlsterm, Halothan is an umlsterm, Kindern is an umlsterm, Ethikkommission is an umlsterm, Kinder is an umlsterm, Eltern is an umlsterm, Praemedikation is an umlsterm, Konzentrationen is an umlsterm, Intubation is an umlsterm, Fluoridspiegel is an umlsterm, Blutdruck is an umlsterm, Kinder is an umlsterm, Fluoridspiegel is an umlsterm, Kinderanaesthesie is an umlsterm, Halothan is an umlsterm, Fluoridwerte is an umlsterm, Nierenfunktion is an umlsterm	DerAnaesthesist.60450022.ger.abstr_task0	Sentence: Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten .	[ "Bei", "Kindern", ",", "dem", "wesentlichen", "Patientenkollektiv", "fuer", "inhalative", "Narkoseeinleitungen", ",", "liegen", "nur", "geringe", "Erfahrungen", "mit", "dem", "vermutlich", "besonders", "geeigneten", "Sevofluran", "vor", ".", "In", "einer", "offenen", ",", "randomisierten", "Studie", "haben", "wir", "daher", "Einschlaf-", "und", "Aufwachzeiten", ",", "Atemwegsreflexe", "und", "Kreislaufwirkungen", "von", "Sevofluran", "(", "S", ")", "mit", "denen", "von", "Halothan", "(", "H", ")", "bei", "Kindern", "(", "Alter", "1", "-", "10", "Jahre", ")", "waehrend", "mindestens", "einstuendigen", "Eingriffen", "verglichen", ".", "Mit", "Zustimmung", "der", "Ethikkommission", "wurden", "40", "Kinder", "der", "Risikogruppen", "ASA", "I", "und", "II", "nach", "schriftlicher", "Einwilligung", "der", "Eltern", "rekrutiert", ".", "Die", "Narkosen", "wurden", "ohne", "Praemedikation", "mit", "ansteigenden", "Konzentrationen", "von", "S", "oder", "H", "in", "N2O", "/", "O2", "(", "65:35", ")", "induziert", ".", "Der", "Frischgasflow", "(", "FGF", ")", "betrug", "6", "l", "/", "min", ".", "Nach", "Relaxation", "und", "Intubation", "wurden", "die", "Narkosen", "mit", "S", "(", "Fi", "2", "-", "2", ",", "4", "Vol", ".", "-%", ")", "oder", "H", "(", "1,1", "-", "1,4", "Vol-%", ")", "in", "N2O", "/", "O2", "(", "65:35", ",", "3", "l", "/", "min", ")", "weitergefuehrt", ".", "Zur", "Ausleitung", "wurde", "der", "FGF", "auf", "6", "l", "/", "min", "erhoeht", ".", "Fluoridspiegel", "wurden", "bei", "Einleitung", ",", "am", "Narkoseende", "sowie", "70", "min", "nach", "Narkose", "bestimmt", ".", "Die", "Gruppen", "waren", "biometrisch", "vergleichbar", ".", "Blutdruck", "und", "Herzfrequenz", "waren", "in", "beiden", "Gruppen", "stabil", ".", "Die", "Einschlafzeit", "betrug", "183", "+", "/-", "32", "(", "H", ")", "bzw", ".", "129", "+", "/-", "34", "s", "(", "S", ")", "(", "p", "0,01", ")", ",", "die", "Aufwachzeit", "775", "+", "/-", "314", "(", "H", ")", "bzw", ".", "468", "+", "/-", "194", "s", "(", "S", ")", "(", "p", "0,01", ")", ".", "Nach", "S", "wurden", "die", "Kinder", "4,6", "min", "frueher", "extubiert", "(", "p", "0,01", ")", ".", "Die", "Atemwegsvertraeglichkeit", "war", "bei", "beiden", "Gasen", "gut", ".", "Der", "Fluoridspiegel", "(", "S", ")", "betrug", "am", "Narkoseende", "23,1", "+", "/-", "1,2", "µmol", "/", "l", ",", "70", "min", "spaeter", "18,6", "+", "/-", "0,9", "µmol", "/", "l", "(", "p", "0,01", ")", ".", "Mit", "Sevofluran", "steht", "ein", "neues", ",", "sicheres", "Anaesthetikum", "fuer", "die", "Kinderanaesthesie", "zur", "Verfuegung", ",", "das", "bei", "vergleichbar", "geringer", "Atemwegsirritation", "wegen", "der", "hoeheren", "Induktions-", "und", "Aufwachgeschwindigkeit", "dem", "Halothan", "ueberlegen", "ist", ".", "Die", "Fluoridwerte", "unter", "S", "lassen", "eine", "wesentliche", "Beeintraechtigung", "der", "Nierenfunktion", "nicht", "erwarten", "." ]	[ "umlsterm" ]
Kindern is an umlsterm, Patientenkollektiv is an umlsterm, Atemwegsreflexe is an umlsterm, Halothan is an umlsterm, Kindern is an umlsterm, Ethikkommission is an umlsterm, Kinder is an umlsterm, Eltern is an umlsterm, Praemedikation is an umlsterm, Konzentrationen is an umlsterm, Intubation is an umlsterm, Fluoridspiegel is an umlsterm, Blutdruck is an umlsterm, Kinder is an umlsterm, Fluoridspiegel is an umlsterm, Kinderanaesthesie is an umlsterm, Halothan is an umlsterm, Fluoridwerte is an umlsterm, Nierenfunktion is an umlsterm	DerAnaesthesist.60450022.ger.abstr_task1	Sentence: Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten . Instructions: please typing these entity words according to sentence: Kindern, Patientenkollektiv, Atemwegsreflexe, Halothan, Kindern, Ethikkommission, Kinder, Eltern, Praemedikation, Konzentrationen, Intubation, Fluoridspiegel, Blutdruck, Kinder, Fluoridspiegel, Kinderanaesthesie, Halothan, Fluoridwerte, Nierenfunktion Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten .	[ "Bei", "Kindern", ",", "dem", "wesentlichen", "Patientenkollektiv", "fuer", "inhalative", "Narkoseeinleitungen", ",", "liegen", "nur", "geringe", "Erfahrungen", "mit", "dem", "vermutlich", "besonders", "geeigneten", "Sevofluran", "vor", ".", "In", "einer", "offenen", ",", "randomisierten", "Studie", "haben", "wir", "daher", "Einschlaf-", "und", "Aufwachzeiten", ",", "Atemwegsreflexe", "und", "Kreislaufwirkungen", "von", "Sevofluran", "(", "S", ")", "mit", "denen", "von", "Halothan", "(", "H", ")", "bei", "Kindern", "(", "Alter", "1", "-", "10", "Jahre", ")", "waehrend", "mindestens", "einstuendigen", "Eingriffen", "verglichen", ".", "Mit", "Zustimmung", "der", "Ethikkommission", "wurden", "40", "Kinder", "der", "Risikogruppen", "ASA", "I", "und", "II", "nach", "schriftlicher", "Einwilligung", "der", "Eltern", "rekrutiert", ".", "Die", "Narkosen", "wurden", "ohne", "Praemedikation", "mit", "ansteigenden", "Konzentrationen", "von", "S", "oder", "H", "in", "N2O", "/", "O2", "(", "65:35", ")", "induziert", ".", "Der", "Frischgasflow", "(", "FGF", ")", "betrug", "6", "l", "/", "min", ".", "Nach", "Relaxation", "und", "Intubation", "wurden", "die", "Narkosen", "mit", "S", "(", "Fi", "2", "-", "2", ",", "4", "Vol", ".", "-%", ")", "oder", "H", "(", "1,1", "-", "1,4", "Vol-%", ")", "in", "N2O", "/", "O2", "(", "65:35", ",", "3", "l", "/", "min", ")", "weitergefuehrt", ".", "Zur", "Ausleitung", "wurde", "der", "FGF", "auf", "6", "l", "/", "min", "erhoeht", ".", "Fluoridspiegel", "wurden", "bei", "Einleitung", ",", "am", "Narkoseende", "sowie", "70", "min", "nach", "Narkose", "bestimmt", ".", "Die", "Gruppen", "waren", "biometrisch", "vergleichbar", ".", "Blutdruck", "und", "Herzfrequenz", "waren", "in", "beiden", "Gruppen", "stabil", ".", "Die", "Einschlafzeit", "betrug", "183", "+", "/-", "32", "(", "H", ")", "bzw", ".", "129", "+", "/-", "34", "s", "(", "S", ")", "(", "p", "0,01", ")", ",", "die", "Aufwachzeit", "775", "+", "/-", "314", "(", "H", ")", "bzw", ".", "468", "+", "/-", "194", "s", "(", "S", ")", "(", "p", "0,01", ")", ".", "Nach", "S", "wurden", "die", "Kinder", "4,6", "min", "frueher", "extubiert", "(", "p", "0,01", ")", ".", "Die", "Atemwegsvertraeglichkeit", "war", "bei", "beiden", "Gasen", "gut", ".", "Der", "Fluoridspiegel", "(", "S", ")", "betrug", "am", "Narkoseende", "23,1", "+", "/-", "1,2", "µmol", "/", "l", ",", "70", "min", "spaeter", "18,6", "+", "/-", "0,9", "µmol", "/", "l", "(", "p", "0,01", ")", ".", "Mit", "Sevofluran", "steht", "ein", "neues", ",", "sicheres", "Anaesthetikum", "fuer", "die", "Kinderanaesthesie", "zur", "Verfuegung", ",", "das", "bei", "vergleichbar", "geringer", "Atemwegsirritation", "wegen", "der", "hoeheren", "Induktions-", "und", "Aufwachgeschwindigkeit", "dem", "Halothan", "ueberlegen", "ist", ".", "Die", "Fluoridwerte", "unter", "S", "lassen", "eine", "wesentliche", "Beeintraechtigung", "der", "Nierenfunktion", "nicht", "erwarten", "." ]	[ "umlsterm" ]
Kindern, Patientenkollektiv, Atemwegsreflexe, Halothan, Kindern, Ethikkommission, Kinder, Eltern, Praemedikation, Konzentrationen, Intubation, Fluoridspiegel, Blutdruck, Kinder, Fluoridspiegel, Kinderanaesthesie, Halothan, Fluoridwerte, Nierenfunktion	DerAnaesthesist.60450022.ger.abstr_task2	Sentence: Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten .	[ "Bei", "Kindern", ",", "dem", "wesentlichen", "Patientenkollektiv", "fuer", "inhalative", "Narkoseeinleitungen", ",", "liegen", "nur", "geringe", "Erfahrungen", "mit", "dem", "vermutlich", "besonders", "geeigneten", "Sevofluran", "vor", ".", "In", "einer", "offenen", ",", "randomisierten", "Studie", "haben", "wir", "daher", "Einschlaf-", "und", "Aufwachzeiten", ",", "Atemwegsreflexe", "und", "Kreislaufwirkungen", "von", "Sevofluran", "(", "S", ")", "mit", "denen", "von", "Halothan", "(", "H", ")", "bei", "Kindern", "(", "Alter", "1", "-", "10", "Jahre", ")", "waehrend", "mindestens", "einstuendigen", "Eingriffen", "verglichen", ".", "Mit", "Zustimmung", "der", "Ethikkommission", "wurden", "40", "Kinder", "der", "Risikogruppen", "ASA", "I", "und", "II", "nach", "schriftlicher", "Einwilligung", "der", "Eltern", "rekrutiert", ".", "Die", "Narkosen", "wurden", "ohne", "Praemedikation", "mit", "ansteigenden", "Konzentrationen", "von", "S", "oder", "H", "in", "N2O", "/", "O2", "(", "65:35", ")", "induziert", ".", "Der", "Frischgasflow", "(", "FGF", ")", "betrug", "6", "l", "/", "min", ".", "Nach", "Relaxation", "und", "Intubation", "wurden", "die", "Narkosen", "mit", "S", "(", "Fi", "2", "-", "2", ",", "4", "Vol", ".", "-%", ")", "oder", "H", "(", "1,1", "-", "1,4", "Vol-%", ")", "in", "N2O", "/", "O2", "(", "65:35", ",", "3", "l", "/", "min", ")", "weitergefuehrt", ".", "Zur", "Ausleitung", "wurde", "der", "FGF", "auf", "6", "l", "/", "min", "erhoeht", ".", "Fluoridspiegel", "wurden", "bei", "Einleitung", ",", "am", "Narkoseende", "sowie", "70", "min", "nach", "Narkose", "bestimmt", ".", "Die", "Gruppen", "waren", "biometrisch", "vergleichbar", ".", "Blutdruck", "und", "Herzfrequenz", "waren", "in", "beiden", "Gruppen", "stabil", ".", "Die", "Einschlafzeit", "betrug", "183", "+", "/-", "32", "(", "H", ")", "bzw", ".", "129", "+", "/-", "34", "s", "(", "S", ")", "(", "p", "0,01", ")", ",", "die", "Aufwachzeit", "775", "+", "/-", "314", "(", "H", ")", "bzw", ".", "468", "+", "/-", "194", "s", "(", "S", ")", "(", "p", "0,01", ")", ".", "Nach", "S", "wurden", "die", "Kinder", "4,6", "min", "frueher", "extubiert", "(", "p", "0,01", ")", ".", "Die", "Atemwegsvertraeglichkeit", "war", "bei", "beiden", "Gasen", "gut", ".", "Der", "Fluoridspiegel", "(", "S", ")", "betrug", "am", "Narkoseende", "23,1", "+", "/-", "1,2", "µmol", "/", "l", ",", "70", "min", "spaeter", "18,6", "+", "/-", "0,9", "µmol", "/", "l", "(", "p", "0,01", ")", ".", "Mit", "Sevofluran", "steht", "ein", "neues", ",", "sicheres", "Anaesthetikum", "fuer", "die", "Kinderanaesthesie", "zur", "Verfuegung", ",", "das", "bei", "vergleichbar", "geringer", "Atemwegsirritation", "wegen", "der", "hoeheren", "Induktions-", "und", "Aufwachgeschwindigkeit", "dem", "Halothan", "ueberlegen", "ist", ".", "Die", "Fluoridwerte", "unter", "S", "lassen", "eine", "wesentliche", "Beeintraechtigung", "der", "Nierenfunktion", "nicht", "erwarten", "." ]	[ "umlsterm" ]
c - Fos is a protein_molecule, activated T lymphoid and monocytic cells is a (AND cell_type cell_type), human immunodeficiency virus-1 Tat protein is a protein_molecule	62883_task0	Sentence: Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: (AND cell_type cell_type), protein_molecule	[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.	[ "Upregulation", "of", "c", "-", "Fos", "in", "activated", "T", "lymphoid", "and", "monocytic", "cells", "by", "human", "immunodeficiency", "virus-1", "Tat", "protein", "." ]	[ "(AND cell_line cell_line)", "DNA_domain_or_region", "protein_molecule", "cell_type", "(AND cell_type cell_type)", "virus", "other_name", "cell_line", "DNA_molecule", "", "other_organic_compound", "polynucleotide", "protein_domain_or_region", "tissue", "RNA_molecule" ]
c - Fos is a protein_molecule, activated T lymphoid and monocytic cells is a (AND cell_type cell_type), human immunodeficiency virus-1 Tat protein is a protein_molecule	62883_task1	Sentence: Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Instructions: please typing these entity words according to sentence: c - Fos, activated T lymphoid and monocytic cells, human immunodeficiency virus-1 Tat protein Options: (AND cell_type cell_type), protein_molecule	[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.	[ "Upregulation", "of", "c", "-", "Fos", "in", "activated", "T", "lymphoid", "and", "monocytic", "cells", "by", "human", "immunodeficiency", "virus-1", "Tat", "protein", "." ]	[ "(AND cell_line cell_line)", "DNA_domain_or_region", "protein_molecule", "cell_type", "(AND cell_type cell_type)", "virus", "other_name", "cell_line", "DNA_molecule", "", "other_organic_compound", "polynucleotide", "protein_domain_or_region", "tissue", "RNA_molecule" ]
c - Fos, activated T lymphoid and monocytic cells, human immunodeficiency virus-1 Tat protein	62883_task2	Sentence: Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.	[ "Upregulation", "of", "c", "-", "Fos", "in", "activated", "T", "lymphoid", "and", "monocytic", "cells", "by", "human", "immunodeficiency", "virus-1", "Tat", "protein", "." ]	[ "(AND cell_line cell_line)", "DNA_domain_or_region", "protein_molecule", "cell_type", "(AND cell_type cell_type)", "virus", "other_name", "cell_line", "DNA_molecule", "", "other_organic_compound", "polynucleotide", "protein_domain_or_region", "tissue", "RNA_molecule" ]
cholinesterase is a GENE-Y	11078030_task0	Sentence: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.	[ "The", "new", "cholinesterase", "inhibitors", "for", "Alzheimer", "'s", "disease", ",", "Part", "1", ":", "their", "similarities", "are", "different", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
cholinesterase is a GENE-Y	11078030_task1	Sentence: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Instructions: please typing these entity words according to sentence: cholinesterase Options: GENE-Y	[ "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.	[ "The", "new", "cholinesterase", "inhibitors", "for", "Alzheimer", "'s", "disease", ",", "Part", "1", ":", "their", "similarities", "are", "different", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
cholinesterase	11078030_task2	Sentence: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.	[ "The", "new", "cholinesterase", "inhibitors", "for", "Alzheimer", "'s", "disease", ",", "Part", "1", ":", "their", "similarities", "are", "different", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, liver cancer cell Bel-7402 ] is a Cell, fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, human is a Organism, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, P53 is a Gene_or_gene_product, Bel-7402 is a Cell, FPC is a Simple_chemical, Bel-7402 is a Cell, FPC is a Simple_chemical, chromatin is a Cellular_component, cell is a Cell, DNA is a Cellular_component, FPC is a Simple_chemical, FPC is a Simple_chemical, tumor cell is a Cell, P53 is a Gene_or_gene_product	286_task0	Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell	[ "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O" ]	[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.	[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]	[ "Simple_chemical", "Cell", "Cellular_component", "Organism", "Cancer", "Gene_or_gene_product" ]
fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, liver cancer cell Bel-7402 ] is a Cell, fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, human is a Organism, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, P53 is a Gene_or_gene_product, Bel-7402 is a Cell, FPC is a Simple_chemical, Bel-7402 is a Cell, FPC is a Simple_chemical, chromatin is a Cellular_component, cell is a Cell, DNA is a Cellular_component, FPC is a Simple_chemical, FPC is a Simple_chemical, tumor cell is a Cell, P53 is a Gene_or_gene_product	286_task1	Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please typing these entity words according to sentence: fungus polysaccharides compounds, FPC, liver cancer cell Bel-7402 ], fungus polysaccharides compounds, FPC, human, liver cancer cell Bel-7402, cell, tumor, P53, Bel-7402, FPC, Bel-7402, FPC, chromatin, cell, DNA, FPC, FPC, tumor cell, P53 Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell	[ "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O" ]	[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.	[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]	[ "Simple_chemical", "Cell", "Cellular_component", "Organism", "Cancer", "Gene_or_gene_product" ]
fungus polysaccharides compounds, FPC, liver cancer cell Bel-7402 ], fungus polysaccharides compounds, FPC, human, liver cancer cell Bel-7402, cell, tumor, P53, Bel-7402, FPC, Bel-7402, FPC, chromatin, cell, DNA, FPC, FPC, tumor cell, P53	286_task2	Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O" ]	[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.	[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]	[ "Simple_chemical", "Cell", "Cellular_component", "Organism", "Cancer", "Gene_or_gene_product" ]
Isradipine is a Intervention_Pharmacological, risk of cardiovascular events . is a Participant_Condition	770_task0	Sentence: Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition	[ "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]	Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events .	[ "Isradipine", ",", "raised", "glycosylated", "haemoglobin", ",", "and", "risk", "of", "cardiovascular", "events", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]
Isradipine is a Intervention_Pharmacological, risk of cardiovascular events . is a Participant_Condition	770_task1	Sentence: Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events . Instructions: please typing these entity words according to sentence: Isradipine, risk of cardiovascular events . Options: Intervention_Pharmacological, Participant_Condition	[ "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]	Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events .	[ "Isradipine", ",", "raised", "glycosylated", "haemoglobin", ",", "and", "risk", "of", "cardiovascular", "events", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]
Isradipine, risk of cardiovascular events .	770_task2	Sentence: Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]	Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events .	[ "Isradipine", ",", "raised", "glycosylated", "haemoglobin", ",", "and", "risk", "of", "cardiovascular", "events", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]
Facial nerve is an umlsterm, schwannomas is an umlsterm, benign tumors is an umlsterm, symptom is an umlsterm, facial nerve paralysis is an umlsterm, woman is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm, geniculate ganglion is an umlsterm, patient is an umlsterm, vertigo is an umlsterm, hearing loss is an umlsterm, facial nerve is an umlsterm, tumor is an umlsterm, computed tomography is an umlsterm, magnetic resonance imaging is an umlsterm, schwannoma is an umlsterm, facial nerve is an umlsterm, knowledge is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm	HNO.90470279.eng.abstr_task0	Sentence: Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve .	[ "Facial", "nerve", "schwannomas", "are", "rare", "benign", "tumors", ",", "when", "occurring", ",", "they", "are", "located", "most", "frequently", "in", "the", "distal", "fallopian", "canal", "and", "present", "as", "extracranial", "masses", ".", "The", "predominant", "symptom", "is", "a", "progressive", "facial", "nerve", "paralysis", ".", "We", "report", "a", "20-year", "-", "old", "woman", "with", "an", "intracranial", "schwannoma", "originating", "from", "the", "greater", "superficial", "petrosal", "nerve", "that", "had", "wide", "extension", "into", "the", "pterygopalatine", "fossa", ".", "The", "motor", "facial", "nerve", "including", "the", "geniculate", "ganglion", "was", "not", "affected", ".", "The", "patient", "presented", "with", "vertigo", ",", "progressive", "hearing", "loss", "and", "mild", "facial", "nerve", "synkinesis", "but", "without", "a", "lacrimation", "deficit", ".", "The", "tumor", "was", "detected", "by", "computed", "tomography", "and", "magnetic", "resonance", "imaging", ".", "The", "schwannoma", "was", "completely", "removed", "using", "an", "intracranial", ",", "extradural", "middle", "fossa", "approach", "during", "which", "complete", "preservation", "of", "the", "motor", "facial", "nerve", "was", "possible", ".", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "an", "isolated", "schwannoma", "of", "the", "greater", "superficial", "petrosal", "nerve", "without", "involvement", "of", "the", "motor", "facial", "nerve", "." ]	[ "umlsterm" ]
Facial nerve is an umlsterm, schwannomas is an umlsterm, benign tumors is an umlsterm, symptom is an umlsterm, facial nerve paralysis is an umlsterm, woman is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm, geniculate ganglion is an umlsterm, patient is an umlsterm, vertigo is an umlsterm, hearing loss is an umlsterm, facial nerve is an umlsterm, tumor is an umlsterm, computed tomography is an umlsterm, magnetic resonance imaging is an umlsterm, schwannoma is an umlsterm, facial nerve is an umlsterm, knowledge is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm	HNO.90470279.eng.abstr_task1	Sentence: Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve . Instructions: please typing these entity words according to sentence: Facial nerve, schwannomas, benign tumors, symptom, facial nerve paralysis, woman, schwannoma, nerve, facial nerve, geniculate ganglion, patient, vertigo, hearing loss, facial nerve, tumor, computed tomography, magnetic resonance imaging, schwannoma, facial nerve, knowledge, schwannoma, nerve, facial nerve Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve .	[ "Facial", "nerve", "schwannomas", "are", "rare", "benign", "tumors", ",", "when", "occurring", ",", "they", "are", "located", "most", "frequently", "in", "the", "distal", "fallopian", "canal", "and", "present", "as", "extracranial", "masses", ".", "The", "predominant", "symptom", "is", "a", "progressive", "facial", "nerve", "paralysis", ".", "We", "report", "a", "20-year", "-", "old", "woman", "with", "an", "intracranial", "schwannoma", "originating", "from", "the", "greater", "superficial", "petrosal", "nerve", "that", "had", "wide", "extension", "into", "the", "pterygopalatine", "fossa", ".", "The", "motor", "facial", "nerve", "including", "the", "geniculate", "ganglion", "was", "not", "affected", ".", "The", "patient", "presented", "with", "vertigo", ",", "progressive", "hearing", "loss", "and", "mild", "facial", "nerve", "synkinesis", "but", "without", "a", "lacrimation", "deficit", ".", "The", "tumor", "was", "detected", "by", "computed", "tomography", "and", "magnetic", "resonance", "imaging", ".", "The", "schwannoma", "was", "completely", "removed", "using", "an", "intracranial", ",", "extradural", "middle", "fossa", "approach", "during", "which", "complete", "preservation", "of", "the", "motor", "facial", "nerve", "was", "possible", ".", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "an", "isolated", "schwannoma", "of", "the", "greater", "superficial", "petrosal", "nerve", "without", "involvement", "of", "the", "motor", "facial", "nerve", "." ]	[ "umlsterm" ]
Facial nerve, schwannomas, benign tumors, symptom, facial nerve paralysis, woman, schwannoma, nerve, facial nerve, geniculate ganglion, patient, vertigo, hearing loss, facial nerve, tumor, computed tomography, magnetic resonance imaging, schwannoma, facial nerve, knowledge, schwannoma, nerve, facial nerve	HNO.90470279.eng.abstr_task2	Sentence: Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve .	[ "Facial", "nerve", "schwannomas", "are", "rare", "benign", "tumors", ",", "when", "occurring", ",", "they", "are", "located", "most", "frequently", "in", "the", "distal", "fallopian", "canal", "and", "present", "as", "extracranial", "masses", ".", "The", "predominant", "symptom", "is", "a", "progressive", "facial", "nerve", "paralysis", ".", "We", "report", "a", "20-year", "-", "old", "woman", "with", "an", "intracranial", "schwannoma", "originating", "from", "the", "greater", "superficial", "petrosal", "nerve", "that", "had", "wide", "extension", "into", "the", "pterygopalatine", "fossa", ".", "The", "motor", "facial", "nerve", "including", "the", "geniculate", "ganglion", "was", "not", "affected", ".", "The", "patient", "presented", "with", "vertigo", ",", "progressive", "hearing", "loss", "and", "mild", "facial", "nerve", "synkinesis", "but", "without", "a", "lacrimation", "deficit", ".", "The", "tumor", "was", "detected", "by", "computed", "tomography", "and", "magnetic", "resonance", "imaging", ".", "The", "schwannoma", "was", "completely", "removed", "using", "an", "intracranial", ",", "extradural", "middle", "fossa", "approach", "during", "which", "complete", "preservation", "of", "the", "motor", "facial", "nerve", "was", "possible", ".", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "an", "isolated", "schwannoma", "of", "the", "greater", "superficial", "petrosal", "nerve", "without", "involvement", "of", "the", "motor", "facial", "nerve", "." ]	[ "umlsterm" ]
Age is a Person, from 40 to 80 years old is a Value, bilateral is a Qualifier, age related is a Qualifier, cataracts is a Condition, bilateral is a Qualifier, cataract phacoemulsification combined Intraocular Lens implantation is a Scope, Preoperative is a Temporal, measurement of corneal astigmatism is a Measurement, suitable is a Value, multifocal intraocular lenses implantation is a Procedure	NCT02678962_inc_task0	Sentence: Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Procedure, Scope, Measurement	[ "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "B-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study	[ "Age", "from", "40", "to", "80", "years", "old", ",", "either", "gender", ";", "\n", "Patients", "with", "bilateral", "age", "related", "cataracts", ",", "require", "bilateral", "cataract", "phacoemulsification", "combined", "Intraocular", "Lens", "implantation", ";", "\n", "Willing", "to", "undergo", "second", "eye", "surgery", "within", "7", "days", "after", "first", "eye", "surgery", ";", "\n", "The", "potential", "postoperative", "visual", "acuity", "of", "20/40", "or", "better", "in", "both", "eyes", ";", "\n", "Preoperative", "measurement", "of", "corneal", "astigmatism", "indicate", "the", "subjects", "are", "suitable", "for", "multifocal", "intraocular", "lenses", "implantation", ";", "\n", "Capability", "to", "understand", "the", "informed", "consent", "and", "willing", "and", "able", "to", "attend", "study", "\n" ]	[ "Scope", "Procedure", "Measurement", "Value", "Temporal", "Qualifier", "Condition", "Person" ]
Age is a Person, from 40 to 80 years old is a Value, bilateral is a Qualifier, age related is a Qualifier, cataracts is a Condition, bilateral is a Qualifier, cataract phacoemulsification combined Intraocular Lens implantation is a Scope, Preoperative is a Temporal, measurement of corneal astigmatism is a Measurement, suitable is a Value, multifocal intraocular lenses implantation is a Procedure	NCT02678962_inc_task1	Sentence: Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study Instructions: please typing these entity words according to sentence: Age, from 40 to 80 years old, bilateral, age related, cataracts, bilateral, cataract phacoemulsification combined Intraocular Lens implantation, Preoperative, measurement of corneal astigmatism, suitable, multifocal intraocular lenses implantation Options: Temporal, Condition, Qualifier, Value, Person, Procedure, Scope, Measurement	[ "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "B-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study	[ "Age", "from", "40", "to", "80", "years", "old", ",", "either", "gender", ";", "\n", "Patients", "with", "bilateral", "age", "related", "cataracts", ",", "require", "bilateral", "cataract", "phacoemulsification", "combined", "Intraocular", "Lens", "implantation", ";", "\n", "Willing", "to", "undergo", "second", "eye", "surgery", "within", "7", "days", "after", "first", "eye", "surgery", ";", "\n", "The", "potential", "postoperative", "visual", "acuity", "of", "20/40", "or", "better", "in", "both", "eyes", ";", "\n", "Preoperative", "measurement", "of", "corneal", "astigmatism", "indicate", "the", "subjects", "are", "suitable", "for", "multifocal", "intraocular", "lenses", "implantation", ";", "\n", "Capability", "to", "understand", "the", "informed", "consent", "and", "willing", "and", "able", "to", "attend", "study", "\n" ]	[ "Scope", "Procedure", "Measurement", "Value", "Temporal", "Qualifier", "Condition", "Person" ]
Age, from 40 to 80 years old, bilateral, age related, cataracts, bilateral, cataract phacoemulsification combined Intraocular Lens implantation, Preoperative, measurement of corneal astigmatism, suitable, multifocal intraocular lenses implantation	NCT02678962_inc_task2	Sentence: Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study Instructions: please extract entity words from the input sentence	[ "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "B-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study	[ "Age", "from", "40", "to", "80", "years", "old", ",", "either", "gender", ";", "\n", "Patients", "with", "bilateral", "age", "related", "cataracts", ",", "require", "bilateral", "cataract", "phacoemulsification", "combined", "Intraocular", "Lens", "implantation", ";", "\n", "Willing", "to", "undergo", "second", "eye", "surgery", "within", "7", "days", "after", "first", "eye", "surgery", ";", "\n", "The", "potential", "postoperative", "visual", "acuity", "of", "20/40", "or", "better", "in", "both", "eyes", ";", "\n", "Preoperative", "measurement", "of", "corneal", "astigmatism", "indicate", "the", "subjects", "are", "suitable", "for", "multifocal", "intraocular", "lenses", "implantation", ";", "\n", "Capability", "to", "understand", "the", "informed", "consent", "and", "willing", "and", "able", "to", "attend", "study", "\n" ]	[ "Scope", "Procedure", "Measurement", "Value", "Temporal", "Qualifier", "Condition", "Person" ]
ethylenethiourea is a CHEMICAL, methanol is a CHEMICAL	23578651_task0	Sentence: Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS.	[ "Development", "and", "validation", "of", "ethylenethiourea", "determination", "in", "foods", "using", "methanol", "-", "based", "extraction", ",", "solid", "-", "phase", "extraction", "cleanup", "and", "LC", "-", "MS", "/", "MS", "." ]	[ "CHEMICAL" ]
ethylenethiourea is a CHEMICAL, methanol is a CHEMICAL	23578651_task1	Sentence: Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS. Instructions: please typing these entity words according to sentence: ethylenethiourea, methanol Options: CHEMICAL	[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS.	[ "Development", "and", "validation", "of", "ethylenethiourea", "determination", "in", "foods", "using", "methanol", "-", "based", "extraction", ",", "solid", "-", "phase", "extraction", "cleanup", "and", "LC", "-", "MS", "/", "MS", "." ]	[ "CHEMICAL" ]
ethylenethiourea, methanol	23578651_task2	Sentence: Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS.	[ "Development", "and", "validation", "of", "ethylenethiourea", "determination", "in", "foods", "using", "methanol", "-", "based", "extraction", ",", "solid", "-", "phase", "extraction", "cleanup", "and", "LC", "-", "MS", "/", "MS", "." ]	[ "CHEMICAL" ]
TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, GLRP is a Protein, TFG - beta 2 is a Protein, promoter is a Entity, GLRP is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein	643_task0	Sentence: Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O" ]	Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response.	[ "Soluble", "factors", "secreted", "by", "activated", "T", "-", "lymphocytes", "modulate", "the", "transcription", "of", "the", "immunosuppressive", "cytokine", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "\n", "Coordination", "of", "the", "immune", "response", "to", "injury", "or", "disease", "in", "the", "brain", "is", "postulated", "to", "involve", "bi", "-", "directional", "discourse", "between", "the", "immune", "system", "and", "the", "central", "nervous", "system", ".", "This", "cross", "communication", "involves", "soluble", "mediators", ",", "including", "various", "growth", "factors", ",", "cytokines", ",", "and", "neuropeptides", ".", "In", "this", "report", ",", "we", "demonstrate", "that", "the", "supernatant", "from", "activated", "T", "-", "lymphocytes", "is", "able", "to", "induce", "the", "transcription", "of", "a", "potent", "cytokine", ",", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "The", "activating", "stimulus", "invokes", "signaling", "mechanisms", "distinct", "from", "known", "kinase", "or", "protease", "pathways", ".", "Activation", "of", "TGF", "-", "beta", "2", "transcription", "correlates", "with", "the", "loss", "of", "binding", "activity", "for", "an", "80", "kDA", "glial", "labile", "repressor", "protein", ",", "GLRP", ",", "to", "a", "responsive", "region", "within", "the", "TFG", "-", "beta", "2", "promoter", ".", "Although", "GLRP", "shares", "some", "characteristics", "with", "the", "inducible", "transcription", "factor", "AP-1", ",", "it", "appears", "to", "be", "distinct", "from", "known", "AP-1", "family", "members", ".", "These", "data", "along", "with", "previous", "observations", "demonstrating", "the", "potent", "immunosuppressive", "activity", "of", "TGF", "-", "beta", "2", ",", "support", "a", "model", "for", "a", "feedback", "mechanism", "between", "the", "activated", "T", "-", "lymphocytes", "and", "astrocytes", "via", "TGF", "-", "beta", "2", "to", "regulate", "the", "immune", "response", "." ]	[ "Protein", "Entity" ]
TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, GLRP is a Protein, TFG - beta 2 is a Protein, promoter is a Entity, GLRP is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein	643_task1	Sentence: Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response. Instructions: please typing these entity words according to sentence: TGF - beta 2, TGF - beta 2, TGF - beta 2, GLRP, TFG - beta 2, promoter, GLRP, TGF - beta 2, TGF - beta 2 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O" ]	Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response.	[ "Soluble", "factors", "secreted", "by", "activated", "T", "-", "lymphocytes", "modulate", "the", "transcription", "of", "the", "immunosuppressive", "cytokine", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "\n", "Coordination", "of", "the", "immune", "response", "to", "injury", "or", "disease", "in", "the", "brain", "is", "postulated", "to", "involve", "bi", "-", "directional", "discourse", "between", "the", "immune", "system", "and", "the", "central", "nervous", "system", ".", "This", "cross", "communication", "involves", "soluble", "mediators", ",", "including", "various", "growth", "factors", ",", "cytokines", ",", "and", "neuropeptides", ".", "In", "this", "report", ",", "we", "demonstrate", "that", "the", "supernatant", "from", "activated", "T", "-", "lymphocytes", "is", "able", "to", "induce", "the", "transcription", "of", "a", "potent", "cytokine", ",", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "The", "activating", "stimulus", "invokes", "signaling", "mechanisms", "distinct", "from", "known", "kinase", "or", "protease", "pathways", ".", "Activation", "of", "TGF", "-", "beta", "2", "transcription", "correlates", "with", "the", "loss", "of", "binding", "activity", "for", "an", "80", "kDA", "glial", "labile", "repressor", "protein", ",", "GLRP", ",", "to", "a", "responsive", "region", "within", "the", "TFG", "-", "beta", "2", "promoter", ".", "Although", "GLRP", "shares", "some", "characteristics", "with", "the", "inducible", "transcription", "factor", "AP-1", ",", "it", "appears", "to", "be", "distinct", "from", "known", "AP-1", "family", "members", ".", "These", "data", "along", "with", "previous", "observations", "demonstrating", "the", "potent", "immunosuppressive", "activity", "of", "TGF", "-", "beta", "2", ",", "support", "a", "model", "for", "a", "feedback", "mechanism", "between", "the", "activated", "T", "-", "lymphocytes", "and", "astrocytes", "via", "TGF", "-", "beta", "2", "to", "regulate", "the", "immune", "response", "." ]	[ "Protein", "Entity" ]
TGF - beta 2, TGF - beta 2, TGF - beta 2, GLRP, TFG - beta 2, promoter, GLRP, TGF - beta 2, TGF - beta 2	643_task2	Sentence: Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O" ]	Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response.	[ "Soluble", "factors", "secreted", "by", "activated", "T", "-", "lymphocytes", "modulate", "the", "transcription", "of", "the", "immunosuppressive", "cytokine", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "\n", "Coordination", "of", "the", "immune", "response", "to", "injury", "or", "disease", "in", "the", "brain", "is", "postulated", "to", "involve", "bi", "-", "directional", "discourse", "between", "the", "immune", "system", "and", "the", "central", "nervous", "system", ".", "This", "cross", "communication", "involves", "soluble", "mediators", ",", "including", "various", "growth", "factors", ",", "cytokines", ",", "and", "neuropeptides", ".", "In", "this", "report", ",", "we", "demonstrate", "that", "the", "supernatant", "from", "activated", "T", "-", "lymphocytes", "is", "able", "to", "induce", "the", "transcription", "of", "a", "potent", "cytokine", ",", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "The", "activating", "stimulus", "invokes", "signaling", "mechanisms", "distinct", "from", "known", "kinase", "or", "protease", "pathways", ".", "Activation", "of", "TGF", "-", "beta", "2", "transcription", "correlates", "with", "the", "loss", "of", "binding", "activity", "for", "an", "80", "kDA", "glial", "labile", "repressor", "protein", ",", "GLRP", ",", "to", "a", "responsive", "region", "within", "the", "TFG", "-", "beta", "2", "promoter", ".", "Although", "GLRP", "shares", "some", "characteristics", "with", "the", "inducible", "transcription", "factor", "AP-1", ",", "it", "appears", "to", "be", "distinct", "from", "known", "AP-1", "family", "members", ".", "These", "data", "along", "with", "previous", "observations", "demonstrating", "the", "potent", "immunosuppressive", "activity", "of", "TGF", "-", "beta", "2", ",", "support", "a", "model", "for", "a", "feedback", "mechanism", "between", "the", "activated", "T", "-", "lymphocytes", "and", "astrocytes", "via", "TGF", "-", "beta", "2", "to", "regulate", "the", "immune", "response", "." ]	[ "Protein", "Entity" ]
4-Hydroxypyridazin-3(2H)-one is a CHEMICAL, d - Amino Acid Oxidase is a GENE-Y	23566269_task0	Sentence: 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]	4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.	[ "4-Hydroxypyridazin-3(2H)-one", "Derivatives", "as", "Novel", "d", "-", "Amino", "Acid", "Oxidase", "Inhibitors", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
4-Hydroxypyridazin-3(2H)-one is a CHEMICAL, d - Amino Acid Oxidase is a GENE-Y	23566269_task1	Sentence: 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. Instructions: please typing these entity words according to sentence: 4-Hydroxypyridazin-3(2H)-one, d - Amino Acid Oxidase Options: GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]	4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.	[ "4-Hydroxypyridazin-3(2H)-one", "Derivatives", "as", "Novel", "d", "-", "Amino", "Acid", "Oxidase", "Inhibitors", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
4-Hydroxypyridazin-3(2H)-one, d - Amino Acid Oxidase	23566269_task2	Sentence: 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]	4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.	[ "4-Hydroxypyridazin-3(2H)-one", "Derivatives", "as", "Novel", "d", "-", "Amino", "Acid", "Oxidase", "Inhibitors", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Blutverbrauch is an umlsterm, Herzchirurgie is an umlsterm, Fremdblutverbrauch is an umlsterm, Eigenblutspende is an umlsterm, herzchirurgischen is an umlsterm, herzchirurgischen is an umlsterm	DerAnaesthesist.90480876.ger.abstr_task0	Sentence: Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken .	[ "Fragestellung", ":", "Der", "Blutverbrauch", "in", "der", "Herzchirurgie", "zeigt", "auch", "bei", "vergleichbaren", "Eingriffen", "eine", "weite", "Variationsbreite", ".", "Die", "vorliegende", "Studie", "untersucht", "den", "intraoperativen", "Fremdblutverbrauch", "und", "die", "Eigenblutspende", "bei", "definierten", "herzchirurgischen", "Eingriffen", "an", "12", "herzchirurgischen", "Kliniken", "." ]	[ "umlsterm" ]
Blutverbrauch is an umlsterm, Herzchirurgie is an umlsterm, Fremdblutverbrauch is an umlsterm, Eigenblutspende is an umlsterm, herzchirurgischen is an umlsterm, herzchirurgischen is an umlsterm	DerAnaesthesist.90480876.ger.abstr_task1	Sentence: Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken . Instructions: please typing these entity words according to sentence: Blutverbrauch, Herzchirurgie, Fremdblutverbrauch, Eigenblutspende, herzchirurgischen, herzchirurgischen Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken .	[ "Fragestellung", ":", "Der", "Blutverbrauch", "in", "der", "Herzchirurgie", "zeigt", "auch", "bei", "vergleichbaren", "Eingriffen", "eine", "weite", "Variationsbreite", ".", "Die", "vorliegende", "Studie", "untersucht", "den", "intraoperativen", "Fremdblutverbrauch", "und", "die", "Eigenblutspende", "bei", "definierten", "herzchirurgischen", "Eingriffen", "an", "12", "herzchirurgischen", "Kliniken", "." ]	[ "umlsterm" ]
Blutverbrauch, Herzchirurgie, Fremdblutverbrauch, Eigenblutspende, herzchirurgischen, herzchirurgischen	DerAnaesthesist.90480876.ger.abstr_task2	Sentence: Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken .	[ "Fragestellung", ":", "Der", "Blutverbrauch", "in", "der", "Herzchirurgie", "zeigt", "auch", "bei", "vergleichbaren", "Eingriffen", "eine", "weite", "Variationsbreite", ".", "Die", "vorliegende", "Studie", "untersucht", "den", "intraoperativen", "Fremdblutverbrauch", "und", "die", "Eigenblutspende", "bei", "definierten", "herzchirurgischen", "Eingriffen", "an", "12", "herzchirurgischen", "Kliniken", "." ]	[ "umlsterm" ]
children is an umlsterm, inguinal hernia is an umlsterm, patent is an umlsterm, children is an umlsterm, inguinal hernia is an umlsterm, laparoscopy is an umlsterm, technique is an umlsterm, hernia is an umlsterm, Method is an umlsterm, children is an umlsterm, age is an umlsterm, hernia is an umlsterm, laparoscopy is an umlsterm, laparoscope is an umlsterm, wide - open is an umlsterm, open is an umlsterm, surgical is an umlsterm, patients is an umlsterm, criteria is an umlsterm, open is an umlsterm, patients is an umlsterm, time is an umlsterm, laparoscopy is an umlsterm, complications is an umlsterm, laparoscopy is an umlsterm, laparoscopy is an umlsterm, hernia is an umlsterm, repair is an umlsterm, identification is an umlsterm, patients is an umlsterm, open is an umlsterm, surgery is an umlsterm, operation is an umlsterm, time is an umlsterm, complications is an umlsterm, method is an umlsterm, hospitalization is an umlsterm, operation is an umlsterm, open is an umlsterm, visualization is an umlsterm, method is an umlsterm, bowel is an umlsterm	DerChirurg.90700290.eng.abstr_task0	Sentence: Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning .	[ "Background", ":", "Approximately", "50", "%", "of", "children", "with", "a", "clinical", "unilateral", "inguinal", "hernia", "display", "a", "patent", "processus", "vaginalis", "on", "the", "contralateral", "side", ";", "half", "of", "these", "children", "subsequently", "develop", "an", "inguinal", "hernia", ".", "The", "management", "of", "this", "problem", "is", "still", "controversial", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "usefulness", "of", "intraoperative", "laparoscopy", "in", "a", "no", "-", "puncture", "technique", "through", "the", "opened", "hernia", "sack", ".", "Method", ":", "In", "112", "children", "(", "age", "6", "months", "to", "7", "years", ")", "with", "clinical", "unilateral", "hernia", "laparoscopy", "(", "5", "mm", "laparoscope", ",", "30", "°", "and", "70", "°", ")", ".", "In", "cases", "of", "a", "wide", "-", "open", "contralateral", "internal", "inguinal", "ring", "(", "type", "III", ")", "open", "surgical", "exploration", "was", "performed", ".", "Results", ":", "Nineteen", "patients", "(", "17", "%", ")", "fulfilled", "the", "laparoscopic", "criteria", "of", "a", "type", "III", "ring", ";", "the", "diagnose", "was", "confirmed", "during", "open", "contralateral", "exploration", ".", "Fourteen", "of", "these", "patients", "were", "younger", "than", "two", "years", ".", "The", "median", "time", "for", "laparoscopy", "was", "6", "min", "(", "3", "-", "11", "min", ")", ".", "No", "complications", "associated", "with", "the", "laparoscopy", "were", "observed", ".", "Conclusions", ":", "Intraoperative", "laparoscopy", "during", "unilateral", "hernia", "repair", "allows", "the", "identification", "of", "patients", "who", "profit", "from", "bilateral", "open", "surgery", "during", "the", "same", "operation", "with", "little", "additional", "operating", "time", "and", "so", "far", "with", "no", "resulting", "complications", ".", "Application", "of", "this", "method", "may", "avoid", "a", "second", "hospitalization", "and", "operation", ",", "as", "well", "as", "an", "unnecessary", "routine", "bilateral", "open", "exploration", ".", "As", "an", "additional", "source", "of", "information", "through", "excellent", "visualization", "of", "the", "abdominal", "cavity", ",", "this", "method", "proved", "helpful", "to", "examine", "incarcerated", "bowel", "after", "repositioning", "." ]	[ "umlsterm" ]
children is an umlsterm, inguinal hernia is an umlsterm, patent is an umlsterm, children is an umlsterm, inguinal hernia is an umlsterm, laparoscopy is an umlsterm, technique is an umlsterm, hernia is an umlsterm, Method is an umlsterm, children is an umlsterm, age is an umlsterm, hernia is an umlsterm, laparoscopy is an umlsterm, laparoscope is an umlsterm, wide - open is an umlsterm, open is an umlsterm, surgical is an umlsterm, patients is an umlsterm, criteria is an umlsterm, open is an umlsterm, patients is an umlsterm, time is an umlsterm, laparoscopy is an umlsterm, complications is an umlsterm, laparoscopy is an umlsterm, laparoscopy is an umlsterm, hernia is an umlsterm, repair is an umlsterm, identification is an umlsterm, patients is an umlsterm, open is an umlsterm, surgery is an umlsterm, operation is an umlsterm, time is an umlsterm, complications is an umlsterm, method is an umlsterm, hospitalization is an umlsterm, operation is an umlsterm, open is an umlsterm, visualization is an umlsterm, method is an umlsterm, bowel is an umlsterm	DerChirurg.90700290.eng.abstr_task1	Sentence: Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning . Instructions: please typing these entity words according to sentence: children, inguinal hernia, patent, children, inguinal hernia, laparoscopy, technique, hernia, Method, children, age, hernia, laparoscopy, laparoscope, wide - open, open, surgical, patients, criteria, open, patients, time, laparoscopy, complications, laparoscopy, laparoscopy, hernia, repair, identification, patients, open, surgery, operation, time, complications, method, hospitalization, operation, open, visualization, method, bowel Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning .	[ "Background", ":", "Approximately", "50", "%", "of", "children", "with", "a", "clinical", "unilateral", "inguinal", "hernia", "display", "a", "patent", "processus", "vaginalis", "on", "the", "contralateral", "side", ";", "half", "of", "these", "children", "subsequently", "develop", "an", "inguinal", "hernia", ".", "The", "management", "of", "this", "problem", "is", "still", "controversial", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "usefulness", "of", "intraoperative", "laparoscopy", "in", "a", "no", "-", "puncture", "technique", "through", "the", "opened", "hernia", "sack", ".", "Method", ":", "In", "112", "children", "(", "age", "6", "months", "to", "7", "years", ")", "with", "clinical", "unilateral", "hernia", "laparoscopy", "(", "5", "mm", "laparoscope", ",", "30", "°", "and", "70", "°", ")", ".", "In", "cases", "of", "a", "wide", "-", "open", "contralateral", "internal", "inguinal", "ring", "(", "type", "III", ")", "open", "surgical", "exploration", "was", "performed", ".", "Results", ":", "Nineteen", "patients", "(", "17", "%", ")", "fulfilled", "the", "laparoscopic", "criteria", "of", "a", "type", "III", "ring", ";", "the", "diagnose", "was", "confirmed", "during", "open", "contralateral", "exploration", ".", "Fourteen", "of", "these", "patients", "were", "younger", "than", "two", "years", ".", "The", "median", "time", "for", "laparoscopy", "was", "6", "min", "(", "3", "-", "11", "min", ")", ".", "No", "complications", "associated", "with", "the", "laparoscopy", "were", "observed", ".", "Conclusions", ":", "Intraoperative", "laparoscopy", "during", "unilateral", "hernia", "repair", "allows", "the", "identification", "of", "patients", "who", "profit", "from", "bilateral", "open", "surgery", "during", "the", "same", "operation", "with", "little", "additional", "operating", "time", "and", "so", "far", "with", "no", "resulting", "complications", ".", "Application", "of", "this", "method", "may", "avoid", "a", "second", "hospitalization", "and", "operation", ",", "as", "well", "as", "an", "unnecessary", "routine", "bilateral", "open", "exploration", ".", "As", "an", "additional", "source", "of", "information", "through", "excellent", "visualization", "of", "the", "abdominal", "cavity", ",", "this", "method", "proved", "helpful", "to", "examine", "incarcerated", "bowel", "after", "repositioning", "." ]	[ "umlsterm" ]
children, inguinal hernia, patent, children, inguinal hernia, laparoscopy, technique, hernia, Method, children, age, hernia, laparoscopy, laparoscope, wide - open, open, surgical, patients, criteria, open, patients, time, laparoscopy, complications, laparoscopy, laparoscopy, hernia, repair, identification, patients, open, surgery, operation, time, complications, method, hospitalization, operation, open, visualization, method, bowel	DerChirurg.90700290.eng.abstr_task2	Sentence: Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning .	[ "Background", ":", "Approximately", "50", "%", "of", "children", "with", "a", "clinical", "unilateral", "inguinal", "hernia", "display", "a", "patent", "processus", "vaginalis", "on", "the", "contralateral", "side", ";", "half", "of", "these", "children", "subsequently", "develop", "an", "inguinal", "hernia", ".", "The", "management", "of", "this", "problem", "is", "still", "controversial", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "usefulness", "of", "intraoperative", "laparoscopy", "in", "a", "no", "-", "puncture", "technique", "through", "the", "opened", "hernia", "sack", ".", "Method", ":", "In", "112", "children", "(", "age", "6", "months", "to", "7", "years", ")", "with", "clinical", "unilateral", "hernia", "laparoscopy", "(", "5", "mm", "laparoscope", ",", "30", "°", "and", "70", "°", ")", ".", "In", "cases", "of", "a", "wide", "-", "open", "contralateral", "internal", "inguinal", "ring", "(", "type", "III", ")", "open", "surgical", "exploration", "was", "performed", ".", "Results", ":", "Nineteen", "patients", "(", "17", "%", ")", "fulfilled", "the", "laparoscopic", "criteria", "of", "a", "type", "III", "ring", ";", "the", "diagnose", "was", "confirmed", "during", "open", "contralateral", "exploration", ".", "Fourteen", "of", "these", "patients", "were", "younger", "than", "two", "years", ".", "The", "median", "time", "for", "laparoscopy", "was", "6", "min", "(", "3", "-", "11", "min", ")", ".", "No", "complications", "associated", "with", "the", "laparoscopy", "were", "observed", ".", "Conclusions", ":", "Intraoperative", "laparoscopy", "during", "unilateral", "hernia", "repair", "allows", "the", "identification", "of", "patients", "who", "profit", "from", "bilateral", "open", "surgery", "during", "the", "same", "operation", "with", "little", "additional", "operating", "time", "and", "so", "far", "with", "no", "resulting", "complications", ".", "Application", "of", "this", "method", "may", "avoid", "a", "second", "hospitalization", "and", "operation", ",", "as", "well", "as", "an", "unnecessary", "routine", "bilateral", "open", "exploration", ".", "As", "an", "additional", "source", "of", "information", "through", "excellent", "visualization", "of", "the", "abdominal", "cavity", ",", "this", "method", "proved", "helpful", "to", "examine", "incarcerated", "bowel", "after", "repositioning", "." ]	[ "umlsterm" ]
amino acid decarboxylases is a GENE-N, alanine racemase is a GENE-N	16997906_task0	Sentence: Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N	[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O" ]	Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.	[ "Functional", "classification", "of", "amino", "acid", "decarboxylases", "from", "the", "alanine", "racemase", "structural", "family", "by", "phylogenetic", "studies", "." ]	[ "GENE-N", "CHEMICAL" ]
amino acid decarboxylases is a GENE-N, alanine racemase is a GENE-N	16997906_task1	Sentence: Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Instructions: please typing these entity words according to sentence: amino acid decarboxylases, alanine racemase Options: GENE-N	[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O" ]	Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.	[ "Functional", "classification", "of", "amino", "acid", "decarboxylases", "from", "the", "alanine", "racemase", "structural", "family", "by", "phylogenetic", "studies", "." ]	[ "GENE-N", "CHEMICAL" ]
amino acid decarboxylases, alanine racemase	16997906_task2	Sentence: Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O" ]	Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.	[ "Functional", "classification", "of", "amino", "acid", "decarboxylases", "from", "the", "alanine", "racemase", "structural", "family", "by", "phylogenetic", "studies", "." ]	[ "GENE-N", "CHEMICAL" ]
fibroblasts is an umlsterm, corticoid is an umlsterm, aldosterone is an umlsterm, collagen is an umlsterm, rat is an umlsterm, myocardium is an umlsterm, hypertension is an umlsterm, fibrosis is an umlsterm, pathologic is an umlsterm, hypertrophy is an umlsterm, heart is an umlsterm	Herz.00250299.eng.abstr_task0	Sentence: Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure .	[ "Cardiac", "fibroblasts", "are", "known", "to", "have", "high", "affinity", "corticoid", "receptors", "for", "aldosterone", "and", "account", "for", "the", "accumulation", "of", "collagen", "within", "the", "interstitium", "of", "the", "rat", "myocardium", "in", "acquired", "and", "genetic", "hypertension", ".", "This", "interstitial", "fibrosis", "is", "an", "important", "determinant", "of", "pathologic", "hypertrophy", "in", "chronic", "heart", "failure", "." ]	[ "umlsterm" ]
fibroblasts is an umlsterm, corticoid is an umlsterm, aldosterone is an umlsterm, collagen is an umlsterm, rat is an umlsterm, myocardium is an umlsterm, hypertension is an umlsterm, fibrosis is an umlsterm, pathologic is an umlsterm, hypertrophy is an umlsterm, heart is an umlsterm	Herz.00250299.eng.abstr_task1	Sentence: Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure . Instructions: please typing these entity words according to sentence: fibroblasts, corticoid, aldosterone, collagen, rat, myocardium, hypertension, fibrosis, pathologic, hypertrophy, heart Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure .	[ "Cardiac", "fibroblasts", "are", "known", "to", "have", "high", "affinity", "corticoid", "receptors", "for", "aldosterone", "and", "account", "for", "the", "accumulation", "of", "collagen", "within", "the", "interstitium", "of", "the", "rat", "myocardium", "in", "acquired", "and", "genetic", "hypertension", ".", "This", "interstitial", "fibrosis", "is", "an", "important", "determinant", "of", "pathologic", "hypertrophy", "in", "chronic", "heart", "failure", "." ]	[ "umlsterm" ]
fibroblasts, corticoid, aldosterone, collagen, rat, myocardium, hypertension, fibrosis, pathologic, hypertrophy, heart	Herz.00250299.eng.abstr_task2	Sentence: Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure .	[ "Cardiac", "fibroblasts", "are", "known", "to", "have", "high", "affinity", "corticoid", "receptors", "for", "aldosterone", "and", "account", "for", "the", "accumulation", "of", "collagen", "within", "the", "interstitium", "of", "the", "rat", "myocardium", "in", "acquired", "and", "genetic", "hypertension", ".", "This", "interstitial", "fibrosis", "is", "an", "important", "determinant", "of", "pathologic", "hypertrophy", "in", "chronic", "heart", "failure", "." ]	[ "umlsterm" ]
hematopoietic transcription factor is a protein_family_or_group, PU.1 is a protein_molecule, human multiple myeloma cell lines is a cell_line	101483_task0	Sentence: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line, protein_molecule	[ "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines.	[ "The", "hematopoietic", "transcription", "factor", "PU.1", "is", "downregulated", "in", "human", "multiple", "myeloma", "cell", "lines", "." ]	[ "other_name", "cell_type", "DNA_family_or_group", "protein_family_or_group", "cell_line", "(AND cell_line cell_line cell_line)", "DNA_domain_or_region", "RNA_molecule", "", "body_part", "protein_molecule" ]
hematopoietic transcription factor is a protein_family_or_group, PU.1 is a protein_molecule, human multiple myeloma cell lines is a cell_line	101483_task1	Sentence: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Instructions: please typing these entity words according to sentence: hematopoietic transcription factor, PU.1, human multiple myeloma cell lines Options: protein_family_or_group, cell_line, protein_molecule	[ "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines.	[ "The", "hematopoietic", "transcription", "factor", "PU.1", "is", "downregulated", "in", "human", "multiple", "myeloma", "cell", "lines", "." ]	[ "other_name", "cell_type", "DNA_family_or_group", "protein_family_or_group", "cell_line", "(AND cell_line cell_line cell_line)", "DNA_domain_or_region", "RNA_molecule", "", "body_part", "protein_molecule" ]
hematopoietic transcription factor, PU.1, human multiple myeloma cell lines	101483_task2	Sentence: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Instructions: please extract entity words from the input sentence	[ "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines.	[ "The", "hematopoietic", "transcription", "factor", "PU.1", "is", "downregulated", "in", "human", "multiple", "myeloma", "cell", "lines", "." ]	[ "other_name", "cell_type", "DNA_family_or_group", "protein_family_or_group", "cell_line", "(AND cell_line cell_line cell_line)", "DNA_domain_or_region", "RNA_molecule", "", "body_part", "protein_molecule" ]
alkaline proteinase is a Individual_protein, myosin heavy chain is a Individual_protein, actin is a Individual_protein	241_task0	Sentence: Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O" ]	Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin.	[ "Digestion", "of", "isolated", "myofibrils", "with", "alkaline", "proteinase", "resulted", "in", "the", "degradation", "of", "myosin", "heavy", "chain", "and", "actin", "." ]	[ "Individual_protein" ]
alkaline proteinase is a Individual_protein, myosin heavy chain is a Individual_protein, actin is a Individual_protein	241_task1	Sentence: Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin. Instructions: please typing these entity words according to sentence: alkaline proteinase, myosin heavy chain, actin Options: Individual_protein	[ "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O" ]	Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin.	[ "Digestion", "of", "isolated", "myofibrils", "with", "alkaline", "proteinase", "resulted", "in", "the", "degradation", "of", "myosin", "heavy", "chain", "and", "actin", "." ]	[ "Individual_protein" ]
alkaline proteinase, myosin heavy chain, actin	241_task2	Sentence: Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O" ]	Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin.	[ "Digestion", "of", "isolated", "myofibrils", "with", "alkaline", "proteinase", "resulted", "in", "the", "degradation", "of", "myosin", "heavy", "chain", "and", "actin", "." ]	[ "Individual_protein" ]
COF1 is a Gene, actin - binding protein is a Protein_family_or_group, cofilin is a Individual_protein, Cof is a Individual_protein, Cof is a Individual_protein	875_task0	Sentence: We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, Protein_family_or_group, Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]	We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof.	[ "We", "have", "cloned", "a", "Saccharomyces", "cerevisiae", "gene", "(", "COF1", ")", "encoding", "a", "low", "-", "M(r", ")", "actin", "-", "binding", "protein", "of", "143", "amino", "acid", "(", "aa", ")", "residues", "(", "yeast", "cofilin", ";", "Cof", ")", ";", "its", "aa", "sequence", "is", "35", "%", "identical", "to", "porcine", "Cof", "." ]	[ "Protein_family_or_group", "Individual_protein", "Gene" ]
COF1 is a Gene, actin - binding protein is a Protein_family_or_group, cofilin is a Individual_protein, Cof is a Individual_protein, Cof is a Individual_protein	875_task1	Sentence: We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof. Instructions: please typing these entity words according to sentence: COF1, actin - binding protein, cofilin, Cof, Cof Options: Gene, Protein_family_or_group, Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]	We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof.	[ "We", "have", "cloned", "a", "Saccharomyces", "cerevisiae", "gene", "(", "COF1", ")", "encoding", "a", "low", "-", "M(r", ")", "actin", "-", "binding", "protein", "of", "143", "amino", "acid", "(", "aa", ")", "residues", "(", "yeast", "cofilin", ";", "Cof", ")", ";", "its", "aa", "sequence", "is", "35", "%", "identical", "to", "porcine", "Cof", "." ]	[ "Protein_family_or_group", "Individual_protein", "Gene" ]
COF1, actin - binding protein, cofilin, Cof, Cof	875_task2	Sentence: We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]	We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof.	[ "We", "have", "cloned", "a", "Saccharomyces", "cerevisiae", "gene", "(", "COF1", ")", "encoding", "a", "low", "-", "M(r", ")", "actin", "-", "binding", "protein", "of", "143", "amino", "acid", "(", "aa", ")", "residues", "(", "yeast", "cofilin", ";", "Cof", ")", ";", "its", "aa", "sequence", "is", "35", "%", "identical", "to", "porcine", "Cof", "." ]	[ "Protein_family_or_group", "Individual_protein", "Gene" ]
Neuronatin is a GENE-Y, calcium is a CHEMICAL	23408434_task0	Sentence: Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.	[ "Neuronatin", "-", "mediated", "aberrant", "calcium", "signaling", "and", "endoplasmic", "reticulum", "stress", "underlie", "neuropathology", "in", "Lafora", "disease", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Neuronatin is a GENE-Y, calcium is a CHEMICAL	23408434_task1	Sentence: Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease. Instructions: please typing these entity words according to sentence: Neuronatin, calcium Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.	[ "Neuronatin", "-", "mediated", "aberrant", "calcium", "signaling", "and", "endoplasmic", "reticulum", "stress", "underlie", "neuropathology", "in", "Lafora", "disease", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Neuronatin, calcium	23408434_task2	Sentence: Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.	[ "Neuronatin", "-", "mediated", "aberrant", "calcium", "signaling", "and", "endoplasmic", "reticulum", "stress", "underlie", "neuropathology", "in", "Lafora", "disease", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
cofilin is a Individual_protein, actin is a Individual_protein	503_task0	Sentence: Kinetic studies on the effect of yeast cofilin on yeast actin polymerization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O" ]	Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.	[ "Kinetic", "studies", "on", "the", "effect", "of", "yeast", "cofilin", "on", "yeast", "actin", "polymerization", "." ]	[ "Individual_protein" ]
cofilin is a Individual_protein, actin is a Individual_protein	503_task1	Sentence: Kinetic studies on the effect of yeast cofilin on yeast actin polymerization. Instructions: please typing these entity words according to sentence: cofilin, actin Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O" ]	Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.	[ "Kinetic", "studies", "on", "the", "effect", "of", "yeast", "cofilin", "on", "yeast", "actin", "polymerization", "." ]	[ "Individual_protein" ]
cofilin, actin	503_task2	Sentence: Kinetic studies on the effect of yeast cofilin on yeast actin polymerization. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O" ]	Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.	[ "Kinetic", "studies", "on", "the", "effect", "of", "yeast", "cofilin", "on", "yeast", "actin", "polymerization", "." ]	[ "Individual_protein" ]
pre - core mutant chronic hepatitis B infection is a Participant_Condition, lamivudine is a Intervention_Pharmacological, pre - core mutant of hepatitis B virus ( HBV ) infection is a Participant_Condition, HBeAg in the serum . is a Outcome_Physical, effective is a Outcome_Other, HBV replication is a Outcome_Physical, indicators of liver disease is a Outcome_Physical	3800_task0	Sentence: Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection .	[ "Response", "of", "pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "to", "lamivudine", ".", "The", "proportion", "of", "chronic", "liver", "disease", "associated", "with", "the", "pre", "-", "core", "mutant", "of", "hepatitis", "B", "virus", "(", "HBV", ")", "infection", "is", "increasing", ",", "particularly", "in", "Mediterranean", "Europe", "and", "in", "Asia", ".", "The", "pre", "-", "core", "mutant", "HBV", "is", "unable", "to", "produce", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", ",", "so", "that", "patients", "with", "this", "variant", "do", "not", "present", "with", "HBV", "characterised", "by", "HBeAg", "in", "the", "serum", ".", "Pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "usually", "proceeds", "to", "serious", "liver", "disease", ".", "Wild", "-", "type", "HBV", "infection", "may", "be", "mild", "and", "respond", "relatively", "well", "to", "interferon", "(", "IFN", ")", "alpha", "therapy", ",", "but", "IFN", "alpha", "is", "not", "an", "effective", "therapeutic", "option", "in", "pre", "-", "core", "mutant", "hepatitis", "B", "infection", "and", "new", "therapeutic", "options", "are", "needed", ".", "Clinical", "data", "show", "that", "lamivudine", "is", "an", "effective", "treatment", "for", "patients", "with", "pre", "-", "core", "mutant", "hepatitis", "B", ".", "There", "is", "profound", "suppression", "of", "HBV", "replication", "and", "improvement", "in", "indicators", "of", "liver", "disease", "in", "most", "patients", ".", "In", "conclusion", ",", "lamivudine", "is", "suitable", "for", "treatment", "of", "a", "wide", "range", "of", "patients", "with", "chronic", "hepatitis", "B", ",", "including", "those", "with", "pre", "-", "core", "mutant", "HBV", "infection", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other" ]
pre - core mutant chronic hepatitis B infection is a Participant_Condition, lamivudine is a Intervention_Pharmacological, pre - core mutant of hepatitis B virus ( HBV ) infection is a Participant_Condition, HBeAg in the serum . is a Outcome_Physical, effective is a Outcome_Other, HBV replication is a Outcome_Physical, indicators of liver disease is a Outcome_Physical	3800_task1	Sentence: Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection . Instructions: please typing these entity words according to sentence: pre - core mutant chronic hepatitis B infection, lamivudine, pre - core mutant of hepatitis B virus ( HBV ) infection, HBeAg in the serum ., effective, HBV replication, indicators of liver disease Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection .	[ "Response", "of", "pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "to", "lamivudine", ".", "The", "proportion", "of", "chronic", "liver", "disease", "associated", "with", "the", "pre", "-", "core", "mutant", "of", "hepatitis", "B", "virus", "(", "HBV", ")", "infection", "is", "increasing", ",", "particularly", "in", "Mediterranean", "Europe", "and", "in", "Asia", ".", "The", "pre", "-", "core", "mutant", "HBV", "is", "unable", "to", "produce", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", ",", "so", "that", "patients", "with", "this", "variant", "do", "not", "present", "with", "HBV", "characterised", "by", "HBeAg", "in", "the", "serum", ".", "Pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "usually", "proceeds", "to", "serious", "liver", "disease", ".", "Wild", "-", "type", "HBV", "infection", "may", "be", "mild", "and", "respond", "relatively", "well", "to", "interferon", "(", "IFN", ")", "alpha", "therapy", ",", "but", "IFN", "alpha", "is", "not", "an", "effective", "therapeutic", "option", "in", "pre", "-", "core", "mutant", "hepatitis", "B", "infection", "and", "new", "therapeutic", "options", "are", "needed", ".", "Clinical", "data", "show", "that", "lamivudine", "is", "an", "effective", "treatment", "for", "patients", "with", "pre", "-", "core", "mutant", "hepatitis", "B", ".", "There", "is", "profound", "suppression", "of", "HBV", "replication", "and", "improvement", "in", "indicators", "of", "liver", "disease", "in", "most", "patients", ".", "In", "conclusion", ",", "lamivudine", "is", "suitable", "for", "treatment", "of", "a", "wide", "range", "of", "patients", "with", "chronic", "hepatitis", "B", ",", "including", "those", "with", "pre", "-", "core", "mutant", "HBV", "infection", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other" ]
pre - core mutant chronic hepatitis B infection, lamivudine, pre - core mutant of hepatitis B virus ( HBV ) infection, HBeAg in the serum ., effective, HBV replication, indicators of liver disease	3800_task2	Sentence: Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection .	[ "Response", "of", "pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "to", "lamivudine", ".", "The", "proportion", "of", "chronic", "liver", "disease", "associated", "with", "the", "pre", "-", "core", "mutant", "of", "hepatitis", "B", "virus", "(", "HBV", ")", "infection", "is", "increasing", ",", "particularly", "in", "Mediterranean", "Europe", "and", "in", "Asia", ".", "The", "pre", "-", "core", "mutant", "HBV", "is", "unable", "to", "produce", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", ",", "so", "that", "patients", "with", "this", "variant", "do", "not", "present", "with", "HBV", "characterised", "by", "HBeAg", "in", "the", "serum", ".", "Pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "usually", "proceeds", "to", "serious", "liver", "disease", ".", "Wild", "-", "type", "HBV", "infection", "may", "be", "mild", "and", "respond", "relatively", "well", "to", "interferon", "(", "IFN", ")", "alpha", "therapy", ",", "but", "IFN", "alpha", "is", "not", "an", "effective", "therapeutic", "option", "in", "pre", "-", "core", "mutant", "hepatitis", "B", "infection", "and", "new", "therapeutic", "options", "are", "needed", ".", "Clinical", "data", "show", "that", "lamivudine", "is", "an", "effective", "treatment", "for", "patients", "with", "pre", "-", "core", "mutant", "hepatitis", "B", ".", "There", "is", "profound", "suppression", "of", "HBV", "replication", "and", "improvement", "in", "indicators", "of", "liver", "disease", "in", "most", "patients", ".", "In", "conclusion", ",", "lamivudine", "is", "suitable", "for", "treatment", "of", "a", "wide", "range", "of", "patients", "with", "chronic", "hepatitis", "B", ",", "including", "those", "with", "pre", "-", "core", "mutant", "HBV", "infection", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other" ]
Osteonecrosis is a Condition, planned is a Mood, decompression surgery is a Procedure, autologous stem cell transplant is a Procedure	NCT02893293_inc_task0	Sentence: Osteonecrosis planned decompression surgery with autologous stem cell transplant Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Procedure, Mood	[ "B-Condition", "O", "B-Mood", "B-Procedure", "I-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]	Osteonecrosis planned decompression surgery with autologous stem cell transplant	[ "Osteonecrosis", "\n", "planned", "decompression", "surgery", "with", "autologous", "stem", "cell", "transplant", "\n" ]	[ "Procedure", "Condition", "Mood" ]
Osteonecrosis is a Condition, planned is a Mood, decompression surgery is a Procedure, autologous stem cell transplant is a Procedure	NCT02893293_inc_task1	Sentence: Osteonecrosis planned decompression surgery with autologous stem cell transplant Instructions: please typing these entity words according to sentence: Osteonecrosis, planned, decompression surgery, autologous stem cell transplant Options: Condition, Procedure, Mood	[ "B-Condition", "O", "B-Mood", "B-Procedure", "I-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]	Osteonecrosis planned decompression surgery with autologous stem cell transplant	[ "Osteonecrosis", "\n", "planned", "decompression", "surgery", "with", "autologous", "stem", "cell", "transplant", "\n" ]	[ "Procedure", "Condition", "Mood" ]
Osteonecrosis, planned, decompression surgery, autologous stem cell transplant	NCT02893293_inc_task2	Sentence: Osteonecrosis planned decompression surgery with autologous stem cell transplant Instructions: please extract entity words from the input sentence	[ "B-Condition", "O", "B-Mood", "B-Procedure", "I-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]	Osteonecrosis planned decompression surgery with autologous stem cell transplant	[ "Osteonecrosis", "\n", "planned", "decompression", "surgery", "with", "autologous", "stem", "cell", "transplant", "\n" ]	[ "Procedure", "Condition", "Mood" ]
TGF - alpha is a Protein, EGF is a Protein, Transforming growth factor - alpha is a Protein, TGF - alpha is a Protein, epidermal growth factor is a Protein, EGF is a Protein, L - glutamine : D - fructose-6-phosphate amidotransferase is a Protein, GFAT is a Protein, GFAT is a Protein, EGF is a Protein, EGF is a Protein, GFAT is a Protein, EGF is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, EGF is a Protein, GFAT is a Protein, GFAT is a Protein, GFAT is a Protein, TGF - alpha is a Protein, GFAT is a Protein, EGF is a Protein	562_task0	Sentence: Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]	Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not.	[ "Role", "of", "glucosamine", "synthesis", "in", "the", "stimulation", "of", "TGF", "-", "alpha", "gene", "transcription", "by", "glucose", "and", "EGF", ".", "\n", "Transforming", "growth", "factor", "-", "alpha", "(", "TGF", "-", "alpha", ")", "gene", "transcription", "is", "regulated", "by", "both", "epidermal", "growth", "factor", "(", "EGF", ")", "and", "glucose", ".", "Previous", "studies", "have", "suggested", "that", "the", "metabolism", "of", "glucose", "to", "glucosamine", "through", "the", "enzyme", "L", "-", "glutamine", ":", "D", "-", "fructose-6-phosphate", "amidotransferase", "(", "GFAT", ")", "plays", "a", "critical", "role", "in", "the", "glucose", "signaling", ".", "In", "this", "paper", ",", "we", "compared", "the", "role", "of", "GFAT", "in", "the", "glucose", "and", "EGF", "signals", ".", "We", "found", "that", ",", "although", "EGF", "stimulates", "GFAT", "mRNA", "accumulation", "in", "MDA", "-", "MB-468", "cells", ",", "this", "effect", "of", "EGF", "occurred", "several", "hours", "after", "TGF", "-", "alpha", "transcription", "increased", ".", "MDA", "-", "MB-468", "cells", "also", "exhibited", "a", "TGF", "-", "alpha", "transcriptional", "response", "to", "low", "concentrations", "of", "glucose", ".", "The", "TGF", "-", "alpha", "response", "to", "glucose", "but", "not", "EGF", "could", "be", "inhibited", "by", "a", "blocker", "of", "GFAT", "activity", ".", "Blockade", "of", "GFAT", "was", "confirmed", "by", "using", "Western", "blotting", "with", "the", "RL2", "antibody", ",", "which", "recognizes", "an", "epitope", "on", "proteins", "containing", "N", "-", "acetylglucosamine", ".", "Exposure", "of", "cells", "to", "glucose", "increased", "the", "RL2", "signal", "on", "several", "polypeptides", ",", "but", "this", "change", "could", "be", "blocked", "by", "inhibition", "of", "GFAT", ".", "These", "results", "support", "the", "notion", "that", "glucose", "stimulation", "of", "TGF", "-", "alpha", "expression", "requires", "GFAT", ",", "but", "EGF", "stimulation", "does", "not", ".", "\n" ]	[ "Protein" ]
TGF - alpha is a Protein, EGF is a Protein, Transforming growth factor - alpha is a Protein, TGF - alpha is a Protein, epidermal growth factor is a Protein, EGF is a Protein, L - glutamine : D - fructose-6-phosphate amidotransferase is a Protein, GFAT is a Protein, GFAT is a Protein, EGF is a Protein, EGF is a Protein, GFAT is a Protein, EGF is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, EGF is a Protein, GFAT is a Protein, GFAT is a Protein, GFAT is a Protein, TGF - alpha is a Protein, GFAT is a Protein, EGF is a Protein	562_task1	Sentence: Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not. Instructions: please typing these entity words according to sentence: TGF - alpha, EGF, Transforming growth factor - alpha, TGF - alpha, epidermal growth factor, EGF, L - glutamine : D - fructose-6-phosphate amidotransferase, GFAT, GFAT, EGF, EGF, GFAT, EGF, TGF - alpha, TGF - alpha, TGF - alpha, EGF, GFAT, GFAT, GFAT, TGF - alpha, GFAT, EGF Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]	Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not.	[ "Role", "of", "glucosamine", "synthesis", "in", "the", "stimulation", "of", "TGF", "-", "alpha", "gene", "transcription", "by", "glucose", "and", "EGF", ".", "\n", "Transforming", "growth", "factor", "-", "alpha", "(", "TGF", "-", "alpha", ")", "gene", "transcription", "is", "regulated", "by", "both", "epidermal", "growth", "factor", "(", "EGF", ")", "and", "glucose", ".", "Previous", "studies", "have", "suggested", "that", "the", "metabolism", "of", "glucose", "to", "glucosamine", "through", "the", "enzyme", "L", "-", "glutamine", ":", "D", "-", "fructose-6-phosphate", "amidotransferase", "(", "GFAT", ")", "plays", "a", "critical", "role", "in", "the", "glucose", "signaling", ".", "In", "this", "paper", ",", "we", "compared", "the", "role", "of", "GFAT", "in", "the", "glucose", "and", "EGF", "signals", ".", "We", "found", "that", ",", "although", "EGF", "stimulates", "GFAT", "mRNA", "accumulation", "in", "MDA", "-", "MB-468", "cells", ",", "this", "effect", "of", "EGF", "occurred", "several", "hours", "after", "TGF", "-", "alpha", "transcription", "increased", ".", "MDA", "-", "MB-468", "cells", "also", "exhibited", "a", "TGF", "-", "alpha", "transcriptional", "response", "to", "low", "concentrations", "of", "glucose", ".", "The", "TGF", "-", "alpha", "response", "to", "glucose", "but", "not", "EGF", "could", "be", "inhibited", "by", "a", "blocker", "of", "GFAT", "activity", ".", "Blockade", "of", "GFAT", "was", "confirmed", "by", "using", "Western", "blotting", "with", "the", "RL2", "antibody", ",", "which", "recognizes", "an", "epitope", "on", "proteins", "containing", "N", "-", "acetylglucosamine", ".", "Exposure", "of", "cells", "to", "glucose", "increased", "the", "RL2", "signal", "on", "several", "polypeptides", ",", "but", "this", "change", "could", "be", "blocked", "by", "inhibition", "of", "GFAT", ".", "These", "results", "support", "the", "notion", "that", "glucose", "stimulation", "of", "TGF", "-", "alpha", "expression", "requires", "GFAT", ",", "but", "EGF", "stimulation", "does", "not", ".", "\n" ]	[ "Protein" ]
TGF - alpha, EGF, Transforming growth factor - alpha, TGF - alpha, epidermal growth factor, EGF, L - glutamine : D - fructose-6-phosphate amidotransferase, GFAT, GFAT, EGF, EGF, GFAT, EGF, TGF - alpha, TGF - alpha, TGF - alpha, EGF, GFAT, GFAT, GFAT, TGF - alpha, GFAT, EGF	562_task2	Sentence: Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]	Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not.	[ "Role", "of", "glucosamine", "synthesis", "in", "the", "stimulation", "of", "TGF", "-", "alpha", "gene", "transcription", "by", "glucose", "and", "EGF", ".", "\n", "Transforming", "growth", "factor", "-", "alpha", "(", "TGF", "-", "alpha", ")", "gene", "transcription", "is", "regulated", "by", "both", "epidermal", "growth", "factor", "(", "EGF", ")", "and", "glucose", ".", "Previous", "studies", "have", "suggested", "that", "the", "metabolism", "of", "glucose", "to", "glucosamine", "through", "the", "enzyme", "L", "-", "glutamine", ":", "D", "-", "fructose-6-phosphate", "amidotransferase", "(", "GFAT", ")", "plays", "a", "critical", "role", "in", "the", "glucose", "signaling", ".", "In", "this", "paper", ",", "we", "compared", "the", "role", "of", "GFAT", "in", "the", "glucose", "and", "EGF", "signals", ".", "We", "found", "that", ",", "although", "EGF", "stimulates", "GFAT", "mRNA", "accumulation", "in", "MDA", "-", "MB-468", "cells", ",", "this", "effect", "of", "EGF", "occurred", "several", "hours", "after", "TGF", "-", "alpha", "transcription", "increased", ".", "MDA", "-", "MB-468", "cells", "also", "exhibited", "a", "TGF", "-", "alpha", "transcriptional", "response", "to", "low", "concentrations", "of", "glucose", ".", "The", "TGF", "-", "alpha", "response", "to", "glucose", "but", "not", "EGF", "could", "be", "inhibited", "by", "a", "blocker", "of", "GFAT", "activity", ".", "Blockade", "of", "GFAT", "was", "confirmed", "by", "using", "Western", "blotting", "with", "the", "RL2", "antibody", ",", "which", "recognizes", "an", "epitope", "on", "proteins", "containing", "N", "-", "acetylglucosamine", ".", "Exposure", "of", "cells", "to", "glucose", "increased", "the", "RL2", "signal", "on", "several", "polypeptides", ",", "but", "this", "change", "could", "be", "blocked", "by", "inhibition", "of", "GFAT", ".", "These", "results", "support", "the", "notion", "that", "glucose", "stimulation", "of", "TGF", "-", "alpha", "expression", "requires", "GFAT", ",", "but", "EGF", "stimulation", "does", "not", ".", "\n" ]	[ "Protein" ]
c - fos is a DNA_domain_or_region, c - jun is a DNA_domain_or_region, jun B is a DNA_domain_or_region	84660_task0	Sentence: Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region	[ "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.	[ "Expression", "of", "c", "-", "fos", ",", "c", "-", "jun", "and", "jun", "B", "in", "peripheral", "blood", "lymphocytes", "from", "young", "and", "elderly", "adults", "." ]	[ "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "(AND other_name other_name)", "(OR other_name other_name)", "other_name", "multi_cell", "RNA_molecule", "protein_molecule", "", "DNA_family_or_group", "RNA_N/A", "cell_type", "DNA_domain_or_region", "RNA_family_or_group" ]
c - fos is a DNA_domain_or_region, c - jun is a DNA_domain_or_region, jun B is a DNA_domain_or_region	84660_task1	Sentence: Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults. Instructions: please typing these entity words according to sentence: c - fos, c - jun, jun B Options: DNA_domain_or_region	[ "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.	[ "Expression", "of", "c", "-", "fos", ",", "c", "-", "jun", "and", "jun", "B", "in", "peripheral", "blood", "lymphocytes", "from", "young", "and", "elderly", "adults", "." ]	[ "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "(AND other_name other_name)", "(OR other_name other_name)", "other_name", "multi_cell", "RNA_molecule", "protein_molecule", "", "DNA_family_or_group", "RNA_N/A", "cell_type", "DNA_domain_or_region", "RNA_family_or_group" ]
c - fos, c - jun, jun B	84660_task2	Sentence: Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.	[ "Expression", "of", "c", "-", "fos", ",", "c", "-", "jun", "and", "jun", "B", "in", "peripheral", "blood", "lymphocytes", "from", "young", "and", "elderly", "adults", "." ]	[ "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "(AND other_name other_name)", "(OR other_name other_name)", "other_name", "multi_cell", "RNA_molecule", "protein_molecule", "", "DNA_family_or_group", "RNA_N/A", "cell_type", "DNA_domain_or_region", "RNA_family_or_group" ]
PGH(2 is a compound, mPGES-1 is a protein	DS.d1073_task0	Sentence: Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]	Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1.	[ "Possible", "binding", "site", "for", "the", "substrate", ",", "prostaglandin", "H(2", ")", "(", "PGH(2", ")", ")", ",", "was", "identified", "by", "systematically", "probing", "the", "refined", "molecular", "structure", "of", "mPGES-1", "." ]	[ "protein", "compound" ]
PGH(2 is a compound, mPGES-1 is a protein	DS.d1073_task1	Sentence: Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. Instructions: please typing these entity words according to sentence: PGH(2, mPGES-1 Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]	Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1.	[ "Possible", "binding", "site", "for", "the", "substrate", ",", "prostaglandin", "H(2", ")", "(", "PGH(2", ")", ")", ",", "was", "identified", "by", "systematically", "probing", "the", "refined", "molecular", "structure", "of", "mPGES-1", "." ]	[ "protein", "compound" ]
PGH(2, mPGES-1	DS.d1073_task2	Sentence: Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]	Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1.	[ "Possible", "binding", "site", "for", "the", "substrate", ",", "prostaglandin", "H(2", ")", "(", "PGH(2", ")", ")", ",", "was", "identified", "by", "systematically", "probing", "the", "refined", "molecular", "structure", "of", "mPGES-1", "." ]	[ "protein", "compound" ]
Patienten is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekt is an umlsterm, Lappenplastiken is an umlsterm, Behandlung is an umlsterm, Lebenszufriedenheit is an umlsterm, Fragebogen is an umlsterm, Behandlungsergebnis is an umlsterm, Beruf is an umlsterm, Einkommen is an umlsterm, Arbeit is an umlsterm, koerperliche Leistungsfaehigkeit is an umlsterm, Beschwerdefreiheit is an umlsterm, Patienten is an umlsterm, Referenzwert is an umlsterm, Beins is an umlsterm, Hebedefektmorbiditaet is an umlsterm, Belastbarkeit is an umlsterm, Schmerzen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Patient is an umlsterm, Amputation is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Behandlung is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekten is an umlsterm, Langzeitergebnisse is an umlsterm, Patienten is an umlsterm, Lebenszufriedenheit is an umlsterm, Patienten is an umlsterm	DerUnfallchirurg.81010838.ger.abstr_task0	Sentence: 58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten .	[ "58", "Patienten", "nach", "offenen", "Unterschenkelfrakturen", "mit", "ausgedehntem", "Hautweichteildefekt", ",", "welche", "interdisziplinaer", "mit", "Osteosynthesen", "und", "freien", ",", "mikrovaskulaeren", "Lappenplastiken", "versorgt", "worden", "waren", ",", "wurden", "durchschnittlich", "6", "Jahre", "nach", "der", "Behandlung", "im", "Hinblick", "auf", "ihre", "Lebenszufriedenheit", "untersucht", ".", "Verwendet", "wurde", "hierzu", "ein", "standardisiertes", "Testverfahren", "(", "FLZ", ")", "mit", "nachgewiesener", "Reliabilitaet", "und", "Validitaet", ",", "sowie", "ein", "Fragebogen", "mit", "spezifischen", "Fragen", "zur", "Zufriedenheit", "mit", "dem", "Behandlungsergebnis", ",", "zum", "Lokalbefund", "und", "dessen", "Auswirkungen", ",", "zu", "Beruf", "und", "oekonomischen", "Aspekten", ".", "In", "einzelnen", "Bereichen", "fanden", "sich", "signifikante", "Diskrepanzen", "zu", "einem", "repraesentativen", "Vergleichskollektiv", "aus", "der", "BRD", "-", "West", "(", "z", ".", "B.", "Freizeitgestaltung", "Einkommen", ",", "Arbeit", ",", "Partnerschaft", ",", "koerperliche", "Leistungsfaehigkeit", ",", "Fortbewegungsfaehigkeit", ",", "Beschwerdefreiheit", ")", ".", ",", "Die", "berechneten", ",", "globalen", "\"", "Lebenszufriedenheitsindices", "\"", "der", "untersuchten", "Patienten", "wichen", "statistisch", "schwach", "signifikant", "vom", "Referenzwert", "des", "Vergleichskollektivs", "ab", ".", "Obwohl", "spezifische", "Aspekte", "(", "z", ".", "B.", "Aussehen", "des", "Beins", ",", "Hebedefektmorbiditaet", ",", "Belastbarkeit", ",", "Schmerzen", ")", "langfristig", "durchaus", "kritisch", "beurteilt", "wurden", ",", "zeigten", "sich", "jedoch", "91", "%", "der", "Patienten", "mit", "der", "Behandlung", "zufrieden", ".", "Kein", "einziger", "Patient", "haette", "retrospektiv", "eine", "Amputation", "bevorzugt", "!", "64", "%", "der", "Patienten", "arbeiteten", "nach", "abgeschlossener", "Behandlung", "wieder", ".", "Die", "multimodale", "Behandlung", "von", "Unterschenkelfrakturen", "mit", "begleitenden", "Hautweichteildefekten", "durch", "ein", "erfahrenes", ",", "interdisziplinaeres", "\"", "Traumateam", "\"", ",", "kann", "zufriedenstellende", "Langzeitergebnisse", "liefern", ".", "Diese", "Behandlungsergebnisse", "werden", "von", "der", "ueberwiegenden", "Mehrzahl", "der", "Patienten", "positiv", "beurteilt", ".", "Mit", "einer", "Beeintraechtigung", "der", "Lebenszufriedenheit", "zumindest", "in", "bestimmten", "Bereichen", "muss", "allerdings", "gerechnet", "werden", ".", "Die", "vorliegende", "Studie", "gibt", "wertvolle", "Informationen", "sowohl", "fuer", "differentialtherapeutische", "Ueberlegungen", "als", "auch", "fuer", "das", "Gespraech", "mit", "den", "Patienten", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekt is an umlsterm, Lappenplastiken is an umlsterm, Behandlung is an umlsterm, Lebenszufriedenheit is an umlsterm, Fragebogen is an umlsterm, Behandlungsergebnis is an umlsterm, Beruf is an umlsterm, Einkommen is an umlsterm, Arbeit is an umlsterm, koerperliche Leistungsfaehigkeit is an umlsterm, Beschwerdefreiheit is an umlsterm, Patienten is an umlsterm, Referenzwert is an umlsterm, Beins is an umlsterm, Hebedefektmorbiditaet is an umlsterm, Belastbarkeit is an umlsterm, Schmerzen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Patient is an umlsterm, Amputation is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Behandlung is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekten is an umlsterm, Langzeitergebnisse is an umlsterm, Patienten is an umlsterm, Lebenszufriedenheit is an umlsterm, Patienten is an umlsterm	DerUnfallchirurg.81010838.ger.abstr_task1	Sentence: 58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten . Instructions: please typing these entity words according to sentence: Patienten, Unterschenkelfrakturen, Hautweichteildefekt, Lappenplastiken, Behandlung, Lebenszufriedenheit, Fragebogen, Behandlungsergebnis, Beruf, Einkommen, Arbeit, koerperliche Leistungsfaehigkeit, Beschwerdefreiheit, Patienten, Referenzwert, Beins, Hebedefektmorbiditaet, Belastbarkeit, Schmerzen, Patienten, Behandlung, Patient, Amputation, Patienten, Behandlung, Behandlung, Unterschenkelfrakturen, Hautweichteildefekten, Langzeitergebnisse, Patienten, Lebenszufriedenheit, Patienten Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten .	[ "58", "Patienten", "nach", "offenen", "Unterschenkelfrakturen", "mit", "ausgedehntem", "Hautweichteildefekt", ",", "welche", "interdisziplinaer", "mit", "Osteosynthesen", "und", "freien", ",", "mikrovaskulaeren", "Lappenplastiken", "versorgt", "worden", "waren", ",", "wurden", "durchschnittlich", "6", "Jahre", "nach", "der", "Behandlung", "im", "Hinblick", "auf", "ihre", "Lebenszufriedenheit", "untersucht", ".", "Verwendet", "wurde", "hierzu", "ein", "standardisiertes", "Testverfahren", "(", "FLZ", ")", "mit", "nachgewiesener", "Reliabilitaet", "und", "Validitaet", ",", "sowie", "ein", "Fragebogen", "mit", "spezifischen", "Fragen", "zur", "Zufriedenheit", "mit", "dem", "Behandlungsergebnis", ",", "zum", "Lokalbefund", "und", "dessen", "Auswirkungen", ",", "zu", "Beruf", "und", "oekonomischen", "Aspekten", ".", "In", "einzelnen", "Bereichen", "fanden", "sich", "signifikante", "Diskrepanzen", "zu", "einem", "repraesentativen", "Vergleichskollektiv", "aus", "der", "BRD", "-", "West", "(", "z", ".", "B.", "Freizeitgestaltung", "Einkommen", ",", "Arbeit", ",", "Partnerschaft", ",", "koerperliche", "Leistungsfaehigkeit", ",", "Fortbewegungsfaehigkeit", ",", "Beschwerdefreiheit", ")", ".", ",", "Die", "berechneten", ",", "globalen", "\"", "Lebenszufriedenheitsindices", "\"", "der", "untersuchten", "Patienten", "wichen", "statistisch", "schwach", "signifikant", "vom", "Referenzwert", "des", "Vergleichskollektivs", "ab", ".", "Obwohl", "spezifische", "Aspekte", "(", "z", ".", "B.", "Aussehen", "des", "Beins", ",", "Hebedefektmorbiditaet", ",", "Belastbarkeit", ",", "Schmerzen", ")", "langfristig", "durchaus", "kritisch", "beurteilt", "wurden", ",", "zeigten", "sich", "jedoch", "91", "%", "der", "Patienten", "mit", "der", "Behandlung", "zufrieden", ".", "Kein", "einziger", "Patient", "haette", "retrospektiv", "eine", "Amputation", "bevorzugt", "!", "64", "%", "der", "Patienten", "arbeiteten", "nach", "abgeschlossener", "Behandlung", "wieder", ".", "Die", "multimodale", "Behandlung", "von", "Unterschenkelfrakturen", "mit", "begleitenden", "Hautweichteildefekten", "durch", "ein", "erfahrenes", ",", "interdisziplinaeres", "\"", "Traumateam", "\"", ",", "kann", "zufriedenstellende", "Langzeitergebnisse", "liefern", ".", "Diese", "Behandlungsergebnisse", "werden", "von", "der", "ueberwiegenden", "Mehrzahl", "der", "Patienten", "positiv", "beurteilt", ".", "Mit", "einer", "Beeintraechtigung", "der", "Lebenszufriedenheit", "zumindest", "in", "bestimmten", "Bereichen", "muss", "allerdings", "gerechnet", "werden", ".", "Die", "vorliegende", "Studie", "gibt", "wertvolle", "Informationen", "sowohl", "fuer", "differentialtherapeutische", "Ueberlegungen", "als", "auch", "fuer", "das", "Gespraech", "mit", "den", "Patienten", "." ]	[ "umlsterm" ]
Patienten, Unterschenkelfrakturen, Hautweichteildefekt, Lappenplastiken, Behandlung, Lebenszufriedenheit, Fragebogen, Behandlungsergebnis, Beruf, Einkommen, Arbeit, koerperliche Leistungsfaehigkeit, Beschwerdefreiheit, Patienten, Referenzwert, Beins, Hebedefektmorbiditaet, Belastbarkeit, Schmerzen, Patienten, Behandlung, Patient, Amputation, Patienten, Behandlung, Behandlung, Unterschenkelfrakturen, Hautweichteildefekten, Langzeitergebnisse, Patienten, Lebenszufriedenheit, Patienten	DerUnfallchirurg.81010838.ger.abstr_task2	Sentence: 58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten .	[ "58", "Patienten", "nach", "offenen", "Unterschenkelfrakturen", "mit", "ausgedehntem", "Hautweichteildefekt", ",", "welche", "interdisziplinaer", "mit", "Osteosynthesen", "und", "freien", ",", "mikrovaskulaeren", "Lappenplastiken", "versorgt", "worden", "waren", ",", "wurden", "durchschnittlich", "6", "Jahre", "nach", "der", "Behandlung", "im", "Hinblick", "auf", "ihre", "Lebenszufriedenheit", "untersucht", ".", "Verwendet", "wurde", "hierzu", "ein", "standardisiertes", "Testverfahren", "(", "FLZ", ")", "mit", "nachgewiesener", "Reliabilitaet", "und", "Validitaet", ",", "sowie", "ein", "Fragebogen", "mit", "spezifischen", "Fragen", "zur", "Zufriedenheit", "mit", "dem", "Behandlungsergebnis", ",", "zum", "Lokalbefund", "und", "dessen", "Auswirkungen", ",", "zu", "Beruf", "und", "oekonomischen", "Aspekten", ".", "In", "einzelnen", "Bereichen", "fanden", "sich", "signifikante", "Diskrepanzen", "zu", "einem", "repraesentativen", "Vergleichskollektiv", "aus", "der", "BRD", "-", "West", "(", "z", ".", "B.", "Freizeitgestaltung", "Einkommen", ",", "Arbeit", ",", "Partnerschaft", ",", "koerperliche", "Leistungsfaehigkeit", ",", "Fortbewegungsfaehigkeit", ",", "Beschwerdefreiheit", ")", ".", ",", "Die", "berechneten", ",", "globalen", "\"", "Lebenszufriedenheitsindices", "\"", "der", "untersuchten", "Patienten", "wichen", "statistisch", "schwach", "signifikant", "vom", "Referenzwert", "des", "Vergleichskollektivs", "ab", ".", "Obwohl", "spezifische", "Aspekte", "(", "z", ".", "B.", "Aussehen", "des", "Beins", ",", "Hebedefektmorbiditaet", ",", "Belastbarkeit", ",", "Schmerzen", ")", "langfristig", "durchaus", "kritisch", "beurteilt", "wurden", ",", "zeigten", "sich", "jedoch", "91", "%", "der", "Patienten", "mit", "der", "Behandlung", "zufrieden", ".", "Kein", "einziger", "Patient", "haette", "retrospektiv", "eine", "Amputation", "bevorzugt", "!", "64", "%", "der", "Patienten", "arbeiteten", "nach", "abgeschlossener", "Behandlung", "wieder", ".", "Die", "multimodale", "Behandlung", "von", "Unterschenkelfrakturen", "mit", "begleitenden", "Hautweichteildefekten", "durch", "ein", "erfahrenes", ",", "interdisziplinaeres", "\"", "Traumateam", "\"", ",", "kann", "zufriedenstellende", "Langzeitergebnisse", "liefern", ".", "Diese", "Behandlungsergebnisse", "werden", "von", "der", "ueberwiegenden", "Mehrzahl", "der", "Patienten", "positiv", "beurteilt", ".", "Mit", "einer", "Beeintraechtigung", "der", "Lebenszufriedenheit", "zumindest", "in", "bestimmten", "Bereichen", "muss", "allerdings", "gerechnet", "werden", ".", "Die", "vorliegende", "Studie", "gibt", "wertvolle", "Informationen", "sowohl", "fuer", "differentialtherapeutische", "Ueberlegungen", "als", "auch", "fuer", "das", "Gespraech", "mit", "den", "Patienten", "." ]	[ "umlsterm" ]
Hypotension is an umlsterm, Nitroprussidnatrium is an umlsterm, NPN is an umlsterm, Genehmigung is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Nasen - Septumkorrektur - Operationen is an umlsterm, Hypotension is an umlsterm, NPN is an umlsterm, Fentanyl is an umlsterm, Etomidat is an umlsterm, Isofluran is an umlsterm, Katecholamine is an umlsterm, IL-6 is an umlsterm, Stickstoffmonoxid is an umlsterm	DerAnaesthesist.50440328.ger.abstr_task0	Sentence: Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht .	[ "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "eine", "kontrollierte", "Hypotension", "mit", "Nitroprussidnatrium", "(", "NPN", ")", "das", "Ausmass", "der", "Akutphasenreaktion", "beeinflusst", ".", "Nach", "Genehmigung", "durch", "die", "Ethikkommission", "wurden", "20", "Patienten", "mit", "Nasen", "-", "Septumkorrektur", "-", "Operationen", "untersucht", ",", "von", "denen", "10", "eine", "kontrollierte", "Hypotension", "mit", "NPN", "erhielten", ".", "Die", "Narkose", "wurde", "mit", "Fentanyl", ",", "Etomidat", "eingeleitet", "und", "mit", "Isofluran", "in", "66", "%", "N20", "und", "33", "%", "O2", "fortgefuehrt", ".", "Die", "Interleukin-6-Plasmakonzentrationen", "(", "IL-6", ")", "stiegen", "in", "beiden", "Gruppen", "am", "1", ".", "postoperativen", "Tag", "signifikant", "(", "p", "0,05", ")", "an", ".", "Dabei", "lagen", "die", "Werte", "in", "der", "NPN", "-", "Gruppe", "mit", "31,8", "(", "9", "-", "42", ",", "2", ")", "pg", "/", "ml", "(", "Median", "und", "Streubreite", ")", "signifikant", "ueber", "denen", "der", "Kontrollgruppe", "mit", "15,2", "(", "7,4", "-", "19,0", ")", "pg", "/", "ml", ".", "In", "der", "NPN", "-", "Gruppe", "stiegen", "die", "Plasmakonzentrationen", "der", "Katecholamine", "zum", "intraoperativen", "Messzeitpunkt", "signifikant", "an", ".", "Die", "NPN", "-", "Gabe", "stellte", "einen", "erheblichen", "Stimulus", "fuer", "die", "Freisetzung", "von", "IL-6", "dar", ",", "dem", "wichtigsten", "Mediator", "der", "Akutphasenreaktion", ".", "Als", "Ursache", "hierfuer", "kommen", "das", "beim", "NPN", "-", "Abbau", "entstehende", "Stickstoffmonoxid", "und", "der", "Anstieg", "der", "Katecholamin", "-", "Plasmakonzentrationen", "in", "Betracht", "." ]	[ "umlsterm" ]
Hypotension is an umlsterm, Nitroprussidnatrium is an umlsterm, NPN is an umlsterm, Genehmigung is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Nasen - Septumkorrektur - Operationen is an umlsterm, Hypotension is an umlsterm, NPN is an umlsterm, Fentanyl is an umlsterm, Etomidat is an umlsterm, Isofluran is an umlsterm, Katecholamine is an umlsterm, IL-6 is an umlsterm, Stickstoffmonoxid is an umlsterm	DerAnaesthesist.50440328.ger.abstr_task1	Sentence: Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht . Instructions: please typing these entity words according to sentence: Hypotension, Nitroprussidnatrium, NPN, Genehmigung, Ethikkommission, Patienten, Nasen - Septumkorrektur - Operationen, Hypotension, NPN, Fentanyl, Etomidat, Isofluran, Katecholamine, IL-6, Stickstoffmonoxid Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht .	[ "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "eine", "kontrollierte", "Hypotension", "mit", "Nitroprussidnatrium", "(", "NPN", ")", "das", "Ausmass", "der", "Akutphasenreaktion", "beeinflusst", ".", "Nach", "Genehmigung", "durch", "die", "Ethikkommission", "wurden", "20", "Patienten", "mit", "Nasen", "-", "Septumkorrektur", "-", "Operationen", "untersucht", ",", "von", "denen", "10", "eine", "kontrollierte", "Hypotension", "mit", "NPN", "erhielten", ".", "Die", "Narkose", "wurde", "mit", "Fentanyl", ",", "Etomidat", "eingeleitet", "und", "mit", "Isofluran", "in", "66", "%", "N20", "und", "33", "%", "O2", "fortgefuehrt", ".", "Die", "Interleukin-6-Plasmakonzentrationen", "(", "IL-6", ")", "stiegen", "in", "beiden", "Gruppen", "am", "1", ".", "postoperativen", "Tag", "signifikant", "(", "p", "0,05", ")", "an", ".", "Dabei", "lagen", "die", "Werte", "in", "der", "NPN", "-", "Gruppe", "mit", "31,8", "(", "9", "-", "42", ",", "2", ")", "pg", "/", "ml", "(", "Median", "und", "Streubreite", ")", "signifikant", "ueber", "denen", "der", "Kontrollgruppe", "mit", "15,2", "(", "7,4", "-", "19,0", ")", "pg", "/", "ml", ".", "In", "der", "NPN", "-", "Gruppe", "stiegen", "die", "Plasmakonzentrationen", "der", "Katecholamine", "zum", "intraoperativen", "Messzeitpunkt", "signifikant", "an", ".", "Die", "NPN", "-", "Gabe", "stellte", "einen", "erheblichen", "Stimulus", "fuer", "die", "Freisetzung", "von", "IL-6", "dar", ",", "dem", "wichtigsten", "Mediator", "der", "Akutphasenreaktion", ".", "Als", "Ursache", "hierfuer", "kommen", "das", "beim", "NPN", "-", "Abbau", "entstehende", "Stickstoffmonoxid", "und", "der", "Anstieg", "der", "Katecholamin", "-", "Plasmakonzentrationen", "in", "Betracht", "." ]	[ "umlsterm" ]
Hypotension, Nitroprussidnatrium, NPN, Genehmigung, Ethikkommission, Patienten, Nasen - Septumkorrektur - Operationen, Hypotension, NPN, Fentanyl, Etomidat, Isofluran, Katecholamine, IL-6, Stickstoffmonoxid	DerAnaesthesist.50440328.ger.abstr_task2	Sentence: Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht .	[ "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "eine", "kontrollierte", "Hypotension", "mit", "Nitroprussidnatrium", "(", "NPN", ")", "das", "Ausmass", "der", "Akutphasenreaktion", "beeinflusst", ".", "Nach", "Genehmigung", "durch", "die", "Ethikkommission", "wurden", "20", "Patienten", "mit", "Nasen", "-", "Septumkorrektur", "-", "Operationen", "untersucht", ",", "von", "denen", "10", "eine", "kontrollierte", "Hypotension", "mit", "NPN", "erhielten", ".", "Die", "Narkose", "wurde", "mit", "Fentanyl", ",", "Etomidat", "eingeleitet", "und", "mit", "Isofluran", "in", "66", "%", "N20", "und", "33", "%", "O2", "fortgefuehrt", ".", "Die", "Interleukin-6-Plasmakonzentrationen", "(", "IL-6", ")", "stiegen", "in", "beiden", "Gruppen", "am", "1", ".", "postoperativen", "Tag", "signifikant", "(", "p", "0,05", ")", "an", ".", "Dabei", "lagen", "die", "Werte", "in", "der", "NPN", "-", "Gruppe", "mit", "31,8", "(", "9", "-", "42", ",", "2", ")", "pg", "/", "ml", "(", "Median", "und", "Streubreite", ")", "signifikant", "ueber", "denen", "der", "Kontrollgruppe", "mit", "15,2", "(", "7,4", "-", "19,0", ")", "pg", "/", "ml", ".", "In", "der", "NPN", "-", "Gruppe", "stiegen", "die", "Plasmakonzentrationen", "der", "Katecholamine", "zum", "intraoperativen", "Messzeitpunkt", "signifikant", "an", ".", "Die", "NPN", "-", "Gabe", "stellte", "einen", "erheblichen", "Stimulus", "fuer", "die", "Freisetzung", "von", "IL-6", "dar", ",", "dem", "wichtigsten", "Mediator", "der", "Akutphasenreaktion", ".", "Als", "Ursache", "hierfuer", "kommen", "das", "beim", "NPN", "-", "Abbau", "entstehende", "Stickstoffmonoxid", "und", "der", "Anstieg", "der", "Katecholamin", "-", "Plasmakonzentrationen", "in", "Betracht", "." ]	[ "umlsterm" ]
treatment is an umlsterm, prevention is an umlsterm, immunocompromised is an umlsterm, children is an umlsterm	MonatsschriftKinderheilkunde.81460200.eng.abstr_task0	Sentence: In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed .	[ "In", "order", "to", "point", "out", "optimal", "strategies", "for", "treatment", "and", "prevention", "of", "varicella", "-", "zoster", "-", "infections", "in", "immunocompromised", "children", "the", "current", "proceeding", "as", "well", "as", "possible", "alternatives", "are", "reviewed", "." ]	[ "umlsterm" ]
treatment is an umlsterm, prevention is an umlsterm, immunocompromised is an umlsterm, children is an umlsterm	MonatsschriftKinderheilkunde.81460200.eng.abstr_task1	Sentence: In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed . Instructions: please typing these entity words according to sentence: treatment, prevention, immunocompromised, children Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed .	[ "In", "order", "to", "point", "out", "optimal", "strategies", "for", "treatment", "and", "prevention", "of", "varicella", "-", "zoster", "-", "infections", "in", "immunocompromised", "children", "the", "current", "proceeding", "as", "well", "as", "possible", "alternatives", "are", "reviewed", "." ]	[ "umlsterm" ]
treatment, prevention, immunocompromised, children	MonatsschriftKinderheilkunde.81460200.eng.abstr_task2	Sentence: In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed .	[ "In", "order", "to", "point", "out", "optimal", "strategies", "for", "treatment", "and", "prevention", "of", "varicella", "-", "zoster", "-", "infections", "in", "immunocompromised", "children", "the", "current", "proceeding", "as", "well", "as", "possible", "alternatives", "are", "reviewed", "." ]	[ "umlsterm" ]
Bcl10 is a Protein, Bcl10 is a Protein, beta - actin is a Protein	82_task0	Sentence: NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).	[ "NF", "-", "kappaB", "inhibition", "by", "PMA", "correlated", "to", "PKC", "-", "dependent", "Bcl10", "degradation", ".", "Levels", "of", "intracellular", "protein", "were", "assessed", "following", "24", "h", "stimulation", "with", "PMA", "(", "162", "nM", ")", "or", "HK", "E.", "coli", "(", "5", "x", "107", "CFU", "/", "ml", ")", ".", "(", "A", ")", "Phospho", "-", "PKC", "increased", "in", "response", "to", "PMA", "and", "HK", "E.", "coli", "stimulation", ".", "(", "B", ")", "IkappaB", "decreased", "following", "stimulation", "with", "HK", "E.", "coli", "indicating", "NF", "-", "kappaB", "activation", ".", "(", "C", ")", "Bcl10", "activation", "was", "inhibited", "following", "long", "-", "term", "stimulation", "with", "PMA", ",", "which", "explains", "the", "inhibitory", "effect", "of", "PMA", "on", "NF", "-", "kappaB", "activation", ".", "beta", "-", "actin", "was", "used", "as", "a", "loading", "control", ".", "(", "n", "=", "3", ")", "." ]	[ "Protein" ]
Bcl10 is a Protein, Bcl10 is a Protein, beta - actin is a Protein	82_task1	Sentence: NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3). Instructions: please typing these entity words according to sentence: Bcl10, Bcl10, beta - actin Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).	[ "NF", "-", "kappaB", "inhibition", "by", "PMA", "correlated", "to", "PKC", "-", "dependent", "Bcl10", "degradation", ".", "Levels", "of", "intracellular", "protein", "were", "assessed", "following", "24", "h", "stimulation", "with", "PMA", "(", "162", "nM", ")", "or", "HK", "E.", "coli", "(", "5", "x", "107", "CFU", "/", "ml", ")", ".", "(", "A", ")", "Phospho", "-", "PKC", "increased", "in", "response", "to", "PMA", "and", "HK", "E.", "coli", "stimulation", ".", "(", "B", ")", "IkappaB", "decreased", "following", "stimulation", "with", "HK", "E.", "coli", "indicating", "NF", "-", "kappaB", "activation", ".", "(", "C", ")", "Bcl10", "activation", "was", "inhibited", "following", "long", "-", "term", "stimulation", "with", "PMA", ",", "which", "explains", "the", "inhibitory", "effect", "of", "PMA", "on", "NF", "-", "kappaB", "activation", ".", "beta", "-", "actin", "was", "used", "as", "a", "loading", "control", ".", "(", "n", "=", "3", ")", "." ]	[ "Protein" ]
Bcl10, Bcl10, beta - actin	82_task2	Sentence: NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).	[ "NF", "-", "kappaB", "inhibition", "by", "PMA", "correlated", "to", "PKC", "-", "dependent", "Bcl10", "degradation", ".", "Levels", "of", "intracellular", "protein", "were", "assessed", "following", "24", "h", "stimulation", "with", "PMA", "(", "162", "nM", ")", "or", "HK", "E.", "coli", "(", "5", "x", "107", "CFU", "/", "ml", ")", ".", "(", "A", ")", "Phospho", "-", "PKC", "increased", "in", "response", "to", "PMA", "and", "HK", "E.", "coli", "stimulation", ".", "(", "B", ")", "IkappaB", "decreased", "following", "stimulation", "with", "HK", "E.", "coli", "indicating", "NF", "-", "kappaB", "activation", ".", "(", "C", ")", "Bcl10", "activation", "was", "inhibited", "following", "long", "-", "term", "stimulation", "with", "PMA", ",", "which", "explains", "the", "inhibitory", "effect", "of", "PMA", "on", "NF", "-", "kappaB", "activation", ".", "beta", "-", "actin", "was", "used", "as", "a", "loading", "control", ".", "(", "n", "=", "3", ")", "." ]	[ "Protein" ]
adherence is a Outcome_Mental, mometasone furoate is a Intervention_Pharmacological, MF - DPI is a Intervention_Pharmacological, > or=12 years old is a Participant_Age, mild - to - moderate persistent asthma is a Participant_Condition, MF - DPI 400 microg once - daily in the evening is a Intervention_Pharmacological, MF - DPI 200 microg twice - daily is a Intervention_Pharmacological, Adherence is a Outcome_Mental, actual administered doses is a Outcome_Mental, Health - related quality of life is a Outcome_Mental, healthcare resource utilization is a Outcome_Other, days missed from work or school is a Outcome_Mental, 1233 is a Participant_Sample-size, mean is a Outcome_Other, adherence rates is a Outcome_Mental, Mean is a Outcome_Other, Adherence rates is a Outcome_Mental, missed work / school is a Outcome_Mental	43767_task0	Sentence: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration .	[ "Improved", "adherence", "with", "once", "-", "daily", "versus", "twice", "-", "daily", "dosing", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", ":", "a", "randomized", "open", "-", "label", "study", ".", "BACKGROUND", "Poor", "adherence", "with", "prescribed", "asthma", "medication", "is", "a", "major", "barrier", "to", "positive", "treatment", "outcomes", ".", "This", "study", "was", "designed", "to", "determine", "the", "effect", "of", "a", "once", "-", "daily", "administration", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", "(", "MF", "-", "DPI", ")", "on", "treatment", "adherence", "compared", "with", "a", "twice", "-", "daily", "administration", ".", "METHODS", "This", "was", "a", "12-week", "open", "-", "label", "study", "designed", "to", "mimic", "an", "actual", "clinical", "setting", "in", "patients", ">", "or=12", "years", "old", "with", "mild", "-", "to", "-", "moderate", "persistent", "asthma", ".", "Patients", "were", "randomized", "to", "receive", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "or", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", ".", "Adherence", "was", "assessed", "primarily", "using", "the", "number", "of", "actual", "administered", "doses", "reported", "from", "the", "device", "counter", "divided", "by", "the", "number", "of", "scheduled", "doses", ".", "Self", "-", "reports", "were", "also", "used", "to", "determine", "adherence", ".", "Health", "-", "related", "quality", "of", "life", ",", "healthcare", "resource", "utilization", ",", "and", "days", "missed", "from", "work", "or", "school", "were", "also", "reported", ".", "RESULTS", "1233", "patients", "were", "randomized", ".", "The", "mean", "adherence", "rates", ",", "as", "measured", "by", "the", "automatic", "dose", "counter", ",", "were", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "(", "93.3", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "89.5", "%", ")", ".", "Mean", "adherence", "rates", "based", "on", "self", "-", "reports", "were", "also", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "QD", "PM", "(", "97.2", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "95.3", "%", ")", ".", "Adherence", "rates", "were", "lower", "in", "adolescents", "(", "12", "-", "17", "years", "old", ")", ".", "Health", "-", "related", "quality", "of", "life", "improved", "by", "20", "%", "in", "patients", "using", "MF", "-", "DPI", "once", "-", "daily", "in", "the", "evening", "and", "by", "14", "%", "in", "patients", "using", "MF", "-", "DPI", "twice", "-", "daily", ".", "Very", "few", "(", "<", "8", "%", ")", "patients", "missed", "work", "/", "school", ".", "CONCLUSION", "Mean", "adherence", "rates", "were", "greater", "with", "a", "once", "-", "daily", "dosing", "regimen", "of", "MF", "-", "DPI", "than", "with", "a", "twice", "-", "daily", "dosing", "regimen", ".", "This", "trial", "was", "completed", "prior", "to", "the", "ISMJE", "requirements", "for", "trial", "registration", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Age", "Participant_Sample-size" ]
adherence is a Outcome_Mental, mometasone furoate is a Intervention_Pharmacological, MF - DPI is a Intervention_Pharmacological, > or=12 years old is a Participant_Age, mild - to - moderate persistent asthma is a Participant_Condition, MF - DPI 400 microg once - daily in the evening is a Intervention_Pharmacological, MF - DPI 200 microg twice - daily is a Intervention_Pharmacological, Adherence is a Outcome_Mental, actual administered doses is a Outcome_Mental, Health - related quality of life is a Outcome_Mental, healthcare resource utilization is a Outcome_Other, days missed from work or school is a Outcome_Mental, 1233 is a Participant_Sample-size, mean is a Outcome_Other, adherence rates is a Outcome_Mental, Mean is a Outcome_Other, Adherence rates is a Outcome_Mental, missed work / school is a Outcome_Mental	43767_task1	Sentence: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration . Instructions: please typing these entity words according to sentence: adherence, mometasone furoate, MF - DPI, > or=12 years old, mild - to - moderate persistent asthma, MF - DPI 400 microg once - daily in the evening, MF - DPI 200 microg twice - daily, Adherence, actual administered doses, Health - related quality of life, healthcare resource utilization, days missed from work or school, 1233, mean, adherence rates, Mean, Adherence rates, missed work / school Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration .	[ "Improved", "adherence", "with", "once", "-", "daily", "versus", "twice", "-", "daily", "dosing", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", ":", "a", "randomized", "open", "-", "label", "study", ".", "BACKGROUND", "Poor", "adherence", "with", "prescribed", "asthma", "medication", "is", "a", "major", "barrier", "to", "positive", "treatment", "outcomes", ".", "This", "study", "was", "designed", "to", "determine", "the", "effect", "of", "a", "once", "-", "daily", "administration", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", "(", "MF", "-", "DPI", ")", "on", "treatment", "adherence", "compared", "with", "a", "twice", "-", "daily", "administration", ".", "METHODS", "This", "was", "a", "12-week", "open", "-", "label", "study", "designed", "to", "mimic", "an", "actual", "clinical", "setting", "in", "patients", ">", "or=12", "years", "old", "with", "mild", "-", "to", "-", "moderate", "persistent", "asthma", ".", "Patients", "were", "randomized", "to", "receive", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "or", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", ".", "Adherence", "was", "assessed", "primarily", "using", "the", "number", "of", "actual", "administered", "doses", "reported", "from", "the", "device", "counter", "divided", "by", "the", "number", "of", "scheduled", "doses", ".", "Self", "-", "reports", "were", "also", "used", "to", "determine", "adherence", ".", "Health", "-", "related", "quality", "of", "life", ",", "healthcare", "resource", "utilization", ",", "and", "days", "missed", "from", "work", "or", "school", "were", "also", "reported", ".", "RESULTS", "1233", "patients", "were", "randomized", ".", "The", "mean", "adherence", "rates", ",", "as", "measured", "by", "the", "automatic", "dose", "counter", ",", "were", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "(", "93.3", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "89.5", "%", ")", ".", "Mean", "adherence", "rates", "based", "on", "self", "-", "reports", "were", "also", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "QD", "PM", "(", "97.2", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "95.3", "%", ")", ".", "Adherence", "rates", "were", "lower", "in", "adolescents", "(", "12", "-", "17", "years", "old", ")", ".", "Health", "-", "related", "quality", "of", "life", "improved", "by", "20", "%", "in", "patients", "using", "MF", "-", "DPI", "once", "-", "daily", "in", "the", "evening", "and", "by", "14", "%", "in", "patients", "using", "MF", "-", "DPI", "twice", "-", "daily", ".", "Very", "few", "(", "<", "8", "%", ")", "patients", "missed", "work", "/", "school", ".", "CONCLUSION", "Mean", "adherence", "rates", "were", "greater", "with", "a", "once", "-", "daily", "dosing", "regimen", "of", "MF", "-", "DPI", "than", "with", "a", "twice", "-", "daily", "dosing", "regimen", ".", "This", "trial", "was", "completed", "prior", "to", "the", "ISMJE", "requirements", "for", "trial", "registration", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Age", "Participant_Sample-size" ]
adherence, mometasone furoate, MF - DPI, > or=12 years old, mild - to - moderate persistent asthma, MF - DPI 400 microg once - daily in the evening, MF - DPI 200 microg twice - daily, Adherence, actual administered doses, Health - related quality of life, healthcare resource utilization, days missed from work or school, 1233, mean, adherence rates, Mean, Adherence rates, missed work / school	43767_task2	Sentence: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration .	[ "Improved", "adherence", "with", "once", "-", "daily", "versus", "twice", "-", "daily", "dosing", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", ":", "a", "randomized", "open", "-", "label", "study", ".", "BACKGROUND", "Poor", "adherence", "with", "prescribed", "asthma", "medication", "is", "a", "major", "barrier", "to", "positive", "treatment", "outcomes", ".", "This", "study", "was", "designed", "to", "determine", "the", "effect", "of", "a", "once", "-", "daily", "administration", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", "(", "MF", "-", "DPI", ")", "on", "treatment", "adherence", "compared", "with", "a", "twice", "-", "daily", "administration", ".", "METHODS", "This", "was", "a", "12-week", "open", "-", "label", "study", "designed", "to", "mimic", "an", "actual", "clinical", "setting", "in", "patients", ">", "or=12", "years", "old", "with", "mild", "-", "to", "-", "moderate", "persistent", "asthma", ".", "Patients", "were", "randomized", "to", "receive", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "or", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", ".", "Adherence", "was", "assessed", "primarily", "using", "the", "number", "of", "actual", "administered", "doses", "reported", "from", "the", "device", "counter", "divided", "by", "the", "number", "of", "scheduled", "doses", ".", "Self", "-", "reports", "were", "also", "used", "to", "determine", "adherence", ".", "Health", "-", "related", "quality", "of", "life", ",", "healthcare", "resource", "utilization", ",", "and", "days", "missed", "from", "work", "or", "school", "were", "also", "reported", ".", "RESULTS", "1233", "patients", "were", "randomized", ".", "The", "mean", "adherence", "rates", ",", "as", "measured", "by", "the", "automatic", "dose", "counter", ",", "were", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "(", "93.3", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "89.5", "%", ")", ".", "Mean", "adherence", "rates", "based", "on", "self", "-", "reports", "were", "also", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "QD", "PM", "(", "97.2", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "95.3", "%", ")", ".", "Adherence", "rates", "were", "lower", "in", "adolescents", "(", "12", "-", "17", "years", "old", ")", ".", "Health", "-", "related", "quality", "of", "life", "improved", "by", "20", "%", "in", "patients", "using", "MF", "-", "DPI", "once", "-", "daily", "in", "the", "evening", "and", "by", "14", "%", "in", "patients", "using", "MF", "-", "DPI", "twice", "-", "daily", ".", "Very", "few", "(", "<", "8", "%", ")", "patients", "missed", "work", "/", "school", ".", "CONCLUSION", "Mean", "adherence", "rates", "were", "greater", "with", "a", "once", "-", "daily", "dosing", "regimen", "of", "MF", "-", "DPI", "than", "with", "a", "twice", "-", "daily", "dosing", "regimen", ".", "This", "trial", "was", "completed", "prior", "to", "the", "ISMJE", "requirements", "for", "trial", "registration", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Age", "Participant_Sample-size" ]
cystic fibrosis transmembrane conductance regulator is a Gene, CFTR is a Gene	421_task0	Sentence: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene.	[ "Mutations", "and", "sequence", "variations", "detected", "in", "the", "cystic", "fibrosis", "transmembrane", "conductance", "regulator", "(", "CFTR", ")", "gene", ":", "a", "report", "from", "the", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "Cystic", "fibrosis", "is", "the", "most", "common", "autosomal", "disorder", "in", "the", "Caucasian", "population", ".", "Since", "the", "description", "of", "the", "major", "mutation", "of", "this", "disease", "in", "1989", ",", "over", "150", "of", "additional", "mutations", "have", "been", "identified", "in", "the", "CFTR", "gene", ".", "This", "update", "summarizes", "the", "different", "mutations", "identified", "and", "reported", "before", "March", "15", "by", "members", "of", "the", "international", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "The", "report", "includes", "information", "on", "DNA", "sequence", "variations", "found", "in", "the", "gene", ".", "\n" ]	[ "Gene" ]
cystic fibrosis transmembrane conductance regulator is a Gene, CFTR is a Gene	421_task1	Sentence: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene. Instructions: please typing these entity words according to sentence: cystic fibrosis transmembrane conductance regulator, CFTR Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene.	[ "Mutations", "and", "sequence", "variations", "detected", "in", "the", "cystic", "fibrosis", "transmembrane", "conductance", "regulator", "(", "CFTR", ")", "gene", ":", "a", "report", "from", "the", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "Cystic", "fibrosis", "is", "the", "most", "common", "autosomal", "disorder", "in", "the", "Caucasian", "population", ".", "Since", "the", "description", "of", "the", "major", "mutation", "of", "this", "disease", "in", "1989", ",", "over", "150", "of", "additional", "mutations", "have", "been", "identified", "in", "the", "CFTR", "gene", ".", "This", "update", "summarizes", "the", "different", "mutations", "identified", "and", "reported", "before", "March", "15", "by", "members", "of", "the", "international", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "The", "report", "includes", "information", "on", "DNA", "sequence", "variations", "found", "in", "the", "gene", ".", "\n" ]	[ "Gene" ]
cystic fibrosis transmembrane conductance regulator, CFTR	421_task2	Sentence: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene.	[ "Mutations", "and", "sequence", "variations", "detected", "in", "the", "cystic", "fibrosis", "transmembrane", "conductance", "regulator", "(", "CFTR", ")", "gene", ":", "a", "report", "from", "the", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "Cystic", "fibrosis", "is", "the", "most", "common", "autosomal", "disorder", "in", "the", "Caucasian", "population", ".", "Since", "the", "description", "of", "the", "major", "mutation", "of", "this", "disease", "in", "1989", ",", "over", "150", "of", "additional", "mutations", "have", "been", "identified", "in", "the", "CFTR", "gene", ".", "This", "update", "summarizes", "the", "different", "mutations", "identified", "and", "reported", "before", "March", "15", "by", "members", "of", "the", "international", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "The", "report", "includes", "information", "on", "DNA", "sequence", "variations", "found", "in", "the", "gene", ".", "\n" ]	[ "Gene" ]
amiodarona is a NORMALIZABLES, dicumarínicos is a NORMALIZABLES, GGT is a PROTEINAS, FA is a PROTEINAS, O2 is a NORMALIZABLES, urea is a NORMALIZABLES, creatinina is a NORMALIZABLES, bilirrubina is a NORMALIZABLES, AST is a PROTEINAS, ALT is a PROTEINAS, GGT is a PROTEINAS, dopamina is a NORMALIZABLES, piperacilina / tazobactam is a NORMALIZABLES, vancomicina is a NORMALIZABLES, gentamicina is a NORMALIZABLES	178_task0	Sentence: Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico.	[ "Se", "trata", "de", "una", "señora", "de", "76", "años", ",", "que", "ingresa", "en", "el", "Servicio", "de", "Cirugía", "Vascular", "por", "un", "síndrome", "postflebítico", ".", "Durante", "su", "estancia", "en", "planta", "presenta", "deterioro", "clínico", ",", "motivo", "por", "el", "que", "se", "traslada", "a", "UCI", "el", "10/5/03", "en", "situación", "de", "sepsis", "grave", ".", "\n", "Como", "antecedentes", "de", "interés", "destaca", "HTA", ",", "obesidad", ",", "artrosis", "y", "resección", "de", "adenoma", "tubular", "de", "colón", ".", "En", "agosto", "de", "2000", "se", "intervino", "de", "colecistectomía", "por", "colecistitis", "litiásica", "con", "importante", "plastrón", "inflamatorio", "subhepático", "que", "obligó", "a", "una", "resección", "subtotal", "de", "la", "vesícula", ".", "En", "ese", "ingreso", "desarrolló", "TVP", "de", "EII", "con", "TEP", "posterior", "y", "fibrilación", "auricular", ",", "iniciando", "tratamiento", "con", "amiodarona", "y", "dicumarínicos", ".", "En", "estudio", "ambulatorio", "el", "último", "mes", "por", "clínica", "digestiva", "inespecífica", "observando", "en", "control", "analítico", "elevación", "de", "GGT", "y", "FA", ".", "\n", "A", "la", "exploración", "en", "UCI", "estaba", "estuporosa", ",", "ictérica", "y", "con", "hipotensión", "arterial", ".", "Saturación", "de", "O2", "conservada", "con", "mascarilla", ".", "Auscultación", "cardiaca", "rítmica", "a", "80", "lpm", ",", "sin", "soplos", ".", "Auscultación", "pulmonar", "normal", ".", "El", "abdomen", "era", "globuloso", ",", "doloroso", "a", "la", "palpación", "en", "hemiabdomen", "derecho", ",", "aunque", "sin", "signos", "de", "irritación", "peritoneal", "y", "la", "EII", "mostraba", "buena", "evolución", "de", "su", "trombosis", ".", "\n", "En", "analítica", "destacaba", "leucocitosis", "(", "37.000", "/", "mm3", ")", "con", "neutrofilia", ",", "urea", "1,83", "g", "/", "l", ",", "creatinina", "4,2", "mg", "/", "dl", "bilirrubina", "total", "8,6", "mg", "/", "dl", ",", "con", "fracción", "directa", "de", "5,7", "mg", "/", "dl", ",", "AST", "312", "U", "/", "l", ",", "ALT", "106", "U", "/", "l", ",", "GGT", "416", "U", "/", "l.", "Con", "el", "diagnóstico", "de", "sepsis", "de", "origen", "biliar", ",", "se", "inicia", "tratamiento", "con", "fluidoterapia", ",", "dopamina", "y", "antibiótico", "empírico", "con", "piperacilina", "/", "tazobactam", "obteniendo", "buena", "respuesta", "inicial", ".", "\n", "Pruebas", "complementarias", "realizadas", ":", "TAC", "-", "abdominal", "(", "11/5/03", ")", "que", "evidencia", "múltiples", "imágenes", "hipodensas", "en", "parénquima", "hepático", "que", "sugerían", "abscesos", ".", "Ecocardiograma", "transtorácico", "y", "transesofágico", ",", "que", "confirmó", "la", "existencia", "de", "endocarditis", "a", "nivel", "subvalvular", "mitral", "que", "condicionaba", "insuficiencia", "grado", "II", ".", "Tras", "este", "hallazgo", "se", "añadió", "vancomicina", "y", "gentamicina", "al", "tratamiento", "antibiótico", ".", "PAAF", "de", "una", "lesión", "hepática", ".", "ERCP", "que", "no", "observó", "dilatación", "de", "via", "biliar", ",", "aunque", "se", "realizó", "papilotomía", "para", "asegurar", "el", "drenaje", "biliar", ".", "La", "evolución", "posterior", "fue", "desfavorable", "con", "instauración", "de", "SDMO", "refractario", "y", "exitus", "a", "las", "96", "horas", "de", "su", "ingreso", "en", "UCI", ".", "\n", "Soliciamos", "necropsia", "que", "reveló", "colangiocarcinoma", "multicéntrico", ",", "con", "múltiples", "nódulos", "en", "todo", "el", "órgano", ",", "extensión", "local", "al", "lecho", "vesicular", "y", "a", "vías", "biliares", "extrahepáticas", ",", "metástasis", "regionales", "a", "ganglios", "linfáticos", "del", "hilio", "hepático", "y", "a", "distancia", ",", "manifestadas", "por", "focos", "microscópicos", "a", "nivel", "pulmonar", ".", "\n\n", "Asimismo", "se", "observaba", "extensa", "necrosis", "intratumoral", "con", "sobreinfección", "por", "Enterobacter", "cloacae", ",", "también", "aislado", "en", "sangre", "y", "muestra", "de", "PAAF", ",", "lo", "que", "nos", "hace", "suponer", "que", "fue", "el", "germen", "responsable", "del", "cuadro", "séptico", ".", "\n\n" ]	[ "NORMALIZABLES", "PROTEINAS" ]
amiodarona is a NORMALIZABLES, dicumarínicos is a NORMALIZABLES, GGT is a PROTEINAS, FA is a PROTEINAS, O2 is a NORMALIZABLES, urea is a NORMALIZABLES, creatinina is a NORMALIZABLES, bilirrubina is a NORMALIZABLES, AST is a PROTEINAS, ALT is a PROTEINAS, GGT is a PROTEINAS, dopamina is a NORMALIZABLES, piperacilina / tazobactam is a NORMALIZABLES, vancomicina is a NORMALIZABLES, gentamicina is a NORMALIZABLES	178_task1	Sentence: Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico. Instructions: please typing these entity words according to sentence: amiodarona, dicumarínicos, GGT, FA, O2, urea, creatinina, bilirrubina, AST, ALT, GGT, dopamina, piperacilina / tazobactam, vancomicina, gentamicina Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico.	[ "Se", "trata", "de", "una", "señora", "de", "76", "años", ",", "que", "ingresa", "en", "el", "Servicio", "de", "Cirugía", "Vascular", "por", "un", "síndrome", "postflebítico", ".", "Durante", "su", "estancia", "en", "planta", "presenta", "deterioro", "clínico", ",", "motivo", "por", "el", "que", "se", "traslada", "a", "UCI", "el", "10/5/03", "en", "situación", "de", "sepsis", "grave", ".", "\n", "Como", "antecedentes", "de", "interés", "destaca", "HTA", ",", "obesidad", ",", "artrosis", "y", "resección", "de", "adenoma", "tubular", "de", "colón", ".", "En", "agosto", "de", "2000", "se", "intervino", "de", "colecistectomía", "por", "colecistitis", "litiásica", "con", "importante", "plastrón", "inflamatorio", "subhepático", "que", "obligó", "a", "una", "resección", "subtotal", "de", "la", "vesícula", ".", "En", "ese", "ingreso", "desarrolló", "TVP", "de", "EII", "con", "TEP", "posterior", "y", "fibrilación", "auricular", ",", "iniciando", "tratamiento", "con", "amiodarona", "y", "dicumarínicos", ".", "En", "estudio", "ambulatorio", "el", "último", "mes", "por", "clínica", "digestiva", "inespecífica", "observando", "en", "control", "analítico", "elevación", "de", "GGT", "y", "FA", ".", "\n", "A", "la", "exploración", "en", "UCI", "estaba", "estuporosa", ",", "ictérica", "y", "con", "hipotensión", "arterial", ".", "Saturación", "de", "O2", "conservada", "con", "mascarilla", ".", "Auscultación", "cardiaca", "rítmica", "a", "80", "lpm", ",", "sin", "soplos", ".", "Auscultación", "pulmonar", "normal", ".", "El", "abdomen", "era", "globuloso", ",", "doloroso", "a", "la", "palpación", "en", "hemiabdomen", "derecho", ",", "aunque", "sin", "signos", "de", "irritación", "peritoneal", "y", "la", "EII", "mostraba", "buena", "evolución", "de", "su", "trombosis", ".", "\n", "En", "analítica", "destacaba", "leucocitosis", "(", "37.000", "/", "mm3", ")", "con", "neutrofilia", ",", "urea", "1,83", "g", "/", "l", ",", "creatinina", "4,2", "mg", "/", "dl", "bilirrubina", "total", "8,6", "mg", "/", "dl", ",", "con", "fracción", "directa", "de", "5,7", "mg", "/", "dl", ",", "AST", "312", "U", "/", "l", ",", "ALT", "106", "U", "/", "l", ",", "GGT", "416", "U", "/", "l.", "Con", "el", "diagnóstico", "de", "sepsis", "de", "origen", "biliar", ",", "se", "inicia", "tratamiento", "con", "fluidoterapia", ",", "dopamina", "y", "antibiótico", "empírico", "con", "piperacilina", "/", "tazobactam", "obteniendo", "buena", "respuesta", "inicial", ".", "\n", "Pruebas", "complementarias", "realizadas", ":", "TAC", "-", "abdominal", "(", "11/5/03", ")", "que", "evidencia", "múltiples", "imágenes", "hipodensas", "en", "parénquima", "hepático", "que", "sugerían", "abscesos", ".", "Ecocardiograma", "transtorácico", "y", "transesofágico", ",", "que", "confirmó", "la", "existencia", "de", "endocarditis", "a", "nivel", "subvalvular", "mitral", "que", "condicionaba", "insuficiencia", "grado", "II", ".", "Tras", "este", "hallazgo", "se", "añadió", "vancomicina", "y", "gentamicina", "al", "tratamiento", "antibiótico", ".", "PAAF", "de", "una", "lesión", "hepática", ".", "ERCP", "que", "no", "observó", "dilatación", "de", "via", "biliar", ",", "aunque", "se", "realizó", "papilotomía", "para", "asegurar", "el", "drenaje", "biliar", ".", "La", "evolución", "posterior", "fue", "desfavorable", "con", "instauración", "de", "SDMO", "refractario", "y", "exitus", "a", "las", "96", "horas", "de", "su", "ingreso", "en", "UCI", ".", "\n", "Soliciamos", "necropsia", "que", "reveló", "colangiocarcinoma", "multicéntrico", ",", "con", "múltiples", "nódulos", "en", "todo", "el", "órgano", ",", "extensión", "local", "al", "lecho", "vesicular", "y", "a", "vías", "biliares", "extrahepáticas", ",", "metástasis", "regionales", "a", "ganglios", "linfáticos", "del", "hilio", "hepático", "y", "a", "distancia", ",", "manifestadas", "por", "focos", "microscópicos", "a", "nivel", "pulmonar", ".", "\n\n", "Asimismo", "se", "observaba", "extensa", "necrosis", "intratumoral", "con", "sobreinfección", "por", "Enterobacter", "cloacae", ",", "también", "aislado", "en", "sangre", "y", "muestra", "de", "PAAF", ",", "lo", "que", "nos", "hace", "suponer", "que", "fue", "el", "germen", "responsable", "del", "cuadro", "séptico", ".", "\n\n" ]	[ "NORMALIZABLES", "PROTEINAS" ]
amiodarona, dicumarínicos, GGT, FA, O2, urea, creatinina, bilirrubina, AST, ALT, GGT, dopamina, piperacilina / tazobactam, vancomicina, gentamicina	178_task2	Sentence: Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico.	[ "Se", "trata", "de", "una", "señora", "de", "76", "años", ",", "que", "ingresa", "en", "el", "Servicio", "de", "Cirugía", "Vascular", "por", "un", "síndrome", "postflebítico", ".", "Durante", "su", "estancia", "en", "planta", "presenta", "deterioro", "clínico", ",", "motivo", "por", "el", "que", "se", "traslada", "a", "UCI", "el", "10/5/03", "en", "situación", "de", "sepsis", "grave", ".", "\n", "Como", "antecedentes", "de", "interés", "destaca", "HTA", ",", "obesidad", ",", "artrosis", "y", "resección", "de", "adenoma", "tubular", "de", "colón", ".", "En", "agosto", "de", "2000", "se", "intervino", "de", "colecistectomía", "por", "colecistitis", "litiásica", "con", "importante", "plastrón", "inflamatorio", "subhepático", "que", "obligó", "a", "una", "resección", "subtotal", "de", "la", "vesícula", ".", "En", "ese", "ingreso", "desarrolló", "TVP", "de", "EII", "con", "TEP", "posterior", "y", "fibrilación", "auricular", ",", "iniciando", "tratamiento", "con", "amiodarona", "y", "dicumarínicos", ".", "En", "estudio", "ambulatorio", "el", "último", "mes", "por", "clínica", "digestiva", "inespecífica", "observando", "en", "control", "analítico", "elevación", "de", "GGT", "y", "FA", ".", "\n", "A", "la", "exploración", "en", "UCI", "estaba", "estuporosa", ",", "ictérica", "y", "con", "hipotensión", "arterial", ".", "Saturación", "de", "O2", "conservada", "con", "mascarilla", ".", "Auscultación", "cardiaca", "rítmica", "a", "80", "lpm", ",", "sin", "soplos", ".", "Auscultación", "pulmonar", "normal", ".", "El", "abdomen", "era", "globuloso", ",", "doloroso", "a", "la", "palpación", "en", "hemiabdomen", "derecho", ",", "aunque", "sin", "signos", "de", "irritación", "peritoneal", "y", "la", "EII", "mostraba", "buena", "evolución", "de", "su", "trombosis", ".", "\n", "En", "analítica", "destacaba", "leucocitosis", "(", "37.000", "/", "mm3", ")", "con", "neutrofilia", ",", "urea", "1,83", "g", "/", "l", ",", "creatinina", "4,2", "mg", "/", "dl", "bilirrubina", "total", "8,6", "mg", "/", "dl", ",", "con", "fracción", "directa", "de", "5,7", "mg", "/", "dl", ",", "AST", "312", "U", "/", "l", ",", "ALT", "106", "U", "/", "l", ",", "GGT", "416", "U", "/", "l.", "Con", "el", "diagnóstico", "de", "sepsis", "de", "origen", "biliar", ",", "se", "inicia", "tratamiento", "con", "fluidoterapia", ",", "dopamina", "y", "antibiótico", "empírico", "con", "piperacilina", "/", "tazobactam", "obteniendo", "buena", "respuesta", "inicial", ".", "\n", "Pruebas", "complementarias", "realizadas", ":", "TAC", "-", "abdominal", "(", "11/5/03", ")", "que", "evidencia", "múltiples", "imágenes", "hipodensas", "en", "parénquima", "hepático", "que", "sugerían", "abscesos", ".", "Ecocardiograma", "transtorácico", "y", "transesofágico", ",", "que", "confirmó", "la", "existencia", "de", "endocarditis", "a", "nivel", "subvalvular", "mitral", "que", "condicionaba", "insuficiencia", "grado", "II", ".", "Tras", "este", "hallazgo", "se", "añadió", "vancomicina", "y", "gentamicina", "al", "tratamiento", "antibiótico", ".", "PAAF", "de", "una", "lesión", "hepática", ".", "ERCP", "que", "no", "observó", "dilatación", "de", "via", "biliar", ",", "aunque", "se", "realizó", "papilotomía", "para", "asegurar", "el", "drenaje", "biliar", ".", "La", "evolución", "posterior", "fue", "desfavorable", "con", "instauración", "de", "SDMO", "refractario", "y", "exitus", "a", "las", "96", "horas", "de", "su", "ingreso", "en", "UCI", ".", "\n", "Soliciamos", "necropsia", "que", "reveló", "colangiocarcinoma", "multicéntrico", ",", "con", "múltiples", "nódulos", "en", "todo", "el", "órgano", ",", "extensión", "local", "al", "lecho", "vesicular", "y", "a", "vías", "biliares", "extrahepáticas", ",", "metástasis", "regionales", "a", "ganglios", "linfáticos", "del", "hilio", "hepático", "y", "a", "distancia", ",", "manifestadas", "por", "focos", "microscópicos", "a", "nivel", "pulmonar", ".", "\n\n", "Asimismo", "se", "observaba", "extensa", "necrosis", "intratumoral", "con", "sobreinfección", "por", "Enterobacter", "cloacae", ",", "también", "aislado", "en", "sangre", "y", "muestra", "de", "PAAF", ",", "lo", "que", "nos", "hace", "suponer", "que", "fue", "el", "germen", "responsable", "del", "cuadro", "séptico", ".", "\n\n" ]	[ "NORMALIZABLES", "PROTEINAS" ]
iodine dose is a Intervention_Pharmacological, aortic and hepatic enhancement at multidetector CT : is a Participant_Condition, total body weight ( TBW ) is a Outcome_Physical, lean body weight ( LBW ) is a Outcome_Physical, estimated blood volume ( BV ) is a Outcome_Physical, One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen is a Participant_Condition, correlation coefficients is a Outcome_Physical, correlation of change in CT number per gram is a Outcome_Physical, Adjusted MHE is a Outcome_Physical	43456_task0	Sentence: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability .	[ "Body", "size", "indexes", "for", "optimizing", "iodine", "dose", "for", "aortic", "and", "hepatic", "enhancement", "at", "multidetector", "CT", ":", "comparison", "of", "total", "body", "weight", ",", "lean", "body", "weight", ",", "and", "blood", "volume", ".", "PURPOSE", "To", "evaluate", "and", "compare", "total", "body", "weight", "(", "TBW", ")", ",", "lean", "body", "weight", "(", "LBW", ")", ",", "and", "estimated", "blood", "volume", "(", "BV", ")", "for", "the", "adjustment", "of", "the", "iodine", "dose", "required", "for", "contrast", "material", "-", "enhanced", "multidetector", "computed", "tomography", "(", "CT", ")", "of", "the", "aorta", "and", "liver", ".", "MATERIALS", "AND", "METHODS", "Institutional", "review", "committee", "approval", "and", "written", "informed", "consent", "were", "obtained", ".", "One", "hundred", "twenty", "patients", "(", "54", "men", ",", "66", "women", ";", "mean", "age", ",", "64.1", "years", ";", "range", ",", "19", "-", "88", "years", ")", "who", "underwent", "multidetector", "CT", "of", "the", "upper", "abdomen", "were", "randomized", "into", "three", "groups", "of", "40", "patients", "each", ":", "(", "a", ")", "TBW", "group", "(", "0.6", "g", "of", "iodine", "per", "kilogram", "of", "TBW", ")", ",", "(", "b", ")", "LBW", "group", "(", "0.821", "g", "of", "iodine", "per", "kilogram", "of", "LBW", ")", ",", "and", "(", "c", ")", "BV", "group", "(", "men", ",", "8.6", "g", "of", "iodine", "per", "liter", "of", "BV", ";", "women", ",", "9.9", "g", "of", "iodine", "per", "liter", "of", "BV", ")", ".", "Change", "in", "CT", "number", "between", "unenhanced", "and", "contrast", "-", "enhanced", "images", "per", "gram", "of", "iodine", "and", "maximum", "hepatic", "enhancement", "(", "MHE", ")", "adjusted", "for", "iodine", "dose", "were", "examined", "for", "correlation", "with", "TBW", ",", "LBW", ",", "and", "BV", "by", "using", "linear", "regression", "analysis", ".", "RESULTS", "In", "the", "portal", "venous", "phase", ",", "correlation", "coefficients", "for", "the", "correlation", "of", "change", "in", "CT", "number", "per", "gram", "of", "iodine", "with", "TBW", "for", "the", "aorta", "and", "liver", "were", "-0.71", "and", "-0.79", ",", "respectively", ",", "in", "the", "TBW", "group", ";", "-0.80", "and", "-0.86", ",", "respectively", ",", "in", "the", "LBW", "group", ";", "and", "-0.68", "and", "-0.66", ",", "respectively", ",", "in", "the", "BV", "group", ".", "In", "the", "liver", ",", "they", "were", "marginally", "higher", "in", "the", "LBW", "group", "than", "in", "the", "BV", "group", "(", "P", "=", ".03", ")", ".", "Adjusted", "MHE", "remained", "constant", "at", "77.9", "HU", "+", "/-", "10.2", "(", "standard", "deviation", ")", "in", "the", "LBW", "group", "with", "respect", "to", "TBW", ",", "but", "it", "increased", "in", "the", "TBW", "(", "r", "=", "0.80", ",", "P", "<", ".001", ")", "and", "BV", "(", "r", "=", "0.70", ",", "P", "<", ".001", ")", "groups", "as", "TBW", "increased", ".", "CONCLUSION", "When", "LBW", ",", "rather", "than", "TBW", "or", "BV", ",", "is", "used", ",", "the", "iodine", "dose", "required", "to", "achieve", "consistent", "hepatic", "enhancement", "may", "be", "estimated", "more", "precisely", "and", "with", "reduced", "patient", "-", "to", "-", "patient", "variability", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological" ]
iodine dose is a Intervention_Pharmacological, aortic and hepatic enhancement at multidetector CT : is a Participant_Condition, total body weight ( TBW ) is a Outcome_Physical, lean body weight ( LBW ) is a Outcome_Physical, estimated blood volume ( BV ) is a Outcome_Physical, One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen is a Participant_Condition, correlation coefficients is a Outcome_Physical, correlation of change in CT number per gram is a Outcome_Physical, Adjusted MHE is a Outcome_Physical	43456_task1	Sentence: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability . Instructions: please typing these entity words according to sentence: iodine dose, aortic and hepatic enhancement at multidetector CT :, total body weight ( TBW ), lean body weight ( LBW ), estimated blood volume ( BV ), One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen, correlation coefficients, correlation of change in CT number per gram, Adjusted MHE Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability .	[ "Body", "size", "indexes", "for", "optimizing", "iodine", "dose", "for", "aortic", "and", "hepatic", "enhancement", "at", "multidetector", "CT", ":", "comparison", "of", "total", "body", "weight", ",", "lean", "body", "weight", ",", "and", "blood", "volume", ".", "PURPOSE", "To", "evaluate", "and", "compare", "total", "body", "weight", "(", "TBW", ")", ",", "lean", "body", "weight", "(", "LBW", ")", ",", "and", "estimated", "blood", "volume", "(", "BV", ")", "for", "the", "adjustment", "of", "the", "iodine", "dose", "required", "for", "contrast", "material", "-", "enhanced", "multidetector", "computed", "tomography", "(", "CT", ")", "of", "the", "aorta", "and", "liver", ".", "MATERIALS", "AND", "METHODS", "Institutional", "review", "committee", "approval", "and", "written", "informed", "consent", "were", "obtained", ".", "One", "hundred", "twenty", "patients", "(", "54", "men", ",", "66", "women", ";", "mean", "age", ",", "64.1", "years", ";", "range", ",", "19", "-", "88", "years", ")", "who", "underwent", "multidetector", "CT", "of", "the", "upper", "abdomen", "were", "randomized", "into", "three", "groups", "of", "40", "patients", "each", ":", "(", "a", ")", "TBW", "group", "(", "0.6", "g", "of", "iodine", "per", "kilogram", "of", "TBW", ")", ",", "(", "b", ")", "LBW", "group", "(", "0.821", "g", "of", "iodine", "per", "kilogram", "of", "LBW", ")", ",", "and", "(", "c", ")", "BV", "group", "(", "men", ",", "8.6", "g", "of", "iodine", "per", "liter", "of", "BV", ";", "women", ",", "9.9", "g", "of", "iodine", "per", "liter", "of", "BV", ")", ".", "Change", "in", "CT", "number", "between", "unenhanced", "and", "contrast", "-", "enhanced", "images", "per", "gram", "of", "iodine", "and", "maximum", "hepatic", "enhancement", "(", "MHE", ")", "adjusted", "for", "iodine", "dose", "were", "examined", "for", "correlation", "with", "TBW", ",", "LBW", ",", "and", "BV", "by", "using", "linear", "regression", "analysis", ".", "RESULTS", "In", "the", "portal", "venous", "phase", ",", "correlation", "coefficients", "for", "the", "correlation", "of", "change", "in", "CT", "number", "per", "gram", "of", "iodine", "with", "TBW", "for", "the", "aorta", "and", "liver", "were", "-0.71", "and", "-0.79", ",", "respectively", ",", "in", "the", "TBW", "group", ";", "-0.80", "and", "-0.86", ",", "respectively", ",", "in", "the", "LBW", "group", ";", "and", "-0.68", "and", "-0.66", ",", "respectively", ",", "in", "the", "BV", "group", ".", "In", "the", "liver", ",", "they", "were", "marginally", "higher", "in", "the", "LBW", "group", "than", "in", "the", "BV", "group", "(", "P", "=", ".03", ")", ".", "Adjusted", "MHE", "remained", "constant", "at", "77.9", "HU", "+", "/-", "10.2", "(", "standard", "deviation", ")", "in", "the", "LBW", "group", "with", "respect", "to", "TBW", ",", "but", "it", "increased", "in", "the", "TBW", "(", "r", "=", "0.80", ",", "P", "<", ".001", ")", "and", "BV", "(", "r", "=", "0.70", ",", "P", "<", ".001", ")", "groups", "as", "TBW", "increased", ".", "CONCLUSION", "When", "LBW", ",", "rather", "than", "TBW", "or", "BV", ",", "is", "used", ",", "the", "iodine", "dose", "required", "to", "achieve", "consistent", "hepatic", "enhancement", "may", "be", "estimated", "more", "precisely", "and", "with", "reduced", "patient", "-", "to", "-", "patient", "variability", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological" ]
iodine dose, aortic and hepatic enhancement at multidetector CT :, total body weight ( TBW ), lean body weight ( LBW ), estimated blood volume ( BV ), One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen, correlation coefficients, correlation of change in CT number per gram, Adjusted MHE	43456_task2	Sentence: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability .	[ "Body", "size", "indexes", "for", "optimizing", "iodine", "dose", "for", "aortic", "and", "hepatic", "enhancement", "at", "multidetector", "CT", ":", "comparison", "of", "total", "body", "weight", ",", "lean", "body", "weight", ",", "and", "blood", "volume", ".", "PURPOSE", "To", "evaluate", "and", "compare", "total", "body", "weight", "(", "TBW", ")", ",", "lean", "body", "weight", "(", "LBW", ")", ",", "and", "estimated", "blood", "volume", "(", "BV", ")", "for", "the", "adjustment", "of", "the", "iodine", "dose", "required", "for", "contrast", "material", "-", "enhanced", "multidetector", "computed", "tomography", "(", "CT", ")", "of", "the", "aorta", "and", "liver", ".", "MATERIALS", "AND", "METHODS", "Institutional", "review", "committee", "approval", "and", "written", "informed", "consent", "were", "obtained", ".", "One", "hundred", "twenty", "patients", "(", "54", "men", ",", "66", "women", ";", "mean", "age", ",", "64.1", "years", ";", "range", ",", "19", "-", "88", "years", ")", "who", "underwent", "multidetector", "CT", "of", "the", "upper", "abdomen", "were", "randomized", "into", "three", "groups", "of", "40", "patients", "each", ":", "(", "a", ")", "TBW", "group", "(", "0.6", "g", "of", "iodine", "per", "kilogram", "of", "TBW", ")", ",", "(", "b", ")", "LBW", "group", "(", "0.821", "g", "of", "iodine", "per", "kilogram", "of", "LBW", ")", ",", "and", "(", "c", ")", "BV", "group", "(", "men", ",", "8.6", "g", "of", "iodine", "per", "liter", "of", "BV", ";", "women", ",", "9.9", "g", "of", "iodine", "per", "liter", "of", "BV", ")", ".", "Change", "in", "CT", "number", "between", "unenhanced", "and", "contrast", "-", "enhanced", "images", "per", "gram", "of", "iodine", "and", "maximum", "hepatic", "enhancement", "(", "MHE", ")", "adjusted", "for", "iodine", "dose", "were", "examined", "for", "correlation", "with", "TBW", ",", "LBW", ",", "and", "BV", "by", "using", "linear", "regression", "analysis", ".", "RESULTS", "In", "the", "portal", "venous", "phase", ",", "correlation", "coefficients", "for", "the", "correlation", "of", "change", "in", "CT", "number", "per", "gram", "of", "iodine", "with", "TBW", "for", "the", "aorta", "and", "liver", "were", "-0.71", "and", "-0.79", ",", "respectively", ",", "in", "the", "TBW", "group", ";", "-0.80", "and", "-0.86", ",", "respectively", ",", "in", "the", "LBW", "group", ";", "and", "-0.68", "and", "-0.66", ",", "respectively", ",", "in", "the", "BV", "group", ".", "In", "the", "liver", ",", "they", "were", "marginally", "higher", "in", "the", "LBW", "group", "than", "in", "the", "BV", "group", "(", "P", "=", ".03", ")", ".", "Adjusted", "MHE", "remained", "constant", "at", "77.9", "HU", "+", "/-", "10.2", "(", "standard", "deviation", ")", "in", "the", "LBW", "group", "with", "respect", "to", "TBW", ",", "but", "it", "increased", "in", "the", "TBW", "(", "r", "=", "0.80", ",", "P", "<", ".001", ")", "and", "BV", "(", "r", "=", "0.70", ",", "P", "<", ".001", ")", "groups", "as", "TBW", "increased", ".", "CONCLUSION", "When", "LBW", ",", "rather", "than", "TBW", "or", "BV", ",", "is", "used", ",", "the", "iodine", "dose", "required", "to", "achieve", "consistent", "hepatic", "enhancement", "may", "be", "estimated", "more", "precisely", "and", "with", "reduced", "patient", "-", "to", "-", "patient", "variability", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological" ]
mast cells is a Cell, rheumatoid synovial tissue is a Tissue, mast cell is a Cell, synovial tissue is a Tissue, Synovial tissue is a Tissue, mast cells is a Cell, synovial tissue is a Tissue, tissue is a Tissue, synovia is a Tissue, synovial mast cells is a Cell, Mast cell is a Cell, CD68 positive synovial macrophages is a Cell, Synovial mast cells is a Cell	PMID-17607547_task0	Sentence: Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Cell	[ "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA.	[ "Selective", "activation", "of", "mast", "cells", "in", "rheumatoid", "synovial", "tissue", "results", "in", "production", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", ".", "\n", "OBJECTIVES", "AND", "DESIGN", ":", "\n", "To", "study", "the", "consequences", "of", "mast", "cell", "activation", "in", "human", "synovial", "tissue", ".", "\n", "METHODS", ":", "\n", "Synovial", "tissue", "was", "obtained", "from", "18", "RA", "patients", "and", "mast", "cells", "was", "selectively", "activated", "in", "synovial", "tissue", "explant", "cultures", ".", "Expression", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", "were", "determined", "and", "tissue", "distribution", "of", "IL-1beta", "was", "studied", ".", "\n", "RESULTS", ":", "\n", "Compared", "to", "untreated", "synovia", ",", "selective", "activation", "of", "synovial", "mast", "cells", "increased", "significantly", "the", "production", "of", "TNF", "-", "alpha", "(", "0.49", "+", "/-", "0.88", "vs", ".", "4.56", "+", "/-", "3.18", "pg", "/", "mg", "wet", "tissue", ",", "p", "<", "0.001", ")", "and", "IL-1beta", "(", "0.058", "+", "/-", "0.032", "vs", ".", "2.55", "+", "/-", "1.98", "pg", "/", "mg", "wet", "tissue", ",", "p", "=", "0.013", ")", ".", "The", "expression", "of", "TNF", "-", "alpha", "and", "IL-1beta", "mRNA", "increased", "significantly", "(", "19-fold", "(", "p", "=", "0.009", ")", "and", "13-fold", "(", "p", "=", "0.031", ")", ",", "respectively", ")", ".", "Mast", "cell", "activation", "induced", "IL-1beta", "expression", "in", "particular", "in", "nearby", "CD68", "positive", "synovial", "macrophages", ".", "Secretion", "of", "IL-1Ra", "was", "also", "increased", "but", "to", "a", "lesser", "degree", "than", "that", "of", "IL-1beta", ".", "\n", "CONCLUSIONS", ":", "\n", "Synovial", "mast", "cells", "produce", "proinflammmatory", "cytokines", "and", "may", "thus", "contribute", "to", "the", "inflammation", "in", "RA", ".", "\n" ]	[ "Cell", "Tissue" ]
mast cells is a Cell, rheumatoid synovial tissue is a Tissue, mast cell is a Cell, synovial tissue is a Tissue, Synovial tissue is a Tissue, mast cells is a Cell, synovial tissue is a Tissue, tissue is a Tissue, synovia is a Tissue, synovial mast cells is a Cell, Mast cell is a Cell, CD68 positive synovial macrophages is a Cell, Synovial mast cells is a Cell	PMID-17607547_task1	Sentence: Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA. Instructions: please typing these entity words according to sentence: mast cells, rheumatoid synovial tissue, mast cell, synovial tissue, Synovial tissue, mast cells, synovial tissue, tissue, synovia, synovial mast cells, Mast cell, CD68 positive synovial macrophages, Synovial mast cells Options: Tissue, Cell	[ "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA.	[ "Selective", "activation", "of", "mast", "cells", "in", "rheumatoid", "synovial", "tissue", "results", "in", "production", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", ".", "\n", "OBJECTIVES", "AND", "DESIGN", ":", "\n", "To", "study", "the", "consequences", "of", "mast", "cell", "activation", "in", "human", "synovial", "tissue", ".", "\n", "METHODS", ":", "\n", "Synovial", "tissue", "was", "obtained", "from", "18", "RA", "patients", "and", "mast", "cells", "was", "selectively", "activated", "in", "synovial", "tissue", "explant", "cultures", ".", "Expression", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", "were", "determined", "and", "tissue", "distribution", "of", "IL-1beta", "was", "studied", ".", "\n", "RESULTS", ":", "\n", "Compared", "to", "untreated", "synovia", ",", "selective", "activation", "of", "synovial", "mast", "cells", "increased", "significantly", "the", "production", "of", "TNF", "-", "alpha", "(", "0.49", "+", "/-", "0.88", "vs", ".", "4.56", "+", "/-", "3.18", "pg", "/", "mg", "wet", "tissue", ",", "p", "<", "0.001", ")", "and", "IL-1beta", "(", "0.058", "+", "/-", "0.032", "vs", ".", "2.55", "+", "/-", "1.98", "pg", "/", "mg", "wet", "tissue", ",", "p", "=", "0.013", ")", ".", "The", "expression", "of", "TNF", "-", "alpha", "and", "IL-1beta", "mRNA", "increased", "significantly", "(", "19-fold", "(", "p", "=", "0.009", ")", "and", "13-fold", "(", "p", "=", "0.031", ")", ",", "respectively", ")", ".", "Mast", "cell", "activation", "induced", "IL-1beta", "expression", "in", "particular", "in", "nearby", "CD68", "positive", "synovial", "macrophages", ".", "Secretion", "of", "IL-1Ra", "was", "also", "increased", "but", "to", "a", "lesser", "degree", "than", "that", "of", "IL-1beta", ".", "\n", "CONCLUSIONS", ":", "\n", "Synovial", "mast", "cells", "produce", "proinflammmatory", "cytokines", "and", "may", "thus", "contribute", "to", "the", "inflammation", "in", "RA", ".", "\n" ]	[ "Cell", "Tissue" ]
mast cells, rheumatoid synovial tissue, mast cell, synovial tissue, Synovial tissue, mast cells, synovial tissue, tissue, synovia, synovial mast cells, Mast cell, CD68 positive synovial macrophages, Synovial mast cells	PMID-17607547_task2	Sentence: Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA.	[ "Selective", "activation", "of", "mast", "cells", "in", "rheumatoid", "synovial", "tissue", "results", "in", "production", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", ".", "\n", "OBJECTIVES", "AND", "DESIGN", ":", "\n", "To", "study", "the", "consequences", "of", "mast", "cell", "activation", "in", "human", "synovial", "tissue", ".", "\n", "METHODS", ":", "\n", "Synovial", "tissue", "was", "obtained", "from", "18", "RA", "patients", "and", "mast", "cells", "was", "selectively", "activated", "in", "synovial", "tissue", "explant", "cultures", ".", "Expression", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", "were", "determined", "and", "tissue", "distribution", "of", "IL-1beta", "was", "studied", ".", "\n", "RESULTS", ":", "\n", "Compared", "to", "untreated", "synovia", ",", "selective", "activation", "of", "synovial", "mast", "cells", "increased", "significantly", "the", "production", "of", "TNF", "-", "alpha", "(", "0.49", "+", "/-", "0.88", "vs", ".", "4.56", "+", "/-", "3.18", "pg", "/", "mg", "wet", "tissue", ",", "p", "<", "0.001", ")", "and", "IL-1beta", "(", "0.058", "+", "/-", "0.032", "vs", ".", "2.55", "+", "/-", "1.98", "pg", "/", "mg", "wet", "tissue", ",", "p", "=", "0.013", ")", ".", "The", "expression", "of", "TNF", "-", "alpha", "and", "IL-1beta", "mRNA", "increased", "significantly", "(", "19-fold", "(", "p", "=", "0.009", ")", "and", "13-fold", "(", "p", "=", "0.031", ")", ",", "respectively", ")", ".", "Mast", "cell", "activation", "induced", "IL-1beta", "expression", "in", "particular", "in", "nearby", "CD68", "positive", "synovial", "macrophages", ".", "Secretion", "of", "IL-1Ra", "was", "also", "increased", "but", "to", "a", "lesser", "degree", "than", "that", "of", "IL-1beta", ".", "\n", "CONCLUSIONS", ":", "\n", "Synovial", "mast", "cells", "produce", "proinflammmatory", "cytokines", "and", "may", "thus", "contribute", "to", "the", "inflammation", "in", "RA", ".", "\n" ]	[ "Cell", "Tissue" ]

Estrogen receptor concentration, social factors, natural killer cell activity, early - stage breast cancer patients

100587_task2

Sentence: Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "O", "O", "O", "O", "O", "O" ]

Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model.

[ "Estrogen", "receptor", "concentration", "and", "social", "factors", "as", "predictors", "of", "natural", "killer", "cell", "activity", "in", "early", "-", "stage", "breast", "cancer", "patients", ".", "Confirmation", "of", "a", "model", "." ]

[ "other_name", "(AND multi_cell multi_cell)", "multi_cell", "", "protein_family_or_group", "cell_type", "tissue" ]

Kindern is an umlsterm, Patientenkollektiv is an umlsterm, Atemwegsreflexe is an umlsterm, Halothan is an umlsterm, Kindern is an umlsterm, Ethikkommission is an umlsterm, Kinder is an umlsterm, Eltern is an umlsterm, Praemedikation is an umlsterm, Konzentrationen is an umlsterm, Intubation is an umlsterm, Fluoridspiegel is an umlsterm, Blutdruck is an umlsterm, Kinder is an umlsterm, Fluoridspiegel is an umlsterm, Kinderanaesthesie is an umlsterm, Halothan is an umlsterm, Fluoridwerte is an umlsterm, Nierenfunktion is an umlsterm

DerAnaesthesist.60450022.ger.abstr_task0

Sentence: Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten .

[ "Bei", "Kindern", ",", "dem", "wesentlichen", "Patientenkollektiv", "fuer", "inhalative", "Narkoseeinleitungen", ",", "liegen", "nur", "geringe", "Erfahrungen", "mit", "dem", "vermutlich", "besonders", "geeigneten", "Sevofluran", "vor", ".", "In", "einer", "offenen", ",", "randomisierten", "Studie", "haben", "wir", "daher", "Einschlaf-", "und", "Aufwachzeiten", ",", "Atemwegsreflexe", "und", "Kreislaufwirkungen", "von", "Sevofluran", "(", "S", ")", "mit", "denen", "von", "Halothan", "(", "H", ")", "bei", "Kindern", "(", "Alter", "1", "-", "10", "Jahre", ")", "waehrend", "mindestens", "einstuendigen", "Eingriffen", "verglichen", ".", "Mit", "Zustimmung", "der", "Ethikkommission", "wurden", "40", "Kinder", "der", "Risikogruppen", "ASA", "I", "und", "II", "nach", "schriftlicher", "Einwilligung", "der", "Eltern", "rekrutiert", ".", "Die", "Narkosen", "wurden", "ohne", "Praemedikation", "mit", "ansteigenden", "Konzentrationen", "von", "S", "oder", "H", "in", "N2O", "/", "O2", "(", "65:35", ")", "induziert", ".", "Der", "Frischgasflow", "(", "FGF", ")", "betrug", "6", "l", "/", "min", ".", "Nach", "Relaxation", "und", "Intubation", "wurden", "die", "Narkosen", "mit", "S", "(", "Fi", "2", "-", "2", ",", "4", "Vol", ".", "-%", ")", "oder", "H", "(", "1,1", "-", "1,4", "Vol-%", ")", "in", "N2O", "/", "O2", "(", "65:35", ",", "3", "l", "/", "min", ")", "weitergefuehrt", ".", "Zur", "Ausleitung", "wurde", "der", "FGF", "auf", "6", "l", "/", "min", "erhoeht", ".", "Fluoridspiegel", "wurden", "bei", "Einleitung", ",", "am", "Narkoseende", "sowie", "70", "min", "nach", "Narkose", "bestimmt", ".", "Die", "Gruppen", "waren", "biometrisch", "vergleichbar", ".", "Blutdruck", "und", "Herzfrequenz", "waren", "in", "beiden", "Gruppen", "stabil", ".", "Die", "Einschlafzeit", "betrug", "183", "+", "/-", "32", "(", "H", ")", "bzw", ".", "129", "+", "/-", "34", "s", "(", "S", ")", "(", "p", "0,01", ")", ",", "die", "Aufwachzeit", "775", "+", "/-", "314", "(", "H", ")", "bzw", ".", "468", "+", "/-", "194", "s", "(", "S", ")", "(", "p", "0,01", ")", ".", "Nach", "S", "wurden", "die", "Kinder", "4,6", "min", "frueher", "extubiert", "(", "p", "0,01", ")", ".", "Die", "Atemwegsvertraeglichkeit", "war", "bei", "beiden", "Gasen", "gut", ".", "Der", "Fluoridspiegel", "(", "S", ")", "betrug", "am", "Narkoseende", "23,1", "+", "/-", "1,2", "µmol", "/", "l", ",", "70", "min", "spaeter", "18,6", "+", "/-", "0,9", "µmol", "/", "l", "(", "p", "0,01", ")", ".", "Mit", "Sevofluran", "steht", "ein", "neues", ",", "sicheres", "Anaesthetikum", "fuer", "die", "Kinderanaesthesie", "zur", "Verfuegung", ",", "das", "bei", "vergleichbar", "geringer", "Atemwegsirritation", "wegen", "der", "hoeheren", "Induktions-", "und", "Aufwachgeschwindigkeit", "dem", "Halothan", "ueberlegen", "ist", ".", "Die", "Fluoridwerte", "unter", "S", "lassen", "eine", "wesentliche", "Beeintraechtigung", "der", "Nierenfunktion", "nicht", "erwarten", "." ]

[ "umlsterm" ]

Kindern is an umlsterm, Patientenkollektiv is an umlsterm, Atemwegsreflexe is an umlsterm, Halothan is an umlsterm, Kindern is an umlsterm, Ethikkommission is an umlsterm, Kinder is an umlsterm, Eltern is an umlsterm, Praemedikation is an umlsterm, Konzentrationen is an umlsterm, Intubation is an umlsterm, Fluoridspiegel is an umlsterm, Blutdruck is an umlsterm, Kinder is an umlsterm, Fluoridspiegel is an umlsterm, Kinderanaesthesie is an umlsterm, Halothan is an umlsterm, Fluoridwerte is an umlsterm, Nierenfunktion is an umlsterm

DerAnaesthesist.60450022.ger.abstr_task1

Sentence: Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten . Instructions: please typing these entity words according to sentence: Kindern, Patientenkollektiv, Atemwegsreflexe, Halothan, Kindern, Ethikkommission, Kinder, Eltern, Praemedikation, Konzentrationen, Intubation, Fluoridspiegel, Blutdruck, Kinder, Fluoridspiegel, Kinderanaesthesie, Halothan, Fluoridwerte, Nierenfunktion Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten .

[ "Bei", "Kindern", ",", "dem", "wesentlichen", "Patientenkollektiv", "fuer", "inhalative", "Narkoseeinleitungen", ",", "liegen", "nur", "geringe", "Erfahrungen", "mit", "dem", "vermutlich", "besonders", "geeigneten", "Sevofluran", "vor", ".", "In", "einer", "offenen", ",", "randomisierten", "Studie", "haben", "wir", "daher", "Einschlaf-", "und", "Aufwachzeiten", ",", "Atemwegsreflexe", "und", "Kreislaufwirkungen", "von", "Sevofluran", "(", "S", ")", "mit", "denen", "von", "Halothan", "(", "H", ")", "bei", "Kindern", "(", "Alter", "1", "-", "10", "Jahre", ")", "waehrend", "mindestens", "einstuendigen", "Eingriffen", "verglichen", ".", "Mit", "Zustimmung", "der", "Ethikkommission", "wurden", "40", "Kinder", "der", "Risikogruppen", "ASA", "I", "und", "II", "nach", "schriftlicher", "Einwilligung", "der", "Eltern", "rekrutiert", ".", "Die", "Narkosen", "wurden", "ohne", "Praemedikation", "mit", "ansteigenden", "Konzentrationen", "von", "S", "oder", "H", "in", "N2O", "/", "O2", "(", "65:35", ")", "induziert", ".", "Der", "Frischgasflow", "(", "FGF", ")", "betrug", "6", "l", "/", "min", ".", "Nach", "Relaxation", "und", "Intubation", "wurden", "die", "Narkosen", "mit", "S", "(", "Fi", "2", "-", "2", ",", "4", "Vol", ".", "-%", ")", "oder", "H", "(", "1,1", "-", "1,4", "Vol-%", ")", "in", "N2O", "/", "O2", "(", "65:35", ",", "3", "l", "/", "min", ")", "weitergefuehrt", ".", "Zur", "Ausleitung", "wurde", "der", "FGF", "auf", "6", "l", "/", "min", "erhoeht", ".", "Fluoridspiegel", "wurden", "bei", "Einleitung", ",", "am", "Narkoseende", "sowie", "70", "min", "nach", "Narkose", "bestimmt", ".", "Die", "Gruppen", "waren", "biometrisch", "vergleichbar", ".", "Blutdruck", "und", "Herzfrequenz", "waren", "in", "beiden", "Gruppen", "stabil", ".", "Die", "Einschlafzeit", "betrug", "183", "+", "/-", "32", "(", "H", ")", "bzw", ".", "129", "+", "/-", "34", "s", "(", "S", ")", "(", "p", "0,01", ")", ",", "die", "Aufwachzeit", "775", "+", "/-", "314", "(", "H", ")", "bzw", ".", "468", "+", "/-", "194", "s", "(", "S", ")", "(", "p", "0,01", ")", ".", "Nach", "S", "wurden", "die", "Kinder", "4,6", "min", "frueher", "extubiert", "(", "p", "0,01", ")", ".", "Die", "Atemwegsvertraeglichkeit", "war", "bei", "beiden", "Gasen", "gut", ".", "Der", "Fluoridspiegel", "(", "S", ")", "betrug", "am", "Narkoseende", "23,1", "+", "/-", "1,2", "µmol", "/", "l", ",", "70", "min", "spaeter", "18,6", "+", "/-", "0,9", "µmol", "/", "l", "(", "p", "0,01", ")", ".", "Mit", "Sevofluran", "steht", "ein", "neues", ",", "sicheres", "Anaesthetikum", "fuer", "die", "Kinderanaesthesie", "zur", "Verfuegung", ",", "das", "bei", "vergleichbar", "geringer", "Atemwegsirritation", "wegen", "der", "hoeheren", "Induktions-", "und", "Aufwachgeschwindigkeit", "dem", "Halothan", "ueberlegen", "ist", ".", "Die", "Fluoridwerte", "unter", "S", "lassen", "eine", "wesentliche", "Beeintraechtigung", "der", "Nierenfunktion", "nicht", "erwarten", "." ]

[ "umlsterm" ]

Kindern, Patientenkollektiv, Atemwegsreflexe, Halothan, Kindern, Ethikkommission, Kinder, Eltern, Praemedikation, Konzentrationen, Intubation, Fluoridspiegel, Blutdruck, Kinder, Fluoridspiegel, Kinderanaesthesie, Halothan, Fluoridwerte, Nierenfunktion

DerAnaesthesist.60450022.ger.abstr_task2

Sentence: Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Bei Kindern , dem wesentlichen Patientenkollektiv fuer inhalative Narkoseeinleitungen , liegen nur geringe Erfahrungen mit dem vermutlich besonders geeigneten Sevofluran vor . In einer offenen , randomisierten Studie haben wir daher Einschlaf- und Aufwachzeiten , Atemwegsreflexe und Kreislaufwirkungen von Sevofluran ( S ) mit denen von Halothan ( H ) bei Kindern ( Alter 1-10 Jahre ) waehrend mindestens einstuendigen Eingriffen verglichen . Mit Zustimmung der Ethikkommission wurden 40 Kinder der Risikogruppen ASA I und II nach schriftlicher Einwilligung der Eltern rekrutiert . Die Narkosen wurden ohne Praemedikation mit ansteigenden Konzentrationen von S oder H in N2O/O2 ( 65:35 ) induziert . Der Frischgasflow ( FGF ) betrug 6 l/min . Nach Relaxation und Intubation wurden die Narkosen mit S ( Fi 2-2 , 4 Vol . -%) oder H ( 1,1-1,4 Vol-%) in N2O/O2 ( 65:35 , 3 l/min ) weitergefuehrt . Zur Ausleitung wurde der FGF auf 6 l/min erhoeht . Fluoridspiegel wurden bei Einleitung , am Narkoseende sowie 70 min nach Narkose bestimmt . Die Gruppen waren biometrisch vergleichbar . Blutdruck und Herzfrequenz waren in beiden Gruppen stabil . Die Einschlafzeit betrug 183 +/- 32 ( H ) bzw. 129 +/- 34 s ( S ) ( p 0,01 ) , die Aufwachzeit 775 +/- 314 ( H ) bzw. 468 +/- 194 s ( S ) ( p 0,01 ) . Nach S wurden die Kinder 4,6 min frueher extubiert ( p 0,01 ) . Die Atemwegsvertraeglichkeit war bei beiden Gasen gut . Der Fluoridspiegel ( S ) betrug am Narkoseende 23,1 +/- 1,2 µmol/l, 70 min spaeter 18,6 +/- 0,9 µmol/l ( p 0,01 ) . Mit Sevofluran steht ein neues , sicheres Anaesthetikum fuer die Kinderanaesthesie zur Verfuegung , das bei vergleichbar geringer Atemwegsirritation wegen der hoeheren Induktions- und Aufwachgeschwindigkeit dem Halothan ueberlegen ist . Die Fluoridwerte unter S lassen eine wesentliche Beeintraechtigung der Nierenfunktion nicht erwarten .

[ "Bei", "Kindern", ",", "dem", "wesentlichen", "Patientenkollektiv", "fuer", "inhalative", "Narkoseeinleitungen", ",", "liegen", "nur", "geringe", "Erfahrungen", "mit", "dem", "vermutlich", "besonders", "geeigneten", "Sevofluran", "vor", ".", "In", "einer", "offenen", ",", "randomisierten", "Studie", "haben", "wir", "daher", "Einschlaf-", "und", "Aufwachzeiten", ",", "Atemwegsreflexe", "und", "Kreislaufwirkungen", "von", "Sevofluran", "(", "S", ")", "mit", "denen", "von", "Halothan", "(", "H", ")", "bei", "Kindern", "(", "Alter", "1", "-", "10", "Jahre", ")", "waehrend", "mindestens", "einstuendigen", "Eingriffen", "verglichen", ".", "Mit", "Zustimmung", "der", "Ethikkommission", "wurden", "40", "Kinder", "der", "Risikogruppen", "ASA", "I", "und", "II", "nach", "schriftlicher", "Einwilligung", "der", "Eltern", "rekrutiert", ".", "Die", "Narkosen", "wurden", "ohne", "Praemedikation", "mit", "ansteigenden", "Konzentrationen", "von", "S", "oder", "H", "in", "N2O", "/", "O2", "(", "65:35", ")", "induziert", ".", "Der", "Frischgasflow", "(", "FGF", ")", "betrug", "6", "l", "/", "min", ".", "Nach", "Relaxation", "und", "Intubation", "wurden", "die", "Narkosen", "mit", "S", "(", "Fi", "2", "-", "2", ",", "4", "Vol", ".", "-%", ")", "oder", "H", "(", "1,1", "-", "1,4", "Vol-%", ")", "in", "N2O", "/", "O2", "(", "65:35", ",", "3", "l", "/", "min", ")", "weitergefuehrt", ".", "Zur", "Ausleitung", "wurde", "der", "FGF", "auf", "6", "l", "/", "min", "erhoeht", ".", "Fluoridspiegel", "wurden", "bei", "Einleitung", ",", "am", "Narkoseende", "sowie", "70", "min", "nach", "Narkose", "bestimmt", ".", "Die", "Gruppen", "waren", "biometrisch", "vergleichbar", ".", "Blutdruck", "und", "Herzfrequenz", "waren", "in", "beiden", "Gruppen", "stabil", ".", "Die", "Einschlafzeit", "betrug", "183", "+", "/-", "32", "(", "H", ")", "bzw", ".", "129", "+", "/-", "34", "s", "(", "S", ")", "(", "p", "0,01", ")", ",", "die", "Aufwachzeit", "775", "+", "/-", "314", "(", "H", ")", "bzw", ".", "468", "+", "/-", "194", "s", "(", "S", ")", "(", "p", "0,01", ")", ".", "Nach", "S", "wurden", "die", "Kinder", "4,6", "min", "frueher", "extubiert", "(", "p", "0,01", ")", ".", "Die", "Atemwegsvertraeglichkeit", "war", "bei", "beiden", "Gasen", "gut", ".", "Der", "Fluoridspiegel", "(", "S", ")", "betrug", "am", "Narkoseende", "23,1", "+", "/-", "1,2", "µmol", "/", "l", ",", "70", "min", "spaeter", "18,6", "+", "/-", "0,9", "µmol", "/", "l", "(", "p", "0,01", ")", ".", "Mit", "Sevofluran", "steht", "ein", "neues", ",", "sicheres", "Anaesthetikum", "fuer", "die", "Kinderanaesthesie", "zur", "Verfuegung", ",", "das", "bei", "vergleichbar", "geringer", "Atemwegsirritation", "wegen", "der", "hoeheren", "Induktions-", "und", "Aufwachgeschwindigkeit", "dem", "Halothan", "ueberlegen", "ist", ".", "Die", "Fluoridwerte", "unter", "S", "lassen", "eine", "wesentliche", "Beeintraechtigung", "der", "Nierenfunktion", "nicht", "erwarten", "." ]

[ "umlsterm" ]

c - Fos is a protein_molecule, activated T lymphoid and monocytic cells is a (AND cell_type cell_type), human immunodeficiency virus-1 Tat protein is a protein_molecule

62883_task0

Sentence: Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: (AND cell_type cell_type), protein_molecule

[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.

[ "Upregulation", "of", "c", "-", "Fos", "in", "activated", "T", "lymphoid", "and", "monocytic", "cells", "by", "human", "immunodeficiency", "virus-1", "Tat", "protein", "." ]

[ "(AND cell_line cell_line)", "DNA_domain_or_region", "protein_molecule", "cell_type", "(AND cell_type cell_type)", "virus", "other_name", "cell_line", "DNA_molecule", "", "other_organic_compound", "polynucleotide", "protein_domain_or_region", "tissue", "RNA_molecule" ]

c - Fos is a protein_molecule, activated T lymphoid and monocytic cells is a (AND cell_type cell_type), human immunodeficiency virus-1 Tat protein is a protein_molecule

62883_task1

Sentence: Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Instructions: please typing these entity words according to sentence: c - Fos, activated T lymphoid and monocytic cells, human immunodeficiency virus-1 Tat protein Options: (AND cell_type cell_type), protein_molecule

[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.

[ "Upregulation", "of", "c", "-", "Fos", "in", "activated", "T", "lymphoid", "and", "monocytic", "cells", "by", "human", "immunodeficiency", "virus-1", "Tat", "protein", "." ]

[ "(AND cell_line cell_line)", "DNA_domain_or_region", "protein_molecule", "cell_type", "(AND cell_type cell_type)", "virus", "other_name", "cell_line", "DNA_molecule", "", "other_organic_compound", "polynucleotide", "protein_domain_or_region", "tissue", "RNA_molecule" ]

c - Fos, activated T lymphoid and monocytic cells, human immunodeficiency virus-1 Tat protein

62883_task2

Sentence: Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "I-(AND cell_type cell_type)", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.

[ "Upregulation", "of", "c", "-", "Fos", "in", "activated", "T", "lymphoid", "and", "monocytic", "cells", "by", "human", "immunodeficiency", "virus-1", "Tat", "protein", "." ]

[ "(AND cell_line cell_line)", "DNA_domain_or_region", "protein_molecule", "cell_type", "(AND cell_type cell_type)", "virus", "other_name", "cell_line", "DNA_molecule", "", "other_organic_compound", "polynucleotide", "protein_domain_or_region", "tissue", "RNA_molecule" ]

cholinesterase is a GENE-Y

11078030_task0

Sentence: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.

[ "The", "new", "cholinesterase", "inhibitors", "for", "Alzheimer", "'s", "disease", ",", "Part", "1", ":", "their", "similarities", "are", "different", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

cholinesterase is a GENE-Y

11078030_task1

Sentence: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Instructions: please typing these entity words according to sentence: cholinesterase Options: GENE-Y

[ "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.

[ "The", "new", "cholinesterase", "inhibitors", "for", "Alzheimer", "'s", "disease", ",", "Part", "1", ":", "their", "similarities", "are", "different", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

cholinesterase

11078030_task2

Sentence: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.

[ "The", "new", "cholinesterase", "inhibitors", "for", "Alzheimer", "'s", "disease", ",", "Part", "1", ":", "their", "similarities", "are", "different", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, liver cancer cell Bel-7402 ] is a Cell, fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, human is a Organism, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, P53 is a Gene_or_gene_product, Bel-7402 is a Cell, FPC is a Simple_chemical, Bel-7402 is a Cell, FPC is a Simple_chemical, chromatin is a Cellular_component, cell is a Cell, DNA is a Cellular_component, FPC is a Simple_chemical, FPC is a Simple_chemical, tumor cell is a Cell, P53 is a Gene_or_gene_product

286_task0

Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell

[ "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O" ]

[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.

[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]

[ "Simple_chemical", "Cell", "Cellular_component", "Organism", "Cancer", "Gene_or_gene_product" ]

fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, liver cancer cell Bel-7402 ] is a Cell, fungus polysaccharides compounds is a Simple_chemical, FPC is a Simple_chemical, human is a Organism, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, P53 is a Gene_or_gene_product, Bel-7402 is a Cell, FPC is a Simple_chemical, Bel-7402 is a Cell, FPC is a Simple_chemical, chromatin is a Cellular_component, cell is a Cell, DNA is a Cellular_component, FPC is a Simple_chemical, FPC is a Simple_chemical, tumor cell is a Cell, P53 is a Gene_or_gene_product

286_task1

Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please typing these entity words according to sentence: fungus polysaccharides compounds, FPC, liver cancer cell Bel-7402 ], fungus polysaccharides compounds, FPC, human, liver cancer cell Bel-7402, cell, tumor, P53, Bel-7402, FPC, Bel-7402, FPC, chromatin, cell, DNA, FPC, FPC, tumor cell, P53 Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell

[ "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O" ]

[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.

[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]

[ "Simple_chemical", "Cell", "Cellular_component", "Organism", "Cancer", "Gene_or_gene_product" ]

fungus polysaccharides compounds, FPC, liver cancer cell Bel-7402 ], fungus polysaccharides compounds, FPC, human, liver cancer cell Bel-7402, cell, tumor, P53, Bel-7402, FPC, Bel-7402, FPC, chromatin, cell, DNA, FPC, FPC, tumor cell, P53

286_task2

Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O" ]

[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.

[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]

[ "Simple_chemical", "Cell", "Cellular_component", "Organism", "Cancer", "Gene_or_gene_product" ]

Isradipine is a Intervention_Pharmacological, risk of cardiovascular events . is a Participant_Condition

770_task0

Sentence: Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition

[ "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]

Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events .

[ "Isradipine", ",", "raised", "glycosylated", "haemoglobin", ",", "and", "risk", "of", "cardiovascular", "events", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]

Isradipine is a Intervention_Pharmacological, risk of cardiovascular events . is a Participant_Condition

770_task1

Sentence: Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events . Instructions: please typing these entity words according to sentence: Isradipine, risk of cardiovascular events . Options: Intervention_Pharmacological, Participant_Condition

[ "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]

Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events .

[ "Isradipine", ",", "raised", "glycosylated", "haemoglobin", ",", "and", "risk", "of", "cardiovascular", "events", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]

Isradipine, risk of cardiovascular events .

770_task2

Sentence: Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]

Isradipine , raised glycosylated haemoglobin , and risk of cardiovascular events .

[ "Isradipine", ",", "raised", "glycosylated", "haemoglobin", ",", "and", "risk", "of", "cardiovascular", "events", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]

Facial nerve is an umlsterm, schwannomas is an umlsterm, benign tumors is an umlsterm, symptom is an umlsterm, facial nerve paralysis is an umlsterm, woman is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm, geniculate ganglion is an umlsterm, patient is an umlsterm, vertigo is an umlsterm, hearing loss is an umlsterm, facial nerve is an umlsterm, tumor is an umlsterm, computed tomography is an umlsterm, magnetic resonance imaging is an umlsterm, schwannoma is an umlsterm, facial nerve is an umlsterm, knowledge is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm

HNO.90470279.eng.abstr_task0

Sentence: Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve .

[ "Facial", "nerve", "schwannomas", "are", "rare", "benign", "tumors", ",", "when", "occurring", ",", "they", "are", "located", "most", "frequently", "in", "the", "distal", "fallopian", "canal", "and", "present", "as", "extracranial", "masses", ".", "The", "predominant", "symptom", "is", "a", "progressive", "facial", "nerve", "paralysis", ".", "We", "report", "a", "20-year", "-", "old", "woman", "with", "an", "intracranial", "schwannoma", "originating", "from", "the", "greater", "superficial", "petrosal", "nerve", "that", "had", "wide", "extension", "into", "the", "pterygopalatine", "fossa", ".", "The", "motor", "facial", "nerve", "including", "the", "geniculate", "ganglion", "was", "not", "affected", ".", "The", "patient", "presented", "with", "vertigo", ",", "progressive", "hearing", "loss", "and", "mild", "facial", "nerve", "synkinesis", "but", "without", "a", "lacrimation", "deficit", ".", "The", "tumor", "was", "detected", "by", "computed", "tomography", "and", "magnetic", "resonance", "imaging", ".", "The", "schwannoma", "was", "completely", "removed", "using", "an", "intracranial", ",", "extradural", "middle", "fossa", "approach", "during", "which", "complete", "preservation", "of", "the", "motor", "facial", "nerve", "was", "possible", ".", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "an", "isolated", "schwannoma", "of", "the", "greater", "superficial", "petrosal", "nerve", "without", "involvement", "of", "the", "motor", "facial", "nerve", "." ]

[ "umlsterm" ]

Facial nerve is an umlsterm, schwannomas is an umlsterm, benign tumors is an umlsterm, symptom is an umlsterm, facial nerve paralysis is an umlsterm, woman is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm, geniculate ganglion is an umlsterm, patient is an umlsterm, vertigo is an umlsterm, hearing loss is an umlsterm, facial nerve is an umlsterm, tumor is an umlsterm, computed tomography is an umlsterm, magnetic resonance imaging is an umlsterm, schwannoma is an umlsterm, facial nerve is an umlsterm, knowledge is an umlsterm, schwannoma is an umlsterm, nerve is an umlsterm, facial nerve is an umlsterm

HNO.90470279.eng.abstr_task1

Sentence: Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve . Instructions: please typing these entity words according to sentence: Facial nerve, schwannomas, benign tumors, symptom, facial nerve paralysis, woman, schwannoma, nerve, facial nerve, geniculate ganglion, patient, vertigo, hearing loss, facial nerve, tumor, computed tomography, magnetic resonance imaging, schwannoma, facial nerve, knowledge, schwannoma, nerve, facial nerve Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve .

[ "Facial", "nerve", "schwannomas", "are", "rare", "benign", "tumors", ",", "when", "occurring", ",", "they", "are", "located", "most", "frequently", "in", "the", "distal", "fallopian", "canal", "and", "present", "as", "extracranial", "masses", ".", "The", "predominant", "symptom", "is", "a", "progressive", "facial", "nerve", "paralysis", ".", "We", "report", "a", "20-year", "-", "old", "woman", "with", "an", "intracranial", "schwannoma", "originating", "from", "the", "greater", "superficial", "petrosal", "nerve", "that", "had", "wide", "extension", "into", "the", "pterygopalatine", "fossa", ".", "The", "motor", "facial", "nerve", "including", "the", "geniculate", "ganglion", "was", "not", "affected", ".", "The", "patient", "presented", "with", "vertigo", ",", "progressive", "hearing", "loss", "and", "mild", "facial", "nerve", "synkinesis", "but", "without", "a", "lacrimation", "deficit", ".", "The", "tumor", "was", "detected", "by", "computed", "tomography", "and", "magnetic", "resonance", "imaging", ".", "The", "schwannoma", "was", "completely", "removed", "using", "an", "intracranial", ",", "extradural", "middle", "fossa", "approach", "during", "which", "complete", "preservation", "of", "the", "motor", "facial", "nerve", "was", "possible", ".", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "an", "isolated", "schwannoma", "of", "the", "greater", "superficial", "petrosal", "nerve", "without", "involvement", "of", "the", "motor", "facial", "nerve", "." ]

[ "umlsterm" ]

Facial nerve, schwannomas, benign tumors, symptom, facial nerve paralysis, woman, schwannoma, nerve, facial nerve, geniculate ganglion, patient, vertigo, hearing loss, facial nerve, tumor, computed tomography, magnetic resonance imaging, schwannoma, facial nerve, knowledge, schwannoma, nerve, facial nerve

HNO.90470279.eng.abstr_task2

Sentence: Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Facial nerve schwannomas are rare benign tumors , when occurring , they are located most frequently in the distal fallopian canal and present as extracranial masses . The predominant symptom is a progressive facial nerve paralysis . We report a 20-year-old woman with an intracranial schwannoma originating from the greater superficial petrosal nerve that had wide extension into the pterygopalatine fossa . The motor facial nerve including the geniculate ganglion was not affected . The patient presented with vertigo , progressive hearing loss and mild facial nerve synkinesis but without a lacrimation deficit . The tumor was detected by computed tomography and magnetic resonance imaging . The schwannoma was completely removed using an intracranial , extradural middle fossa approach during which complete preservation of the motor facial nerve was possible . To our knowledge this is the first reported case of an isolated schwannoma of the greater superficial petrosal nerve without involvement of the motor facial nerve .

[ "Facial", "nerve", "schwannomas", "are", "rare", "benign", "tumors", ",", "when", "occurring", ",", "they", "are", "located", "most", "frequently", "in", "the", "distal", "fallopian", "canal", "and", "present", "as", "extracranial", "masses", ".", "The", "predominant", "symptom", "is", "a", "progressive", "facial", "nerve", "paralysis", ".", "We", "report", "a", "20-year", "-", "old", "woman", "with", "an", "intracranial", "schwannoma", "originating", "from", "the", "greater", "superficial", "petrosal", "nerve", "that", "had", "wide", "extension", "into", "the", "pterygopalatine", "fossa", ".", "The", "motor", "facial", "nerve", "including", "the", "geniculate", "ganglion", "was", "not", "affected", ".", "The", "patient", "presented", "with", "vertigo", ",", "progressive", "hearing", "loss", "and", "mild", "facial", "nerve", "synkinesis", "but", "without", "a", "lacrimation", "deficit", ".", "The", "tumor", "was", "detected", "by", "computed", "tomography", "and", "magnetic", "resonance", "imaging", ".", "The", "schwannoma", "was", "completely", "removed", "using", "an", "intracranial", ",", "extradural", "middle", "fossa", "approach", "during", "which", "complete", "preservation", "of", "the", "motor", "facial", "nerve", "was", "possible", ".", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "an", "isolated", "schwannoma", "of", "the", "greater", "superficial", "petrosal", "nerve", "without", "involvement", "of", "the", "motor", "facial", "nerve", "." ]

[ "umlsterm" ]

Age is a Person, from 40 to 80 years old is a Value, bilateral is a Qualifier, age related is a Qualifier, cataracts is a Condition, bilateral is a Qualifier, cataract phacoemulsification combined Intraocular Lens implantation is a Scope, Preoperative is a Temporal, measurement of corneal astigmatism is a Measurement, suitable is a Value, multifocal intraocular lenses implantation is a Procedure

NCT02678962_inc_task0

Sentence: Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Procedure, Scope, Measurement

[ "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "B-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study

[ "Age", "from", "40", "to", "80", "years", "old", ",", "either", "gender", ";", "\n", "Patients", "with", "bilateral", "age", "related", "cataracts", ",", "require", "bilateral", "cataract", "phacoemulsification", "combined", "Intraocular", "Lens", "implantation", ";", "\n", "Willing", "to", "undergo", "second", "eye", "surgery", "within", "7", "days", "after", "first", "eye", "surgery", ";", "\n", "The", "potential", "postoperative", "visual", "acuity", "of", "20/40", "or", "better", "in", "both", "eyes", ";", "\n", "Preoperative", "measurement", "of", "corneal", "astigmatism", "indicate", "the", "subjects", "are", "suitable", "for", "multifocal", "intraocular", "lenses", "implantation", ";", "\n", "Capability", "to", "understand", "the", "informed", "consent", "and", "willing", "and", "able", "to", "attend", "study", "\n" ]

[ "Scope", "Procedure", "Measurement", "Value", "Temporal", "Qualifier", "Condition", "Person" ]

Age is a Person, from 40 to 80 years old is a Value, bilateral is a Qualifier, age related is a Qualifier, cataracts is a Condition, bilateral is a Qualifier, cataract phacoemulsification combined Intraocular Lens implantation is a Scope, Preoperative is a Temporal, measurement of corneal astigmatism is a Measurement, suitable is a Value, multifocal intraocular lenses implantation is a Procedure

NCT02678962_inc_task1

Sentence: Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study Instructions: please typing these entity words according to sentence: Age, from 40 to 80 years old, bilateral, age related, cataracts, bilateral, cataract phacoemulsification combined Intraocular Lens implantation, Preoperative, measurement of corneal astigmatism, suitable, multifocal intraocular lenses implantation Options: Temporal, Condition, Qualifier, Value, Person, Procedure, Scope, Measurement

[ "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "B-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study

[ "Age", "from", "40", "to", "80", "years", "old", ",", "either", "gender", ";", "\n", "Patients", "with", "bilateral", "age", "related", "cataracts", ",", "require", "bilateral", "cataract", "phacoemulsification", "combined", "Intraocular", "Lens", "implantation", ";", "\n", "Willing", "to", "undergo", "second", "eye", "surgery", "within", "7", "days", "after", "first", "eye", "surgery", ";", "\n", "The", "potential", "postoperative", "visual", "acuity", "of", "20/40", "or", "better", "in", "both", "eyes", ";", "\n", "Preoperative", "measurement", "of", "corneal", "astigmatism", "indicate", "the", "subjects", "are", "suitable", "for", "multifocal", "intraocular", "lenses", "implantation", ";", "\n", "Capability", "to", "understand", "the", "informed", "consent", "and", "willing", "and", "able", "to", "attend", "study", "\n" ]

[ "Scope", "Procedure", "Measurement", "Value", "Temporal", "Qualifier", "Condition", "Person" ]

Age, from 40 to 80 years old, bilateral, age related, cataracts, bilateral, cataract phacoemulsification combined Intraocular Lens implantation, Preoperative, measurement of corneal astigmatism, suitable, multifocal intraocular lenses implantation

NCT02678962_inc_task2

Sentence: Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study Instructions: please extract entity words from the input sentence

[ "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "B-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Age from 40 to 80 years old, either gender; Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; Willing to undergo second eye surgery within 7 days after first eye surgery; The potential postoperative visual acuity of 20/40 or better in both eyes; Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation; Capability to understand the informed consent and willing and able to attend study

[ "Age", "from", "40", "to", "80", "years", "old", ",", "either", "gender", ";", "\n", "Patients", "with", "bilateral", "age", "related", "cataracts", ",", "require", "bilateral", "cataract", "phacoemulsification", "combined", "Intraocular", "Lens", "implantation", ";", "\n", "Willing", "to", "undergo", "second", "eye", "surgery", "within", "7", "days", "after", "first", "eye", "surgery", ";", "\n", "The", "potential", "postoperative", "visual", "acuity", "of", "20/40", "or", "better", "in", "both", "eyes", ";", "\n", "Preoperative", "measurement", "of", "corneal", "astigmatism", "indicate", "the", "subjects", "are", "suitable", "for", "multifocal", "intraocular", "lenses", "implantation", ";", "\n", "Capability", "to", "understand", "the", "informed", "consent", "and", "willing", "and", "able", "to", "attend", "study", "\n" ]

[ "Scope", "Procedure", "Measurement", "Value", "Temporal", "Qualifier", "Condition", "Person" ]

ethylenethiourea is a CHEMICAL, methanol is a CHEMICAL

23578651_task0

Sentence: Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS.

[ "Development", "and", "validation", "of", "ethylenethiourea", "determination", "in", "foods", "using", "methanol", "-", "based", "extraction", ",", "solid", "-", "phase", "extraction", "cleanup", "and", "LC", "-", "MS", "/", "MS", "." ]

[ "CHEMICAL" ]

ethylenethiourea is a CHEMICAL, methanol is a CHEMICAL

23578651_task1

Sentence: Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS. Instructions: please typing these entity words according to sentence: ethylenethiourea, methanol Options: CHEMICAL

[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS.

[ "Development", "and", "validation", "of", "ethylenethiourea", "determination", "in", "foods", "using", "methanol", "-", "based", "extraction", ",", "solid", "-", "phase", "extraction", "cleanup", "and", "LC", "-", "MS", "/", "MS", "." ]

[ "CHEMICAL" ]

ethylenethiourea, methanol

23578651_task2

Sentence: Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Development and validation of ethylenethiourea determination in foods using methanol-based extraction, solid-phase extraction cleanup and LC-MS/MS.

[ "Development", "and", "validation", "of", "ethylenethiourea", "determination", "in", "foods", "using", "methanol", "-", "based", "extraction", ",", "solid", "-", "phase", "extraction", "cleanup", "and", "LC", "-", "MS", "/", "MS", "." ]

[ "CHEMICAL" ]

TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, GLRP is a Protein, TFG - beta 2 is a Protein, promoter is a Entity, GLRP is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein

643_task0

Sentence: Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O" ]

Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response.

[ "Soluble", "factors", "secreted", "by", "activated", "T", "-", "lymphocytes", "modulate", "the", "transcription", "of", "the", "immunosuppressive", "cytokine", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "\n", "Coordination", "of", "the", "immune", "response", "to", "injury", "or", "disease", "in", "the", "brain", "is", "postulated", "to", "involve", "bi", "-", "directional", "discourse", "between", "the", "immune", "system", "and", "the", "central", "nervous", "system", ".", "This", "cross", "communication", "involves", "soluble", "mediators", ",", "including", "various", "growth", "factors", ",", "cytokines", ",", "and", "neuropeptides", ".", "In", "this", "report", ",", "we", "demonstrate", "that", "the", "supernatant", "from", "activated", "T", "-", "lymphocytes", "is", "able", "to", "induce", "the", "transcription", "of", "a", "potent", "cytokine", ",", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "The", "activating", "stimulus", "invokes", "signaling", "mechanisms", "distinct", "from", "known", "kinase", "or", "protease", "pathways", ".", "Activation", "of", "TGF", "-", "beta", "2", "transcription", "correlates", "with", "the", "loss", "of", "binding", "activity", "for", "an", "80", "kDA", "glial", "labile", "repressor", "protein", ",", "GLRP", ",", "to", "a", "responsive", "region", "within", "the", "TFG", "-", "beta", "2", "promoter", ".", "Although", "GLRP", "shares", "some", "characteristics", "with", "the", "inducible", "transcription", "factor", "AP-1", ",", "it", "appears", "to", "be", "distinct", "from", "known", "AP-1", "family", "members", ".", "These", "data", "along", "with", "previous", "observations", "demonstrating", "the", "potent", "immunosuppressive", "activity", "of", "TGF", "-", "beta", "2", ",", "support", "a", "model", "for", "a", "feedback", "mechanism", "between", "the", "activated", "T", "-", "lymphocytes", "and", "astrocytes", "via", "TGF", "-", "beta", "2", "to", "regulate", "the", "immune", "response", "." ]

[ "Protein", "Entity" ]

TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein, GLRP is a Protein, TFG - beta 2 is a Protein, promoter is a Entity, GLRP is a Protein, TGF - beta 2 is a Protein, TGF - beta 2 is a Protein

643_task1

Sentence: Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response. Instructions: please typing these entity words according to sentence: TGF - beta 2, TGF - beta 2, TGF - beta 2, GLRP, TFG - beta 2, promoter, GLRP, TGF - beta 2, TGF - beta 2 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O" ]

Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response.

[ "Soluble", "factors", "secreted", "by", "activated", "T", "-", "lymphocytes", "modulate", "the", "transcription", "of", "the", "immunosuppressive", "cytokine", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "\n", "Coordination", "of", "the", "immune", "response", "to", "injury", "or", "disease", "in", "the", "brain", "is", "postulated", "to", "involve", "bi", "-", "directional", "discourse", "between", "the", "immune", "system", "and", "the", "central", "nervous", "system", ".", "This", "cross", "communication", "involves", "soluble", "mediators", ",", "including", "various", "growth", "factors", ",", "cytokines", ",", "and", "neuropeptides", ".", "In", "this", "report", ",", "we", "demonstrate", "that", "the", "supernatant", "from", "activated", "T", "-", "lymphocytes", "is", "able", "to", "induce", "the", "transcription", "of", "a", "potent", "cytokine", ",", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "The", "activating", "stimulus", "invokes", "signaling", "mechanisms", "distinct", "from", "known", "kinase", "or", "protease", "pathways", ".", "Activation", "of", "TGF", "-", "beta", "2", "transcription", "correlates", "with", "the", "loss", "of", "binding", "activity", "for", "an", "80", "kDA", "glial", "labile", "repressor", "protein", ",", "GLRP", ",", "to", "a", "responsive", "region", "within", "the", "TFG", "-", "beta", "2", "promoter", ".", "Although", "GLRP", "shares", "some", "characteristics", "with", "the", "inducible", "transcription", "factor", "AP-1", ",", "it", "appears", "to", "be", "distinct", "from", "known", "AP-1", "family", "members", ".", "These", "data", "along", "with", "previous", "observations", "demonstrating", "the", "potent", "immunosuppressive", "activity", "of", "TGF", "-", "beta", "2", ",", "support", "a", "model", "for", "a", "feedback", "mechanism", "between", "the", "activated", "T", "-", "lymphocytes", "and", "astrocytes", "via", "TGF", "-", "beta", "2", "to", "regulate", "the", "immune", "response", "." ]

[ "Protein", "Entity" ]

TGF - beta 2, TGF - beta 2, TGF - beta 2, GLRP, TFG - beta 2, promoter, GLRP, TGF - beta 2, TGF - beta 2

643_task2

Sentence: Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O" ]

Soluble factors secreted by activated T-lymphocytes modulate the transcription of the immunosuppressive cytokine TGF-beta 2 in glial cells. Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system. This cross communication involves soluble mediators, including various growth factors, cytokines, and neuropeptides. In this report, we demonstrate that the supernatant from activated T-lymphocytes is able to induce the transcription of a potent cytokine, TGF-beta 2 in glial cells. The activating stimulus invokes signaling mechanisms distinct from known kinase or protease pathways. Activation of TGF-beta 2 transcription correlates with the loss of binding activity for an 80 kDA glial labile repressor protein, GLRP, to a responsive region within the TFG-beta 2 promoter. Although GLRP shares some characteristics with the inducible transcription factor AP-1, it appears to be distinct from known AP-1 family members. These data along with previous observations demonstrating the potent immunosuppressive activity of TGF-beta 2, support a model for a feedback mechanism between the activated T-lymphocytes and astrocytes via TGF-beta 2 to regulate the immune response.

[ "Soluble", "factors", "secreted", "by", "activated", "T", "-", "lymphocytes", "modulate", "the", "transcription", "of", "the", "immunosuppressive", "cytokine", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "\n", "Coordination", "of", "the", "immune", "response", "to", "injury", "or", "disease", "in", "the", "brain", "is", "postulated", "to", "involve", "bi", "-", "directional", "discourse", "between", "the", "immune", "system", "and", "the", "central", "nervous", "system", ".", "This", "cross", "communication", "involves", "soluble", "mediators", ",", "including", "various", "growth", "factors", ",", "cytokines", ",", "and", "neuropeptides", ".", "In", "this", "report", ",", "we", "demonstrate", "that", "the", "supernatant", "from", "activated", "T", "-", "lymphocytes", "is", "able", "to", "induce", "the", "transcription", "of", "a", "potent", "cytokine", ",", "TGF", "-", "beta", "2", "in", "glial", "cells", ".", "The", "activating", "stimulus", "invokes", "signaling", "mechanisms", "distinct", "from", "known", "kinase", "or", "protease", "pathways", ".", "Activation", "of", "TGF", "-", "beta", "2", "transcription", "correlates", "with", "the", "loss", "of", "binding", "activity", "for", "an", "80", "kDA", "glial", "labile", "repressor", "protein", ",", "GLRP", ",", "to", "a", "responsive", "region", "within", "the", "TFG", "-", "beta", "2", "promoter", ".", "Although", "GLRP", "shares", "some", "characteristics", "with", "the", "inducible", "transcription", "factor", "AP-1", ",", "it", "appears", "to", "be", "distinct", "from", "known", "AP-1", "family", "members", ".", "These", "data", "along", "with", "previous", "observations", "demonstrating", "the", "potent", "immunosuppressive", "activity", "of", "TGF", "-", "beta", "2", ",", "support", "a", "model", "for", "a", "feedback", "mechanism", "between", "the", "activated", "T", "-", "lymphocytes", "and", "astrocytes", "via", "TGF", "-", "beta", "2", "to", "regulate", "the", "immune", "response", "." ]

[ "Protein", "Entity" ]

4-Hydroxypyridazin-3(2H)-one is a CHEMICAL, d - Amino Acid Oxidase is a GENE-Y

23566269_task0

Sentence: 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]

4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.

[ "4-Hydroxypyridazin-3(2H)-one", "Derivatives", "as", "Novel", "d", "-", "Amino", "Acid", "Oxidase", "Inhibitors", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

4-Hydroxypyridazin-3(2H)-one is a CHEMICAL, d - Amino Acid Oxidase is a GENE-Y

23566269_task1

Sentence: 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. Instructions: please typing these entity words according to sentence: 4-Hydroxypyridazin-3(2H)-one, d - Amino Acid Oxidase Options: GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]

4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.

[ "4-Hydroxypyridazin-3(2H)-one", "Derivatives", "as", "Novel", "d", "-", "Amino", "Acid", "Oxidase", "Inhibitors", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

4-Hydroxypyridazin-3(2H)-one, d - Amino Acid Oxidase

23566269_task2

Sentence: 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O" ]

4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.

[ "4-Hydroxypyridazin-3(2H)-one", "Derivatives", "as", "Novel", "d", "-", "Amino", "Acid", "Oxidase", "Inhibitors", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Blutverbrauch is an umlsterm, Herzchirurgie is an umlsterm, Fremdblutverbrauch is an umlsterm, Eigenblutspende is an umlsterm, herzchirurgischen is an umlsterm, herzchirurgischen is an umlsterm

DerAnaesthesist.90480876.ger.abstr_task0

Sentence: Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken .

[ "Fragestellung", ":", "Der", "Blutverbrauch", "in", "der", "Herzchirurgie", "zeigt", "auch", "bei", "vergleichbaren", "Eingriffen", "eine", "weite", "Variationsbreite", ".", "Die", "vorliegende", "Studie", "untersucht", "den", "intraoperativen", "Fremdblutverbrauch", "und", "die", "Eigenblutspende", "bei", "definierten", "herzchirurgischen", "Eingriffen", "an", "12", "herzchirurgischen", "Kliniken", "." ]

[ "umlsterm" ]

Blutverbrauch is an umlsterm, Herzchirurgie is an umlsterm, Fremdblutverbrauch is an umlsterm, Eigenblutspende is an umlsterm, herzchirurgischen is an umlsterm, herzchirurgischen is an umlsterm

DerAnaesthesist.90480876.ger.abstr_task1

Sentence: Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken . Instructions: please typing these entity words according to sentence: Blutverbrauch, Herzchirurgie, Fremdblutverbrauch, Eigenblutspende, herzchirurgischen, herzchirurgischen Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken .

[ "Fragestellung", ":", "Der", "Blutverbrauch", "in", "der", "Herzchirurgie", "zeigt", "auch", "bei", "vergleichbaren", "Eingriffen", "eine", "weite", "Variationsbreite", ".", "Die", "vorliegende", "Studie", "untersucht", "den", "intraoperativen", "Fremdblutverbrauch", "und", "die", "Eigenblutspende", "bei", "definierten", "herzchirurgischen", "Eingriffen", "an", "12", "herzchirurgischen", "Kliniken", "." ]

[ "umlsterm" ]

Blutverbrauch, Herzchirurgie, Fremdblutverbrauch, Eigenblutspende, herzchirurgischen, herzchirurgischen

DerAnaesthesist.90480876.ger.abstr_task2

Sentence: Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

Fragestellung : Der Blutverbrauch in der Herzchirurgie zeigt auch bei vergleichbaren Eingriffen eine weite Variationsbreite . Die vorliegende Studie untersucht den intraoperativen Fremdblutverbrauch und die Eigenblutspende bei definierten herzchirurgischen Eingriffen an 12 herzchirurgischen Kliniken .

[ "Fragestellung", ":", "Der", "Blutverbrauch", "in", "der", "Herzchirurgie", "zeigt", "auch", "bei", "vergleichbaren", "Eingriffen", "eine", "weite", "Variationsbreite", ".", "Die", "vorliegende", "Studie", "untersucht", "den", "intraoperativen", "Fremdblutverbrauch", "und", "die", "Eigenblutspende", "bei", "definierten", "herzchirurgischen", "Eingriffen", "an", "12", "herzchirurgischen", "Kliniken", "." ]

[ "umlsterm" ]

children is an umlsterm, inguinal hernia is an umlsterm, patent is an umlsterm, children is an umlsterm, inguinal hernia is an umlsterm, laparoscopy is an umlsterm, technique is an umlsterm, hernia is an umlsterm, Method is an umlsterm, children is an umlsterm, age is an umlsterm, hernia is an umlsterm, laparoscopy is an umlsterm, laparoscope is an umlsterm, wide - open is an umlsterm, open is an umlsterm, surgical is an umlsterm, patients is an umlsterm, criteria is an umlsterm, open is an umlsterm, patients is an umlsterm, time is an umlsterm, laparoscopy is an umlsterm, complications is an umlsterm, laparoscopy is an umlsterm, laparoscopy is an umlsterm, hernia is an umlsterm, repair is an umlsterm, identification is an umlsterm, patients is an umlsterm, open is an umlsterm, surgery is an umlsterm, operation is an umlsterm, time is an umlsterm, complications is an umlsterm, method is an umlsterm, hospitalization is an umlsterm, operation is an umlsterm, open is an umlsterm, visualization is an umlsterm, method is an umlsterm, bowel is an umlsterm

DerChirurg.90700290.eng.abstr_task0

Sentence: Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning .

[ "Background", ":", "Approximately", "50", "%", "of", "children", "with", "a", "clinical", "unilateral", "inguinal", "hernia", "display", "a", "patent", "processus", "vaginalis", "on", "the", "contralateral", "side", ";", "half", "of", "these", "children", "subsequently", "develop", "an", "inguinal", "hernia", ".", "The", "management", "of", "this", "problem", "is", "still", "controversial", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "usefulness", "of", "intraoperative", "laparoscopy", "in", "a", "no", "-", "puncture", "technique", "through", "the", "opened", "hernia", "sack", ".", "Method", ":", "In", "112", "children", "(", "age", "6", "months", "to", "7", "years", ")", "with", "clinical", "unilateral", "hernia", "laparoscopy", "(", "5", "mm", "laparoscope", ",", "30", "°", "and", "70", "°", ")", ".", "In", "cases", "of", "a", "wide", "-", "open", "contralateral", "internal", "inguinal", "ring", "(", "type", "III", ")", "open", "surgical", "exploration", "was", "performed", ".", "Results", ":", "Nineteen", "patients", "(", "17", "%", ")", "fulfilled", "the", "laparoscopic", "criteria", "of", "a", "type", "III", "ring", ";", "the", "diagnose", "was", "confirmed", "during", "open", "contralateral", "exploration", ".", "Fourteen", "of", "these", "patients", "were", "younger", "than", "two", "years", ".", "The", "median", "time", "for", "laparoscopy", "was", "6", "min", "(", "3", "-", "11", "min", ")", ".", "No", "complications", "associated", "with", "the", "laparoscopy", "were", "observed", ".", "Conclusions", ":", "Intraoperative", "laparoscopy", "during", "unilateral", "hernia", "repair", "allows", "the", "identification", "of", "patients", "who", "profit", "from", "bilateral", "open", "surgery", "during", "the", "same", "operation", "with", "little", "additional", "operating", "time", "and", "so", "far", "with", "no", "resulting", "complications", ".", "Application", "of", "this", "method", "may", "avoid", "a", "second", "hospitalization", "and", "operation", ",", "as", "well", "as", "an", "unnecessary", "routine", "bilateral", "open", "exploration", ".", "As", "an", "additional", "source", "of", "information", "through", "excellent", "visualization", "of", "the", "abdominal", "cavity", ",", "this", "method", "proved", "helpful", "to", "examine", "incarcerated", "bowel", "after", "repositioning", "." ]

[ "umlsterm" ]

children is an umlsterm, inguinal hernia is an umlsterm, patent is an umlsterm, children is an umlsterm, inguinal hernia is an umlsterm, laparoscopy is an umlsterm, technique is an umlsterm, hernia is an umlsterm, Method is an umlsterm, children is an umlsterm, age is an umlsterm, hernia is an umlsterm, laparoscopy is an umlsterm, laparoscope is an umlsterm, wide - open is an umlsterm, open is an umlsterm, surgical is an umlsterm, patients is an umlsterm, criteria is an umlsterm, open is an umlsterm, patients is an umlsterm, time is an umlsterm, laparoscopy is an umlsterm, complications is an umlsterm, laparoscopy is an umlsterm, laparoscopy is an umlsterm, hernia is an umlsterm, repair is an umlsterm, identification is an umlsterm, patients is an umlsterm, open is an umlsterm, surgery is an umlsterm, operation is an umlsterm, time is an umlsterm, complications is an umlsterm, method is an umlsterm, hospitalization is an umlsterm, operation is an umlsterm, open is an umlsterm, visualization is an umlsterm, method is an umlsterm, bowel is an umlsterm

DerChirurg.90700290.eng.abstr_task1

Sentence: Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning . Instructions: please typing these entity words according to sentence: children, inguinal hernia, patent, children, inguinal hernia, laparoscopy, technique, hernia, Method, children, age, hernia, laparoscopy, laparoscope, wide - open, open, surgical, patients, criteria, open, patients, time, laparoscopy, complications, laparoscopy, laparoscopy, hernia, repair, identification, patients, open, surgery, operation, time, complications, method, hospitalization, operation, open, visualization, method, bowel Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning .

[ "Background", ":", "Approximately", "50", "%", "of", "children", "with", "a", "clinical", "unilateral", "inguinal", "hernia", "display", "a", "patent", "processus", "vaginalis", "on", "the", "contralateral", "side", ";", "half", "of", "these", "children", "subsequently", "develop", "an", "inguinal", "hernia", ".", "The", "management", "of", "this", "problem", "is", "still", "controversial", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "usefulness", "of", "intraoperative", "laparoscopy", "in", "a", "no", "-", "puncture", "technique", "through", "the", "opened", "hernia", "sack", ".", "Method", ":", "In", "112", "children", "(", "age", "6", "months", "to", "7", "years", ")", "with", "clinical", "unilateral", "hernia", "laparoscopy", "(", "5", "mm", "laparoscope", ",", "30", "°", "and", "70", "°", ")", ".", "In", "cases", "of", "a", "wide", "-", "open", "contralateral", "internal", "inguinal", "ring", "(", "type", "III", ")", "open", "surgical", "exploration", "was", "performed", ".", "Results", ":", "Nineteen", "patients", "(", "17", "%", ")", "fulfilled", "the", "laparoscopic", "criteria", "of", "a", "type", "III", "ring", ";", "the", "diagnose", "was", "confirmed", "during", "open", "contralateral", "exploration", ".", "Fourteen", "of", "these", "patients", "were", "younger", "than", "two", "years", ".", "The", "median", "time", "for", "laparoscopy", "was", "6", "min", "(", "3", "-", "11", "min", ")", ".", "No", "complications", "associated", "with", "the", "laparoscopy", "were", "observed", ".", "Conclusions", ":", "Intraoperative", "laparoscopy", "during", "unilateral", "hernia", "repair", "allows", "the", "identification", "of", "patients", "who", "profit", "from", "bilateral", "open", "surgery", "during", "the", "same", "operation", "with", "little", "additional", "operating", "time", "and", "so", "far", "with", "no", "resulting", "complications", ".", "Application", "of", "this", "method", "may", "avoid", "a", "second", "hospitalization", "and", "operation", ",", "as", "well", "as", "an", "unnecessary", "routine", "bilateral", "open", "exploration", ".", "As", "an", "additional", "source", "of", "information", "through", "excellent", "visualization", "of", "the", "abdominal", "cavity", ",", "this", "method", "proved", "helpful", "to", "examine", "incarcerated", "bowel", "after", "repositioning", "." ]

[ "umlsterm" ]

children, inguinal hernia, patent, children, inguinal hernia, laparoscopy, technique, hernia, Method, children, age, hernia, laparoscopy, laparoscope, wide - open, open, surgical, patients, criteria, open, patients, time, laparoscopy, complications, laparoscopy, laparoscopy, hernia, repair, identification, patients, open, surgery, operation, time, complications, method, hospitalization, operation, open, visualization, method, bowel

DerChirurg.90700290.eng.abstr_task2

Sentence: Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Background : Approximately 50 % of children with a clinical unilateral inguinal hernia display a patent processus vaginalis on the contralateral side ; half of these children subsequently develop an inguinal hernia . The management of this problem is still controversial . The purpose of this study was to evaluate the usefulness of intraoperative laparoscopy in a no-puncture technique through the opened hernia sack . Method : In 112 children ( age 6 months to 7 years ) with clinical unilateral hernia laparoscopy ( 5 mm laparoscope , 30 ° and 70 ° ) . In cases of a wide-open contralateral internal inguinal ring ( type III ) open surgical exploration was performed . Results : Nineteen patients ( 17 % ) fulfilled the laparoscopic criteria of a type III ring ; the diagnose was confirmed during open contralateral exploration . Fourteen of these patients were younger than two years . The median time for laparoscopy was 6 min ( 3-11 min ) . No complications associated with the laparoscopy were observed . Conclusions : Intraoperative laparoscopy during unilateral hernia repair allows the identification of patients who profit from bilateral open surgery during the same operation with little additional operating time and so far with no resulting complications . Application of this method may avoid a second hospitalization and operation , as well as an unnecessary routine bilateral open exploration . As an additional source of information through excellent visualization of the abdominal cavity , this method proved helpful to examine incarcerated bowel after repositioning .

[ "Background", ":", "Approximately", "50", "%", "of", "children", "with", "a", "clinical", "unilateral", "inguinal", "hernia", "display", "a", "patent", "processus", "vaginalis", "on", "the", "contralateral", "side", ";", "half", "of", "these", "children", "subsequently", "develop", "an", "inguinal", "hernia", ".", "The", "management", "of", "this", "problem", "is", "still", "controversial", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "usefulness", "of", "intraoperative", "laparoscopy", "in", "a", "no", "-", "puncture", "technique", "through", "the", "opened", "hernia", "sack", ".", "Method", ":", "In", "112", "children", "(", "age", "6", "months", "to", "7", "years", ")", "with", "clinical", "unilateral", "hernia", "laparoscopy", "(", "5", "mm", "laparoscope", ",", "30", "°", "and", "70", "°", ")", ".", "In", "cases", "of", "a", "wide", "-", "open", "contralateral", "internal", "inguinal", "ring", "(", "type", "III", ")", "open", "surgical", "exploration", "was", "performed", ".", "Results", ":", "Nineteen", "patients", "(", "17", "%", ")", "fulfilled", "the", "laparoscopic", "criteria", "of", "a", "type", "III", "ring", ";", "the", "diagnose", "was", "confirmed", "during", "open", "contralateral", "exploration", ".", "Fourteen", "of", "these", "patients", "were", "younger", "than", "two", "years", ".", "The", "median", "time", "for", "laparoscopy", "was", "6", "min", "(", "3", "-", "11", "min", ")", ".", "No", "complications", "associated", "with", "the", "laparoscopy", "were", "observed", ".", "Conclusions", ":", "Intraoperative", "laparoscopy", "during", "unilateral", "hernia", "repair", "allows", "the", "identification", "of", "patients", "who", "profit", "from", "bilateral", "open", "surgery", "during", "the", "same", "operation", "with", "little", "additional", "operating", "time", "and", "so", "far", "with", "no", "resulting", "complications", ".", "Application", "of", "this", "method", "may", "avoid", "a", "second", "hospitalization", "and", "operation", ",", "as", "well", "as", "an", "unnecessary", "routine", "bilateral", "open", "exploration", ".", "As", "an", "additional", "source", "of", "information", "through", "excellent", "visualization", "of", "the", "abdominal", "cavity", ",", "this", "method", "proved", "helpful", "to", "examine", "incarcerated", "bowel", "after", "repositioning", "." ]

[ "umlsterm" ]

amino acid decarboxylases is a GENE-N, alanine racemase is a GENE-N

16997906_task0

Sentence: Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N

[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O" ]

Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.

[ "Functional", "classification", "of", "amino", "acid", "decarboxylases", "from", "the", "alanine", "racemase", "structural", "family", "by", "phylogenetic", "studies", "." ]

[ "GENE-N", "CHEMICAL" ]

amino acid decarboxylases is a GENE-N, alanine racemase is a GENE-N

16997906_task1

Sentence: Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Instructions: please typing these entity words according to sentence: amino acid decarboxylases, alanine racemase Options: GENE-N

[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O" ]

Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.

[ "Functional", "classification", "of", "amino", "acid", "decarboxylases", "from", "the", "alanine", "racemase", "structural", "family", "by", "phylogenetic", "studies", "." ]

[ "GENE-N", "CHEMICAL" ]

amino acid decarboxylases, alanine racemase

16997906_task2

Sentence: Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O" ]

Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.

[ "Functional", "classification", "of", "amino", "acid", "decarboxylases", "from", "the", "alanine", "racemase", "structural", "family", "by", "phylogenetic", "studies", "." ]

[ "GENE-N", "CHEMICAL" ]

fibroblasts is an umlsterm, corticoid is an umlsterm, aldosterone is an umlsterm, collagen is an umlsterm, rat is an umlsterm, myocardium is an umlsterm, hypertension is an umlsterm, fibrosis is an umlsterm, pathologic is an umlsterm, hypertrophy is an umlsterm, heart is an umlsterm

Herz.00250299.eng.abstr_task0

Sentence: Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure .

[ "Cardiac", "fibroblasts", "are", "known", "to", "have", "high", "affinity", "corticoid", "receptors", "for", "aldosterone", "and", "account", "for", "the", "accumulation", "of", "collagen", "within", "the", "interstitium", "of", "the", "rat", "myocardium", "in", "acquired", "and", "genetic", "hypertension", ".", "This", "interstitial", "fibrosis", "is", "an", "important", "determinant", "of", "pathologic", "hypertrophy", "in", "chronic", "heart", "failure", "." ]

[ "umlsterm" ]

fibroblasts is an umlsterm, corticoid is an umlsterm, aldosterone is an umlsterm, collagen is an umlsterm, rat is an umlsterm, myocardium is an umlsterm, hypertension is an umlsterm, fibrosis is an umlsterm, pathologic is an umlsterm, hypertrophy is an umlsterm, heart is an umlsterm

Herz.00250299.eng.abstr_task1

Sentence: Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure . Instructions: please typing these entity words according to sentence: fibroblasts, corticoid, aldosterone, collagen, rat, myocardium, hypertension, fibrosis, pathologic, hypertrophy, heart Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure .

[ "Cardiac", "fibroblasts", "are", "known", "to", "have", "high", "affinity", "corticoid", "receptors", "for", "aldosterone", "and", "account", "for", "the", "accumulation", "of", "collagen", "within", "the", "interstitium", "of", "the", "rat", "myocardium", "in", "acquired", "and", "genetic", "hypertension", ".", "This", "interstitial", "fibrosis", "is", "an", "important", "determinant", "of", "pathologic", "hypertrophy", "in", "chronic", "heart", "failure", "." ]

[ "umlsterm" ]

fibroblasts, corticoid, aldosterone, collagen, rat, myocardium, hypertension, fibrosis, pathologic, hypertrophy, heart

Herz.00250299.eng.abstr_task2

Sentence: Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Cardiac fibroblasts are known to have high affinity corticoid receptors for aldosterone and account for the accumulation of collagen within the interstitium of the rat myocardium in acquired and genetic hypertension . This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure .

[ "Cardiac", "fibroblasts", "are", "known", "to", "have", "high", "affinity", "corticoid", "receptors", "for", "aldosterone", "and", "account", "for", "the", "accumulation", "of", "collagen", "within", "the", "interstitium", "of", "the", "rat", "myocardium", "in", "acquired", "and", "genetic", "hypertension", ".", "This", "interstitial", "fibrosis", "is", "an", "important", "determinant", "of", "pathologic", "hypertrophy", "in", "chronic", "heart", "failure", "." ]

[ "umlsterm" ]

hematopoietic transcription factor is a protein_family_or_group, PU.1 is a protein_molecule, human multiple myeloma cell lines is a cell_line

101483_task0

Sentence: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line, protein_molecule

[ "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines.

[ "The", "hematopoietic", "transcription", "factor", "PU.1", "is", "downregulated", "in", "human", "multiple", "myeloma", "cell", "lines", "." ]

[ "other_name", "cell_type", "DNA_family_or_group", "protein_family_or_group", "cell_line", "(AND cell_line cell_line cell_line)", "DNA_domain_or_region", "RNA_molecule", "", "body_part", "protein_molecule" ]

hematopoietic transcription factor is a protein_family_or_group, PU.1 is a protein_molecule, human multiple myeloma cell lines is a cell_line

101483_task1

Sentence: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Instructions: please typing these entity words according to sentence: hematopoietic transcription factor, PU.1, human multiple myeloma cell lines Options: protein_family_or_group, cell_line, protein_molecule

[ "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines.

[ "The", "hematopoietic", "transcription", "factor", "PU.1", "is", "downregulated", "in", "human", "multiple", "myeloma", "cell", "lines", "." ]

[ "other_name", "cell_type", "DNA_family_or_group", "protein_family_or_group", "cell_line", "(AND cell_line cell_line cell_line)", "DNA_domain_or_region", "RNA_molecule", "", "body_part", "protein_molecule" ]

hematopoietic transcription factor, PU.1, human multiple myeloma cell lines

101483_task2

Sentence: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Instructions: please extract entity words from the input sentence

[ "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines.

[ "The", "hematopoietic", "transcription", "factor", "PU.1", "is", "downregulated", "in", "human", "multiple", "myeloma", "cell", "lines", "." ]

[ "other_name", "cell_type", "DNA_family_or_group", "protein_family_or_group", "cell_line", "(AND cell_line cell_line cell_line)", "DNA_domain_or_region", "RNA_molecule", "", "body_part", "protein_molecule" ]

alkaline proteinase is a Individual_protein, myosin heavy chain is a Individual_protein, actin is a Individual_protein

241_task0

Sentence: Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O" ]

Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin.

[ "Digestion", "of", "isolated", "myofibrils", "with", "alkaline", "proteinase", "resulted", "in", "the", "degradation", "of", "myosin", "heavy", "chain", "and", "actin", "." ]

[ "Individual_protein" ]

alkaline proteinase is a Individual_protein, myosin heavy chain is a Individual_protein, actin is a Individual_protein

241_task1

Sentence: Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin. Instructions: please typing these entity words according to sentence: alkaline proteinase, myosin heavy chain, actin Options: Individual_protein

[ "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O" ]

Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin.

[ "Digestion", "of", "isolated", "myofibrils", "with", "alkaline", "proteinase", "resulted", "in", "the", "degradation", "of", "myosin", "heavy", "chain", "and", "actin", "." ]

[ "Individual_protein" ]

alkaline proteinase, myosin heavy chain, actin

241_task2

Sentence: Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O" ]

Digestion of isolated myofibrils with alkaline proteinase resulted in the degradation of myosin heavy chain and actin.

[ "Digestion", "of", "isolated", "myofibrils", "with", "alkaline", "proteinase", "resulted", "in", "the", "degradation", "of", "myosin", "heavy", "chain", "and", "actin", "." ]

[ "Individual_protein" ]

COF1 is a Gene, actin - binding protein is a Protein_family_or_group, cofilin is a Individual_protein, Cof is a Individual_protein, Cof is a Individual_protein

875_task0

Sentence: We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, Protein_family_or_group, Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]

We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof.

[ "We", "have", "cloned", "a", "Saccharomyces", "cerevisiae", "gene", "(", "COF1", ")", "encoding", "a", "low", "-", "M(r", ")", "actin", "-", "binding", "protein", "of", "143", "amino", "acid", "(", "aa", ")", "residues", "(", "yeast", "cofilin", ";", "Cof", ")", ";", "its", "aa", "sequence", "is", "35", "%", "identical", "to", "porcine", "Cof", "." ]

[ "Protein_family_or_group", "Individual_protein", "Gene" ]

COF1 is a Gene, actin - binding protein is a Protein_family_or_group, cofilin is a Individual_protein, Cof is a Individual_protein, Cof is a Individual_protein

875_task1

Sentence: We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof. Instructions: please typing these entity words according to sentence: COF1, actin - binding protein, cofilin, Cof, Cof Options: Gene, Protein_family_or_group, Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]

We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof.

[ "We", "have", "cloned", "a", "Saccharomyces", "cerevisiae", "gene", "(", "COF1", ")", "encoding", "a", "low", "-", "M(r", ")", "actin", "-", "binding", "protein", "of", "143", "amino", "acid", "(", "aa", ")", "residues", "(", "yeast", "cofilin", ";", "Cof", ")", ";", "its", "aa", "sequence", "is", "35", "%", "identical", "to", "porcine", "Cof", "." ]

[ "Protein_family_or_group", "Individual_protein", "Gene" ]

COF1, actin - binding protein, cofilin, Cof, Cof

875_task2

Sentence: We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]

We have cloned a Saccharomyces cerevisiae gene (COF1) encoding a low-M(r) actin-binding protein of 143 amino acid (aa) residues (yeast cofilin; Cof); its aa sequence is 35% identical to porcine Cof.

[ "We", "have", "cloned", "a", "Saccharomyces", "cerevisiae", "gene", "(", "COF1", ")", "encoding", "a", "low", "-", "M(r", ")", "actin", "-", "binding", "protein", "of", "143", "amino", "acid", "(", "aa", ")", "residues", "(", "yeast", "cofilin", ";", "Cof", ")", ";", "its", "aa", "sequence", "is", "35", "%", "identical", "to", "porcine", "Cof", "." ]

[ "Protein_family_or_group", "Individual_protein", "Gene" ]

Neuronatin is a GENE-Y, calcium is a CHEMICAL

23408434_task0

Sentence: Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.

[ "Neuronatin", "-", "mediated", "aberrant", "calcium", "signaling", "and", "endoplasmic", "reticulum", "stress", "underlie", "neuropathology", "in", "Lafora", "disease", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Neuronatin is a GENE-Y, calcium is a CHEMICAL

23408434_task1

Sentence: Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease. Instructions: please typing these entity words according to sentence: Neuronatin, calcium Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.

[ "Neuronatin", "-", "mediated", "aberrant", "calcium", "signaling", "and", "endoplasmic", "reticulum", "stress", "underlie", "neuropathology", "in", "Lafora", "disease", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Neuronatin, calcium

23408434_task2

Sentence: Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.

[ "Neuronatin", "-", "mediated", "aberrant", "calcium", "signaling", "and", "endoplasmic", "reticulum", "stress", "underlie", "neuropathology", "in", "Lafora", "disease", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

cofilin is a Individual_protein, actin is a Individual_protein

503_task0

Sentence: Kinetic studies on the effect of yeast cofilin on yeast actin polymerization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O" ]

Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.

[ "Kinetic", "studies", "on", "the", "effect", "of", "yeast", "cofilin", "on", "yeast", "actin", "polymerization", "." ]

[ "Individual_protein" ]

cofilin is a Individual_protein, actin is a Individual_protein

503_task1

Sentence: Kinetic studies on the effect of yeast cofilin on yeast actin polymerization. Instructions: please typing these entity words according to sentence: cofilin, actin Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O" ]

Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.

[ "Kinetic", "studies", "on", "the", "effect", "of", "yeast", "cofilin", "on", "yeast", "actin", "polymerization", "." ]

[ "Individual_protein" ]

cofilin, actin

503_task2

Sentence: Kinetic studies on the effect of yeast cofilin on yeast actin polymerization. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O" ]

Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.

[ "Kinetic", "studies", "on", "the", "effect", "of", "yeast", "cofilin", "on", "yeast", "actin", "polymerization", "." ]

[ "Individual_protein" ]

pre - core mutant chronic hepatitis B infection is a Participant_Condition, lamivudine is a Intervention_Pharmacological, pre - core mutant of hepatitis B virus ( HBV ) infection is a Participant_Condition, HBeAg in the serum . is a Outcome_Physical, effective is a Outcome_Other, HBV replication is a Outcome_Physical, indicators of liver disease is a Outcome_Physical

3800_task0

Sentence: Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection .

[ "Response", "of", "pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "to", "lamivudine", ".", "The", "proportion", "of", "chronic", "liver", "disease", "associated", "with", "the", "pre", "-", "core", "mutant", "of", "hepatitis", "B", "virus", "(", "HBV", ")", "infection", "is", "increasing", ",", "particularly", "in", "Mediterranean", "Europe", "and", "in", "Asia", ".", "The", "pre", "-", "core", "mutant", "HBV", "is", "unable", "to", "produce", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", ",", "so", "that", "patients", "with", "this", "variant", "do", "not", "present", "with", "HBV", "characterised", "by", "HBeAg", "in", "the", "serum", ".", "Pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "usually", "proceeds", "to", "serious", "liver", "disease", ".", "Wild", "-", "type", "HBV", "infection", "may", "be", "mild", "and", "respond", "relatively", "well", "to", "interferon", "(", "IFN", ")", "alpha", "therapy", ",", "but", "IFN", "alpha", "is", "not", "an", "effective", "therapeutic", "option", "in", "pre", "-", "core", "mutant", "hepatitis", "B", "infection", "and", "new", "therapeutic", "options", "are", "needed", ".", "Clinical", "data", "show", "that", "lamivudine", "is", "an", "effective", "treatment", "for", "patients", "with", "pre", "-", "core", "mutant", "hepatitis", "B", ".", "There", "is", "profound", "suppression", "of", "HBV", "replication", "and", "improvement", "in", "indicators", "of", "liver", "disease", "in", "most", "patients", ".", "In", "conclusion", ",", "lamivudine", "is", "suitable", "for", "treatment", "of", "a", "wide", "range", "of", "patients", "with", "chronic", "hepatitis", "B", ",", "including", "those", "with", "pre", "-", "core", "mutant", "HBV", "infection", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other" ]

pre - core mutant chronic hepatitis B infection is a Participant_Condition, lamivudine is a Intervention_Pharmacological, pre - core mutant of hepatitis B virus ( HBV ) infection is a Participant_Condition, HBeAg in the serum . is a Outcome_Physical, effective is a Outcome_Other, HBV replication is a Outcome_Physical, indicators of liver disease is a Outcome_Physical

3800_task1

Sentence: Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection . Instructions: please typing these entity words according to sentence: pre - core mutant chronic hepatitis B infection, lamivudine, pre - core mutant of hepatitis B virus ( HBV ) infection, HBeAg in the serum ., effective, HBV replication, indicators of liver disease Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection .

[ "Response", "of", "pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "to", "lamivudine", ".", "The", "proportion", "of", "chronic", "liver", "disease", "associated", "with", "the", "pre", "-", "core", "mutant", "of", "hepatitis", "B", "virus", "(", "HBV", ")", "infection", "is", "increasing", ",", "particularly", "in", "Mediterranean", "Europe", "and", "in", "Asia", ".", "The", "pre", "-", "core", "mutant", "HBV", "is", "unable", "to", "produce", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", ",", "so", "that", "patients", "with", "this", "variant", "do", "not", "present", "with", "HBV", "characterised", "by", "HBeAg", "in", "the", "serum", ".", "Pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "usually", "proceeds", "to", "serious", "liver", "disease", ".", "Wild", "-", "type", "HBV", "infection", "may", "be", "mild", "and", "respond", "relatively", "well", "to", "interferon", "(", "IFN", ")", "alpha", "therapy", ",", "but", "IFN", "alpha", "is", "not", "an", "effective", "therapeutic", "option", "in", "pre", "-", "core", "mutant", "hepatitis", "B", "infection", "and", "new", "therapeutic", "options", "are", "needed", ".", "Clinical", "data", "show", "that", "lamivudine", "is", "an", "effective", "treatment", "for", "patients", "with", "pre", "-", "core", "mutant", "hepatitis", "B", ".", "There", "is", "profound", "suppression", "of", "HBV", "replication", "and", "improvement", "in", "indicators", "of", "liver", "disease", "in", "most", "patients", ".", "In", "conclusion", ",", "lamivudine", "is", "suitable", "for", "treatment", "of", "a", "wide", "range", "of", "patients", "with", "chronic", "hepatitis", "B", ",", "including", "those", "with", "pre", "-", "core", "mutant", "HBV", "infection", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other" ]

pre - core mutant chronic hepatitis B infection, lamivudine, pre - core mutant of hepatitis B virus ( HBV ) infection, HBeAg in the serum ., effective, HBV replication, indicators of liver disease

3800_task2

Sentence: Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Response of pre-core mutant chronic hepatitis B infection to lamivudine . The proportion of chronic liver disease associated with the pre-core mutant of hepatitis B virus ( HBV ) infection is increasing , particularly in Mediterranean Europe and in Asia . The pre-core mutant HBV is unable to produce hepatitis B e antigen ( HBeAg ) , so that patients with this variant do not present with HBV characterised by HBeAg in the serum . Pre-core mutant chronic hepatitis B infection usually proceeds to serious liver disease . Wild-type HBV infection may be mild and respond relatively well to interferon ( IFN ) alpha therapy , but IFN alpha is not an effective therapeutic option in pre-core mutant hepatitis B infection and new therapeutic options are needed . Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B . There is profound suppression of HBV replication and improvement in indicators of liver disease in most patients . In conclusion , lamivudine is suitable for treatment of a wide range of patients with chronic hepatitis B , including those with pre-core mutant HBV infection .

[ "Response", "of", "pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "to", "lamivudine", ".", "The", "proportion", "of", "chronic", "liver", "disease", "associated", "with", "the", "pre", "-", "core", "mutant", "of", "hepatitis", "B", "virus", "(", "HBV", ")", "infection", "is", "increasing", ",", "particularly", "in", "Mediterranean", "Europe", "and", "in", "Asia", ".", "The", "pre", "-", "core", "mutant", "HBV", "is", "unable", "to", "produce", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", ",", "so", "that", "patients", "with", "this", "variant", "do", "not", "present", "with", "HBV", "characterised", "by", "HBeAg", "in", "the", "serum", ".", "Pre", "-", "core", "mutant", "chronic", "hepatitis", "B", "infection", "usually", "proceeds", "to", "serious", "liver", "disease", ".", "Wild", "-", "type", "HBV", "infection", "may", "be", "mild", "and", "respond", "relatively", "well", "to", "interferon", "(", "IFN", ")", "alpha", "therapy", ",", "but", "IFN", "alpha", "is", "not", "an", "effective", "therapeutic", "option", "in", "pre", "-", "core", "mutant", "hepatitis", "B", "infection", "and", "new", "therapeutic", "options", "are", "needed", ".", "Clinical", "data", "show", "that", "lamivudine", "is", "an", "effective", "treatment", "for", "patients", "with", "pre", "-", "core", "mutant", "hepatitis", "B", ".", "There", "is", "profound", "suppression", "of", "HBV", "replication", "and", "improvement", "in", "indicators", "of", "liver", "disease", "in", "most", "patients", ".", "In", "conclusion", ",", "lamivudine", "is", "suitable", "for", "treatment", "of", "a", "wide", "range", "of", "patients", "with", "chronic", "hepatitis", "B", ",", "including", "those", "with", "pre", "-", "core", "mutant", "HBV", "infection", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other" ]

Osteonecrosis is a Condition, planned is a Mood, decompression surgery is a Procedure, autologous stem cell transplant is a Procedure

NCT02893293_inc_task0

Sentence: Osteonecrosis planned decompression surgery with autologous stem cell transplant Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Procedure, Mood

[ "B-Condition", "O", "B-Mood", "B-Procedure", "I-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]

Osteonecrosis planned decompression surgery with autologous stem cell transplant

[ "Osteonecrosis", "\n", "planned", "decompression", "surgery", "with", "autologous", "stem", "cell", "transplant", "\n" ]

[ "Procedure", "Condition", "Mood" ]

Osteonecrosis is a Condition, planned is a Mood, decompression surgery is a Procedure, autologous stem cell transplant is a Procedure

NCT02893293_inc_task1

Sentence: Osteonecrosis planned decompression surgery with autologous stem cell transplant Instructions: please typing these entity words according to sentence: Osteonecrosis, planned, decompression surgery, autologous stem cell transplant Options: Condition, Procedure, Mood

[ "B-Condition", "O", "B-Mood", "B-Procedure", "I-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]

Osteonecrosis planned decompression surgery with autologous stem cell transplant

[ "Osteonecrosis", "\n", "planned", "decompression", "surgery", "with", "autologous", "stem", "cell", "transplant", "\n" ]

[ "Procedure", "Condition", "Mood" ]

Osteonecrosis, planned, decompression surgery, autologous stem cell transplant

NCT02893293_inc_task2

Sentence: Osteonecrosis planned decompression surgery with autologous stem cell transplant Instructions: please extract entity words from the input sentence

[ "B-Condition", "O", "B-Mood", "B-Procedure", "I-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]

Osteonecrosis planned decompression surgery with autologous stem cell transplant

[ "Osteonecrosis", "\n", "planned", "decompression", "surgery", "with", "autologous", "stem", "cell", "transplant", "\n" ]

[ "Procedure", "Condition", "Mood" ]

TGF - alpha is a Protein, EGF is a Protein, Transforming growth factor - alpha is a Protein, TGF - alpha is a Protein, epidermal growth factor is a Protein, EGF is a Protein, L - glutamine : D - fructose-6-phosphate amidotransferase is a Protein, GFAT is a Protein, GFAT is a Protein, EGF is a Protein, EGF is a Protein, GFAT is a Protein, EGF is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, EGF is a Protein, GFAT is a Protein, GFAT is a Protein, GFAT is a Protein, TGF - alpha is a Protein, GFAT is a Protein, EGF is a Protein

562_task0

Sentence: Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]

Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not.

[ "Role", "of", "glucosamine", "synthesis", "in", "the", "stimulation", "of", "TGF", "-", "alpha", "gene", "transcription", "by", "glucose", "and", "EGF", ".", "\n", "Transforming", "growth", "factor", "-", "alpha", "(", "TGF", "-", "alpha", ")", "gene", "transcription", "is", "regulated", "by", "both", "epidermal", "growth", "factor", "(", "EGF", ")", "and", "glucose", ".", "Previous", "studies", "have", "suggested", "that", "the", "metabolism", "of", "glucose", "to", "glucosamine", "through", "the", "enzyme", "L", "-", "glutamine", ":", "D", "-", "fructose-6-phosphate", "amidotransferase", "(", "GFAT", ")", "plays", "a", "critical", "role", "in", "the", "glucose", "signaling", ".", "In", "this", "paper", ",", "we", "compared", "the", "role", "of", "GFAT", "in", "the", "glucose", "and", "EGF", "signals", ".", "We", "found", "that", ",", "although", "EGF", "stimulates", "GFAT", "mRNA", "accumulation", "in", "MDA", "-", "MB-468", "cells", ",", "this", "effect", "of", "EGF", "occurred", "several", "hours", "after", "TGF", "-", "alpha", "transcription", "increased", ".", "MDA", "-", "MB-468", "cells", "also", "exhibited", "a", "TGF", "-", "alpha", "transcriptional", "response", "to", "low", "concentrations", "of", "glucose", ".", "The", "TGF", "-", "alpha", "response", "to", "glucose", "but", "not", "EGF", "could", "be", "inhibited", "by", "a", "blocker", "of", "GFAT", "activity", ".", "Blockade", "of", "GFAT", "was", "confirmed", "by", "using", "Western", "blotting", "with", "the", "RL2", "antibody", ",", "which", "recognizes", "an", "epitope", "on", "proteins", "containing", "N", "-", "acetylglucosamine", ".", "Exposure", "of", "cells", "to", "glucose", "increased", "the", "RL2", "signal", "on", "several", "polypeptides", ",", "but", "this", "change", "could", "be", "blocked", "by", "inhibition", "of", "GFAT", ".", "These", "results", "support", "the", "notion", "that", "glucose", "stimulation", "of", "TGF", "-", "alpha", "expression", "requires", "GFAT", ",", "but", "EGF", "stimulation", "does", "not", ".", "\n" ]

[ "Protein" ]

TGF - alpha is a Protein, EGF is a Protein, Transforming growth factor - alpha is a Protein, TGF - alpha is a Protein, epidermal growth factor is a Protein, EGF is a Protein, L - glutamine : D - fructose-6-phosphate amidotransferase is a Protein, GFAT is a Protein, GFAT is a Protein, EGF is a Protein, EGF is a Protein, GFAT is a Protein, EGF is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, TGF - alpha is a Protein, EGF is a Protein, GFAT is a Protein, GFAT is a Protein, GFAT is a Protein, TGF - alpha is a Protein, GFAT is a Protein, EGF is a Protein

562_task1

Sentence: Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not. Instructions: please typing these entity words according to sentence: TGF - alpha, EGF, Transforming growth factor - alpha, TGF - alpha, epidermal growth factor, EGF, L - glutamine : D - fructose-6-phosphate amidotransferase, GFAT, GFAT, EGF, EGF, GFAT, EGF, TGF - alpha, TGF - alpha, TGF - alpha, EGF, GFAT, GFAT, GFAT, TGF - alpha, GFAT, EGF Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]

Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not.

[ "Role", "of", "glucosamine", "synthesis", "in", "the", "stimulation", "of", "TGF", "-", "alpha", "gene", "transcription", "by", "glucose", "and", "EGF", ".", "\n", "Transforming", "growth", "factor", "-", "alpha", "(", "TGF", "-", "alpha", ")", "gene", "transcription", "is", "regulated", "by", "both", "epidermal", "growth", "factor", "(", "EGF", ")", "and", "glucose", ".", "Previous", "studies", "have", "suggested", "that", "the", "metabolism", "of", "glucose", "to", "glucosamine", "through", "the", "enzyme", "L", "-", "glutamine", ":", "D", "-", "fructose-6-phosphate", "amidotransferase", "(", "GFAT", ")", "plays", "a", "critical", "role", "in", "the", "glucose", "signaling", ".", "In", "this", "paper", ",", "we", "compared", "the", "role", "of", "GFAT", "in", "the", "glucose", "and", "EGF", "signals", ".", "We", "found", "that", ",", "although", "EGF", "stimulates", "GFAT", "mRNA", "accumulation", "in", "MDA", "-", "MB-468", "cells", ",", "this", "effect", "of", "EGF", "occurred", "several", "hours", "after", "TGF", "-", "alpha", "transcription", "increased", ".", "MDA", "-", "MB-468", "cells", "also", "exhibited", "a", "TGF", "-", "alpha", "transcriptional", "response", "to", "low", "concentrations", "of", "glucose", ".", "The", "TGF", "-", "alpha", "response", "to", "glucose", "but", "not", "EGF", "could", "be", "inhibited", "by", "a", "blocker", "of", "GFAT", "activity", ".", "Blockade", "of", "GFAT", "was", "confirmed", "by", "using", "Western", "blotting", "with", "the", "RL2", "antibody", ",", "which", "recognizes", "an", "epitope", "on", "proteins", "containing", "N", "-", "acetylglucosamine", ".", "Exposure", "of", "cells", "to", "glucose", "increased", "the", "RL2", "signal", "on", "several", "polypeptides", ",", "but", "this", "change", "could", "be", "blocked", "by", "inhibition", "of", "GFAT", ".", "These", "results", "support", "the", "notion", "that", "glucose", "stimulation", "of", "TGF", "-", "alpha", "expression", "requires", "GFAT", ",", "but", "EGF", "stimulation", "does", "not", ".", "\n" ]

[ "Protein" ]

TGF - alpha, EGF, Transforming growth factor - alpha, TGF - alpha, epidermal growth factor, EGF, L - glutamine : D - fructose-6-phosphate amidotransferase, GFAT, GFAT, EGF, EGF, GFAT, EGF, TGF - alpha, TGF - alpha, TGF - alpha, EGF, GFAT, GFAT, GFAT, TGF - alpha, GFAT, EGF

562_task2

Sentence: Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]

Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Transforming growth factor-alpha (TGF-alpha) gene transcription is regulated by both epidermal growth factor (EGF) and glucose. Previous studies have suggested that the metabolism of glucose to glucosamine through the enzyme L-glutamine: D-fructose-6-phosphate amidotransferase (GFAT) plays a critical role in the glucose signaling. In this paper, we compared the role of GFAT in the glucose and EGF signals. We found that, although EGF stimulates GFAT mRNA accumulation in MDA-MB-468 cells, this effect of EGF occurred several hours after TGF-alpha transcription increased. MDA-MB-468 cells also exhibited a TGF-alpha transcriptional response to low concentrations of glucose. The TGF-alpha response to glucose but not EGF could be inhibited by a blocker of GFAT activity. Blockade of GFAT was confirmed by using Western blotting with the RL2 antibody, which recognizes an epitope on proteins containing N-acetylglucosamine. Exposure of cells to glucose increased the RL2 signal on several polypeptides, but this change could be blocked by inhibition of GFAT. These results support the notion that glucose stimulation of TGF-alpha expression requires GFAT, but EGF stimulation does not.

[ "Role", "of", "glucosamine", "synthesis", "in", "the", "stimulation", "of", "TGF", "-", "alpha", "gene", "transcription", "by", "glucose", "and", "EGF", ".", "\n", "Transforming", "growth", "factor", "-", "alpha", "(", "TGF", "-", "alpha", ")", "gene", "transcription", "is", "regulated", "by", "both", "epidermal", "growth", "factor", "(", "EGF", ")", "and", "glucose", ".", "Previous", "studies", "have", "suggested", "that", "the", "metabolism", "of", "glucose", "to", "glucosamine", "through", "the", "enzyme", "L", "-", "glutamine", ":", "D", "-", "fructose-6-phosphate", "amidotransferase", "(", "GFAT", ")", "plays", "a", "critical", "role", "in", "the", "glucose", "signaling", ".", "In", "this", "paper", ",", "we", "compared", "the", "role", "of", "GFAT", "in", "the", "glucose", "and", "EGF", "signals", ".", "We", "found", "that", ",", "although", "EGF", "stimulates", "GFAT", "mRNA", "accumulation", "in", "MDA", "-", "MB-468", "cells", ",", "this", "effect", "of", "EGF", "occurred", "several", "hours", "after", "TGF", "-", "alpha", "transcription", "increased", ".", "MDA", "-", "MB-468", "cells", "also", "exhibited", "a", "TGF", "-", "alpha", "transcriptional", "response", "to", "low", "concentrations", "of", "glucose", ".", "The", "TGF", "-", "alpha", "response", "to", "glucose", "but", "not", "EGF", "could", "be", "inhibited", "by", "a", "blocker", "of", "GFAT", "activity", ".", "Blockade", "of", "GFAT", "was", "confirmed", "by", "using", "Western", "blotting", "with", "the", "RL2", "antibody", ",", "which", "recognizes", "an", "epitope", "on", "proteins", "containing", "N", "-", "acetylglucosamine", ".", "Exposure", "of", "cells", "to", "glucose", "increased", "the", "RL2", "signal", "on", "several", "polypeptides", ",", "but", "this", "change", "could", "be", "blocked", "by", "inhibition", "of", "GFAT", ".", "These", "results", "support", "the", "notion", "that", "glucose", "stimulation", "of", "TGF", "-", "alpha", "expression", "requires", "GFAT", ",", "but", "EGF", "stimulation", "does", "not", ".", "\n" ]

[ "Protein" ]

c - fos is a DNA_domain_or_region, c - jun is a DNA_domain_or_region, jun B is a DNA_domain_or_region

84660_task0

Sentence: Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region

[ "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.

[ "Expression", "of", "c", "-", "fos", ",", "c", "-", "jun", "and", "jun", "B", "in", "peripheral", "blood", "lymphocytes", "from", "young", "and", "elderly", "adults", "." ]

[ "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "(AND other_name other_name)", "(OR other_name other_name)", "other_name", "multi_cell", "RNA_molecule", "protein_molecule", "", "DNA_family_or_group", "RNA_N/A", "cell_type", "DNA_domain_or_region", "RNA_family_or_group" ]

c - fos is a DNA_domain_or_region, c - jun is a DNA_domain_or_region, jun B is a DNA_domain_or_region

84660_task1

Sentence: Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults. Instructions: please typing these entity words according to sentence: c - fos, c - jun, jun B Options: DNA_domain_or_region

[ "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.

[ "Expression", "of", "c", "-", "fos", ",", "c", "-", "jun", "and", "jun", "B", "in", "peripheral", "blood", "lymphocytes", "from", "young", "and", "elderly", "adults", "." ]

[ "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "(AND other_name other_name)", "(OR other_name other_name)", "other_name", "multi_cell", "RNA_molecule", "protein_molecule", "", "DNA_family_or_group", "RNA_N/A", "cell_type", "DNA_domain_or_region", "RNA_family_or_group" ]

c - fos, c - jun, jun B

84660_task2

Sentence: Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Expression of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.

[ "Expression", "of", "c", "-", "fos", ",", "c", "-", "jun", "and", "jun", "B", "in", "peripheral", "blood", "lymphocytes", "from", "young", "and", "elderly", "adults", "." ]

[ "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "(AND other_name other_name)", "(OR other_name other_name)", "other_name", "multi_cell", "RNA_molecule", "protein_molecule", "", "DNA_family_or_group", "RNA_N/A", "cell_type", "DNA_domain_or_region", "RNA_family_or_group" ]

PGH(2 is a compound, mPGES-1 is a protein

DS.d1073_task0

Sentence: Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]

Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1.

[ "Possible", "binding", "site", "for", "the", "substrate", ",", "prostaglandin", "H(2", ")", "(", "PGH(2", ")", ")", ",", "was", "identified", "by", "systematically", "probing", "the", "refined", "molecular", "structure", "of", "mPGES-1", "." ]

[ "protein", "compound" ]

PGH(2 is a compound, mPGES-1 is a protein

DS.d1073_task1

Sentence: Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. Instructions: please typing these entity words according to sentence: PGH(2, mPGES-1 Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]

Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1.

[ "Possible", "binding", "site", "for", "the", "substrate", ",", "prostaglandin", "H(2", ")", "(", "PGH(2", ")", ")", ",", "was", "identified", "by", "systematically", "probing", "the", "refined", "molecular", "structure", "of", "mPGES-1", "." ]

[ "protein", "compound" ]

PGH(2, mPGES-1

DS.d1073_task2

Sentence: Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]

Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1.

[ "Possible", "binding", "site", "for", "the", "substrate", ",", "prostaglandin", "H(2", ")", "(", "PGH(2", ")", ")", ",", "was", "identified", "by", "systematically", "probing", "the", "refined", "molecular", "structure", "of", "mPGES-1", "." ]

[ "protein", "compound" ]

Patienten is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekt is an umlsterm, Lappenplastiken is an umlsterm, Behandlung is an umlsterm, Lebenszufriedenheit is an umlsterm, Fragebogen is an umlsterm, Behandlungsergebnis is an umlsterm, Beruf is an umlsterm, Einkommen is an umlsterm, Arbeit is an umlsterm, koerperliche Leistungsfaehigkeit is an umlsterm, Beschwerdefreiheit is an umlsterm, Patienten is an umlsterm, Referenzwert is an umlsterm, Beins is an umlsterm, Hebedefektmorbiditaet is an umlsterm, Belastbarkeit is an umlsterm, Schmerzen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Patient is an umlsterm, Amputation is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Behandlung is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekten is an umlsterm, Langzeitergebnisse is an umlsterm, Patienten is an umlsterm, Lebenszufriedenheit is an umlsterm, Patienten is an umlsterm

DerUnfallchirurg.81010838.ger.abstr_task0

Sentence: 58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten .

[ "58", "Patienten", "nach", "offenen", "Unterschenkelfrakturen", "mit", "ausgedehntem", "Hautweichteildefekt", ",", "welche", "interdisziplinaer", "mit", "Osteosynthesen", "und", "freien", ",", "mikrovaskulaeren", "Lappenplastiken", "versorgt", "worden", "waren", ",", "wurden", "durchschnittlich", "6", "Jahre", "nach", "der", "Behandlung", "im", "Hinblick", "auf", "ihre", "Lebenszufriedenheit", "untersucht", ".", "Verwendet", "wurde", "hierzu", "ein", "standardisiertes", "Testverfahren", "(", "FLZ", ")", "mit", "nachgewiesener", "Reliabilitaet", "und", "Validitaet", ",", "sowie", "ein", "Fragebogen", "mit", "spezifischen", "Fragen", "zur", "Zufriedenheit", "mit", "dem", "Behandlungsergebnis", ",", "zum", "Lokalbefund", "und", "dessen", "Auswirkungen", ",", "zu", "Beruf", "und", "oekonomischen", "Aspekten", ".", "In", "einzelnen", "Bereichen", "fanden", "sich", "signifikante", "Diskrepanzen", "zu", "einem", "repraesentativen", "Vergleichskollektiv", "aus", "der", "BRD", "-", "West", "(", "z", ".", "B.", "Freizeitgestaltung", "Einkommen", ",", "Arbeit", ",", "Partnerschaft", ",", "koerperliche", "Leistungsfaehigkeit", ",", "Fortbewegungsfaehigkeit", ",", "Beschwerdefreiheit", ")", ".", ",", "Die", "berechneten", ",", "globalen", "\"", "Lebenszufriedenheitsindices", "\"", "der", "untersuchten", "Patienten", "wichen", "statistisch", "schwach", "signifikant", "vom", "Referenzwert", "des", "Vergleichskollektivs", "ab", ".", "Obwohl", "spezifische", "Aspekte", "(", "z", ".", "B.", "Aussehen", "des", "Beins", ",", "Hebedefektmorbiditaet", ",", "Belastbarkeit", ",", "Schmerzen", ")", "langfristig", "durchaus", "kritisch", "beurteilt", "wurden", ",", "zeigten", "sich", "jedoch", "91", "%", "der", "Patienten", "mit", "der", "Behandlung", "zufrieden", ".", "Kein", "einziger", "Patient", "haette", "retrospektiv", "eine", "Amputation", "bevorzugt", "!", "64", "%", "der", "Patienten", "arbeiteten", "nach", "abgeschlossener", "Behandlung", "wieder", ".", "Die", "multimodale", "Behandlung", "von", "Unterschenkelfrakturen", "mit", "begleitenden", "Hautweichteildefekten", "durch", "ein", "erfahrenes", ",", "interdisziplinaeres", "\"", "Traumateam", "\"", ",", "kann", "zufriedenstellende", "Langzeitergebnisse", "liefern", ".", "Diese", "Behandlungsergebnisse", "werden", "von", "der", "ueberwiegenden", "Mehrzahl", "der", "Patienten", "positiv", "beurteilt", ".", "Mit", "einer", "Beeintraechtigung", "der", "Lebenszufriedenheit", "zumindest", "in", "bestimmten", "Bereichen", "muss", "allerdings", "gerechnet", "werden", ".", "Die", "vorliegende", "Studie", "gibt", "wertvolle", "Informationen", "sowohl", "fuer", "differentialtherapeutische", "Ueberlegungen", "als", "auch", "fuer", "das", "Gespraech", "mit", "den", "Patienten", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekt is an umlsterm, Lappenplastiken is an umlsterm, Behandlung is an umlsterm, Lebenszufriedenheit is an umlsterm, Fragebogen is an umlsterm, Behandlungsergebnis is an umlsterm, Beruf is an umlsterm, Einkommen is an umlsterm, Arbeit is an umlsterm, koerperliche Leistungsfaehigkeit is an umlsterm, Beschwerdefreiheit is an umlsterm, Patienten is an umlsterm, Referenzwert is an umlsterm, Beins is an umlsterm, Hebedefektmorbiditaet is an umlsterm, Belastbarkeit is an umlsterm, Schmerzen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Patient is an umlsterm, Amputation is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Behandlung is an umlsterm, Unterschenkelfrakturen is an umlsterm, Hautweichteildefekten is an umlsterm, Langzeitergebnisse is an umlsterm, Patienten is an umlsterm, Lebenszufriedenheit is an umlsterm, Patienten is an umlsterm

DerUnfallchirurg.81010838.ger.abstr_task1

Sentence: 58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten . Instructions: please typing these entity words according to sentence: Patienten, Unterschenkelfrakturen, Hautweichteildefekt, Lappenplastiken, Behandlung, Lebenszufriedenheit, Fragebogen, Behandlungsergebnis, Beruf, Einkommen, Arbeit, koerperliche Leistungsfaehigkeit, Beschwerdefreiheit, Patienten, Referenzwert, Beins, Hebedefektmorbiditaet, Belastbarkeit, Schmerzen, Patienten, Behandlung, Patient, Amputation, Patienten, Behandlung, Behandlung, Unterschenkelfrakturen, Hautweichteildefekten, Langzeitergebnisse, Patienten, Lebenszufriedenheit, Patienten Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten .

[ "58", "Patienten", "nach", "offenen", "Unterschenkelfrakturen", "mit", "ausgedehntem", "Hautweichteildefekt", ",", "welche", "interdisziplinaer", "mit", "Osteosynthesen", "und", "freien", ",", "mikrovaskulaeren", "Lappenplastiken", "versorgt", "worden", "waren", ",", "wurden", "durchschnittlich", "6", "Jahre", "nach", "der", "Behandlung", "im", "Hinblick", "auf", "ihre", "Lebenszufriedenheit", "untersucht", ".", "Verwendet", "wurde", "hierzu", "ein", "standardisiertes", "Testverfahren", "(", "FLZ", ")", "mit", "nachgewiesener", "Reliabilitaet", "und", "Validitaet", ",", "sowie", "ein", "Fragebogen", "mit", "spezifischen", "Fragen", "zur", "Zufriedenheit", "mit", "dem", "Behandlungsergebnis", ",", "zum", "Lokalbefund", "und", "dessen", "Auswirkungen", ",", "zu", "Beruf", "und", "oekonomischen", "Aspekten", ".", "In", "einzelnen", "Bereichen", "fanden", "sich", "signifikante", "Diskrepanzen", "zu", "einem", "repraesentativen", "Vergleichskollektiv", "aus", "der", "BRD", "-", "West", "(", "z", ".", "B.", "Freizeitgestaltung", "Einkommen", ",", "Arbeit", ",", "Partnerschaft", ",", "koerperliche", "Leistungsfaehigkeit", ",", "Fortbewegungsfaehigkeit", ",", "Beschwerdefreiheit", ")", ".", ",", "Die", "berechneten", ",", "globalen", "\"", "Lebenszufriedenheitsindices", "\"", "der", "untersuchten", "Patienten", "wichen", "statistisch", "schwach", "signifikant", "vom", "Referenzwert", "des", "Vergleichskollektivs", "ab", ".", "Obwohl", "spezifische", "Aspekte", "(", "z", ".", "B.", "Aussehen", "des", "Beins", ",", "Hebedefektmorbiditaet", ",", "Belastbarkeit", ",", "Schmerzen", ")", "langfristig", "durchaus", "kritisch", "beurteilt", "wurden", ",", "zeigten", "sich", "jedoch", "91", "%", "der", "Patienten", "mit", "der", "Behandlung", "zufrieden", ".", "Kein", "einziger", "Patient", "haette", "retrospektiv", "eine", "Amputation", "bevorzugt", "!", "64", "%", "der", "Patienten", "arbeiteten", "nach", "abgeschlossener", "Behandlung", "wieder", ".", "Die", "multimodale", "Behandlung", "von", "Unterschenkelfrakturen", "mit", "begleitenden", "Hautweichteildefekten", "durch", "ein", "erfahrenes", ",", "interdisziplinaeres", "\"", "Traumateam", "\"", ",", "kann", "zufriedenstellende", "Langzeitergebnisse", "liefern", ".", "Diese", "Behandlungsergebnisse", "werden", "von", "der", "ueberwiegenden", "Mehrzahl", "der", "Patienten", "positiv", "beurteilt", ".", "Mit", "einer", "Beeintraechtigung", "der", "Lebenszufriedenheit", "zumindest", "in", "bestimmten", "Bereichen", "muss", "allerdings", "gerechnet", "werden", ".", "Die", "vorliegende", "Studie", "gibt", "wertvolle", "Informationen", "sowohl", "fuer", "differentialtherapeutische", "Ueberlegungen", "als", "auch", "fuer", "das", "Gespraech", "mit", "den", "Patienten", "." ]

[ "umlsterm" ]

Patienten, Unterschenkelfrakturen, Hautweichteildefekt, Lappenplastiken, Behandlung, Lebenszufriedenheit, Fragebogen, Behandlungsergebnis, Beruf, Einkommen, Arbeit, koerperliche Leistungsfaehigkeit, Beschwerdefreiheit, Patienten, Referenzwert, Beins, Hebedefektmorbiditaet, Belastbarkeit, Schmerzen, Patienten, Behandlung, Patient, Amputation, Patienten, Behandlung, Behandlung, Unterschenkelfrakturen, Hautweichteildefekten, Langzeitergebnisse, Patienten, Lebenszufriedenheit, Patienten

DerUnfallchirurg.81010838.ger.abstr_task2

Sentence: 58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

58 Patienten nach offenen Unterschenkelfrakturen mit ausgedehntem Hautweichteildefekt , welche interdisziplinaer mit Osteosynthesen und freien , mikrovaskulaeren Lappenplastiken versorgt worden waren , wurden durchschnittlich 6 Jahre nach der Behandlung im Hinblick auf ihre Lebenszufriedenheit untersucht . Verwendet wurde hierzu ein standardisiertes Testverfahren ( FLZ ) mit nachgewiesener Reliabilitaet und Validitaet , sowie ein Fragebogen mit spezifischen Fragen zur Zufriedenheit mit dem Behandlungsergebnis , zum Lokalbefund und dessen Auswirkungen , zu Beruf und oekonomischen Aspekten . In einzelnen Bereichen fanden sich signifikante Diskrepanzen zu einem repraesentativen Vergleichskollektiv aus der BRD-West ( z . B. Freizeitgestaltung Einkommen , Arbeit , Partnerschaft , koerperliche Leistungsfaehigkeit , Fortbewegungsfaehigkeit , Beschwerdefreiheit ) . , Die berechneten , globalen " Lebenszufriedenheitsindices " der untersuchten Patienten wichen statistisch schwach signifikant vom Referenzwert des Vergleichskollektivs ab . Obwohl spezifische Aspekte ( z . B. Aussehen des Beins , Hebedefektmorbiditaet , Belastbarkeit , Schmerzen ) langfristig durchaus kritisch beurteilt wurden , zeigten sich jedoch 91 % der Patienten mit der Behandlung zufrieden . Kein einziger Patient haette retrospektiv eine Amputation bevorzugt ! 64 % der Patienten arbeiteten nach abgeschlossener Behandlung wieder . Die multimodale Behandlung von Unterschenkelfrakturen mit begleitenden Hautweichteildefekten durch ein erfahrenes , interdisziplinaeres " Traumateam " , kann zufriedenstellende Langzeitergebnisse liefern . Diese Behandlungsergebnisse werden von der ueberwiegenden Mehrzahl der Patienten positiv beurteilt . Mit einer Beeintraechtigung der Lebenszufriedenheit zumindest in bestimmten Bereichen muss allerdings gerechnet werden . Die vorliegende Studie gibt wertvolle Informationen sowohl fuer differentialtherapeutische Ueberlegungen als auch fuer das Gespraech mit den Patienten .

[ "58", "Patienten", "nach", "offenen", "Unterschenkelfrakturen", "mit", "ausgedehntem", "Hautweichteildefekt", ",", "welche", "interdisziplinaer", "mit", "Osteosynthesen", "und", "freien", ",", "mikrovaskulaeren", "Lappenplastiken", "versorgt", "worden", "waren", ",", "wurden", "durchschnittlich", "6", "Jahre", "nach", "der", "Behandlung", "im", "Hinblick", "auf", "ihre", "Lebenszufriedenheit", "untersucht", ".", "Verwendet", "wurde", "hierzu", "ein", "standardisiertes", "Testverfahren", "(", "FLZ", ")", "mit", "nachgewiesener", "Reliabilitaet", "und", "Validitaet", ",", "sowie", "ein", "Fragebogen", "mit", "spezifischen", "Fragen", "zur", "Zufriedenheit", "mit", "dem", "Behandlungsergebnis", ",", "zum", "Lokalbefund", "und", "dessen", "Auswirkungen", ",", "zu", "Beruf", "und", "oekonomischen", "Aspekten", ".", "In", "einzelnen", "Bereichen", "fanden", "sich", "signifikante", "Diskrepanzen", "zu", "einem", "repraesentativen", "Vergleichskollektiv", "aus", "der", "BRD", "-", "West", "(", "z", ".", "B.", "Freizeitgestaltung", "Einkommen", ",", "Arbeit", ",", "Partnerschaft", ",", "koerperliche", "Leistungsfaehigkeit", ",", "Fortbewegungsfaehigkeit", ",", "Beschwerdefreiheit", ")", ".", ",", "Die", "berechneten", ",", "globalen", "\"", "Lebenszufriedenheitsindices", "\"", "der", "untersuchten", "Patienten", "wichen", "statistisch", "schwach", "signifikant", "vom", "Referenzwert", "des", "Vergleichskollektivs", "ab", ".", "Obwohl", "spezifische", "Aspekte", "(", "z", ".", "B.", "Aussehen", "des", "Beins", ",", "Hebedefektmorbiditaet", ",", "Belastbarkeit", ",", "Schmerzen", ")", "langfristig", "durchaus", "kritisch", "beurteilt", "wurden", ",", "zeigten", "sich", "jedoch", "91", "%", "der", "Patienten", "mit", "der", "Behandlung", "zufrieden", ".", "Kein", "einziger", "Patient", "haette", "retrospektiv", "eine", "Amputation", "bevorzugt", "!", "64", "%", "der", "Patienten", "arbeiteten", "nach", "abgeschlossener", "Behandlung", "wieder", ".", "Die", "multimodale", "Behandlung", "von", "Unterschenkelfrakturen", "mit", "begleitenden", "Hautweichteildefekten", "durch", "ein", "erfahrenes", ",", "interdisziplinaeres", "\"", "Traumateam", "\"", ",", "kann", "zufriedenstellende", "Langzeitergebnisse", "liefern", ".", "Diese", "Behandlungsergebnisse", "werden", "von", "der", "ueberwiegenden", "Mehrzahl", "der", "Patienten", "positiv", "beurteilt", ".", "Mit", "einer", "Beeintraechtigung", "der", "Lebenszufriedenheit", "zumindest", "in", "bestimmten", "Bereichen", "muss", "allerdings", "gerechnet", "werden", ".", "Die", "vorliegende", "Studie", "gibt", "wertvolle", "Informationen", "sowohl", "fuer", "differentialtherapeutische", "Ueberlegungen", "als", "auch", "fuer", "das", "Gespraech", "mit", "den", "Patienten", "." ]

[ "umlsterm" ]

Hypotension is an umlsterm, Nitroprussidnatrium is an umlsterm, NPN is an umlsterm, Genehmigung is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Nasen - Septumkorrektur - Operationen is an umlsterm, Hypotension is an umlsterm, NPN is an umlsterm, Fentanyl is an umlsterm, Etomidat is an umlsterm, Isofluran is an umlsterm, Katecholamine is an umlsterm, IL-6 is an umlsterm, Stickstoffmonoxid is an umlsterm

DerAnaesthesist.50440328.ger.abstr_task0

Sentence: Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht .

[ "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "eine", "kontrollierte", "Hypotension", "mit", "Nitroprussidnatrium", "(", "NPN", ")", "das", "Ausmass", "der", "Akutphasenreaktion", "beeinflusst", ".", "Nach", "Genehmigung", "durch", "die", "Ethikkommission", "wurden", "20", "Patienten", "mit", "Nasen", "-", "Septumkorrektur", "-", "Operationen", "untersucht", ",", "von", "denen", "10", "eine", "kontrollierte", "Hypotension", "mit", "NPN", "erhielten", ".", "Die", "Narkose", "wurde", "mit", "Fentanyl", ",", "Etomidat", "eingeleitet", "und", "mit", "Isofluran", "in", "66", "%", "N20", "und", "33", "%", "O2", "fortgefuehrt", ".", "Die", "Interleukin-6-Plasmakonzentrationen", "(", "IL-6", ")", "stiegen", "in", "beiden", "Gruppen", "am", "1", ".", "postoperativen", "Tag", "signifikant", "(", "p", "0,05", ")", "an", ".", "Dabei", "lagen", "die", "Werte", "in", "der", "NPN", "-", "Gruppe", "mit", "31,8", "(", "9", "-", "42", ",", "2", ")", "pg", "/", "ml", "(", "Median", "und", "Streubreite", ")", "signifikant", "ueber", "denen", "der", "Kontrollgruppe", "mit", "15,2", "(", "7,4", "-", "19,0", ")", "pg", "/", "ml", ".", "In", "der", "NPN", "-", "Gruppe", "stiegen", "die", "Plasmakonzentrationen", "der", "Katecholamine", "zum", "intraoperativen", "Messzeitpunkt", "signifikant", "an", ".", "Die", "NPN", "-", "Gabe", "stellte", "einen", "erheblichen", "Stimulus", "fuer", "die", "Freisetzung", "von", "IL-6", "dar", ",", "dem", "wichtigsten", "Mediator", "der", "Akutphasenreaktion", ".", "Als", "Ursache", "hierfuer", "kommen", "das", "beim", "NPN", "-", "Abbau", "entstehende", "Stickstoffmonoxid", "und", "der", "Anstieg", "der", "Katecholamin", "-", "Plasmakonzentrationen", "in", "Betracht", "." ]

[ "umlsterm" ]

Hypotension is an umlsterm, Nitroprussidnatrium is an umlsterm, NPN is an umlsterm, Genehmigung is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Nasen - Septumkorrektur - Operationen is an umlsterm, Hypotension is an umlsterm, NPN is an umlsterm, Fentanyl is an umlsterm, Etomidat is an umlsterm, Isofluran is an umlsterm, Katecholamine is an umlsterm, IL-6 is an umlsterm, Stickstoffmonoxid is an umlsterm

DerAnaesthesist.50440328.ger.abstr_task1

Sentence: Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht . Instructions: please typing these entity words according to sentence: Hypotension, Nitroprussidnatrium, NPN, Genehmigung, Ethikkommission, Patienten, Nasen - Septumkorrektur - Operationen, Hypotension, NPN, Fentanyl, Etomidat, Isofluran, Katecholamine, IL-6, Stickstoffmonoxid Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht .

[ "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "eine", "kontrollierte", "Hypotension", "mit", "Nitroprussidnatrium", "(", "NPN", ")", "das", "Ausmass", "der", "Akutphasenreaktion", "beeinflusst", ".", "Nach", "Genehmigung", "durch", "die", "Ethikkommission", "wurden", "20", "Patienten", "mit", "Nasen", "-", "Septumkorrektur", "-", "Operationen", "untersucht", ",", "von", "denen", "10", "eine", "kontrollierte", "Hypotension", "mit", "NPN", "erhielten", ".", "Die", "Narkose", "wurde", "mit", "Fentanyl", ",", "Etomidat", "eingeleitet", "und", "mit", "Isofluran", "in", "66", "%", "N20", "und", "33", "%", "O2", "fortgefuehrt", ".", "Die", "Interleukin-6-Plasmakonzentrationen", "(", "IL-6", ")", "stiegen", "in", "beiden", "Gruppen", "am", "1", ".", "postoperativen", "Tag", "signifikant", "(", "p", "0,05", ")", "an", ".", "Dabei", "lagen", "die", "Werte", "in", "der", "NPN", "-", "Gruppe", "mit", "31,8", "(", "9", "-", "42", ",", "2", ")", "pg", "/", "ml", "(", "Median", "und", "Streubreite", ")", "signifikant", "ueber", "denen", "der", "Kontrollgruppe", "mit", "15,2", "(", "7,4", "-", "19,0", ")", "pg", "/", "ml", ".", "In", "der", "NPN", "-", "Gruppe", "stiegen", "die", "Plasmakonzentrationen", "der", "Katecholamine", "zum", "intraoperativen", "Messzeitpunkt", "signifikant", "an", ".", "Die", "NPN", "-", "Gabe", "stellte", "einen", "erheblichen", "Stimulus", "fuer", "die", "Freisetzung", "von", "IL-6", "dar", ",", "dem", "wichtigsten", "Mediator", "der", "Akutphasenreaktion", ".", "Als", "Ursache", "hierfuer", "kommen", "das", "beim", "NPN", "-", "Abbau", "entstehende", "Stickstoffmonoxid", "und", "der", "Anstieg", "der", "Katecholamin", "-", "Plasmakonzentrationen", "in", "Betracht", "." ]

[ "umlsterm" ]

Hypotension, Nitroprussidnatrium, NPN, Genehmigung, Ethikkommission, Patienten, Nasen - Septumkorrektur - Operationen, Hypotension, NPN, Fentanyl, Etomidat, Isofluran, Katecholamine, IL-6, Stickstoffmonoxid

DerAnaesthesist.50440328.ger.abstr_task2

Sentence: Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die vorliegende Untersuchung ging der Frage nach , ob eine kontrollierte Hypotension mit Nitroprussidnatrium ( NPN ) das Ausmass der Akutphasenreaktion beeinflusst . Nach Genehmigung durch die Ethikkommission wurden 20 Patienten mit Nasen-Septumkorrektur-Operationen untersucht , von denen 10 eine kontrollierte Hypotension mit NPN erhielten . Die Narkose wurde mit Fentanyl , Etomidat eingeleitet und mit Isofluran in 66% N20 und 33% O2 fortgefuehrt . Die Interleukin-6-Plasmakonzentrationen ( IL-6) stiegen in beiden Gruppen am 1. postoperativen Tag signifikant ( p 0,05 ) an . Dabei lagen die Werte in der NPN-Gruppe mit 31,8 ( 9-42 , 2 ) pg/ml ( Median und Streubreite ) signifikant ueber denen der Kontrollgruppe mit 15,2 ( 7,4-19,0) pg/ml . In der NPN-Gruppe stiegen die Plasmakonzentrationen der Katecholamine zum intraoperativen Messzeitpunkt signifikant an . Die NPN-Gabe stellte einen erheblichen Stimulus fuer die Freisetzung von IL-6 dar , dem wichtigsten Mediator der Akutphasenreaktion . Als Ursache hierfuer kommen das beim NPN-Abbau entstehende Stickstoffmonoxid und der Anstieg der Katecholamin-Plasmakonzentrationen in Betracht .

[ "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "eine", "kontrollierte", "Hypotension", "mit", "Nitroprussidnatrium", "(", "NPN", ")", "das", "Ausmass", "der", "Akutphasenreaktion", "beeinflusst", ".", "Nach", "Genehmigung", "durch", "die", "Ethikkommission", "wurden", "20", "Patienten", "mit", "Nasen", "-", "Septumkorrektur", "-", "Operationen", "untersucht", ",", "von", "denen", "10", "eine", "kontrollierte", "Hypotension", "mit", "NPN", "erhielten", ".", "Die", "Narkose", "wurde", "mit", "Fentanyl", ",", "Etomidat", "eingeleitet", "und", "mit", "Isofluran", "in", "66", "%", "N20", "und", "33", "%", "O2", "fortgefuehrt", ".", "Die", "Interleukin-6-Plasmakonzentrationen", "(", "IL-6", ")", "stiegen", "in", "beiden", "Gruppen", "am", "1", ".", "postoperativen", "Tag", "signifikant", "(", "p", "0,05", ")", "an", ".", "Dabei", "lagen", "die", "Werte", "in", "der", "NPN", "-", "Gruppe", "mit", "31,8", "(", "9", "-", "42", ",", "2", ")", "pg", "/", "ml", "(", "Median", "und", "Streubreite", ")", "signifikant", "ueber", "denen", "der", "Kontrollgruppe", "mit", "15,2", "(", "7,4", "-", "19,0", ")", "pg", "/", "ml", ".", "In", "der", "NPN", "-", "Gruppe", "stiegen", "die", "Plasmakonzentrationen", "der", "Katecholamine", "zum", "intraoperativen", "Messzeitpunkt", "signifikant", "an", ".", "Die", "NPN", "-", "Gabe", "stellte", "einen", "erheblichen", "Stimulus", "fuer", "die", "Freisetzung", "von", "IL-6", "dar", ",", "dem", "wichtigsten", "Mediator", "der", "Akutphasenreaktion", ".", "Als", "Ursache", "hierfuer", "kommen", "das", "beim", "NPN", "-", "Abbau", "entstehende", "Stickstoffmonoxid", "und", "der", "Anstieg", "der", "Katecholamin", "-", "Plasmakonzentrationen", "in", "Betracht", "." ]

[ "umlsterm" ]

treatment is an umlsterm, prevention is an umlsterm, immunocompromised is an umlsterm, children is an umlsterm

MonatsschriftKinderheilkunde.81460200.eng.abstr_task0

Sentence: In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed .

[ "In", "order", "to", "point", "out", "optimal", "strategies", "for", "treatment", "and", "prevention", "of", "varicella", "-", "zoster", "-", "infections", "in", "immunocompromised", "children", "the", "current", "proceeding", "as", "well", "as", "possible", "alternatives", "are", "reviewed", "." ]

[ "umlsterm" ]

treatment is an umlsterm, prevention is an umlsterm, immunocompromised is an umlsterm, children is an umlsterm

MonatsschriftKinderheilkunde.81460200.eng.abstr_task1

Sentence: In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed . Instructions: please typing these entity words according to sentence: treatment, prevention, immunocompromised, children Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed .

[ "In", "order", "to", "point", "out", "optimal", "strategies", "for", "treatment", "and", "prevention", "of", "varicella", "-", "zoster", "-", "infections", "in", "immunocompromised", "children", "the", "current", "proceeding", "as", "well", "as", "possible", "alternatives", "are", "reviewed", "." ]

[ "umlsterm" ]

treatment, prevention, immunocompromised, children

MonatsschriftKinderheilkunde.81460200.eng.abstr_task2

Sentence: In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In order to point out optimal strategies for treatment and prevention of varicella-zoster-infections in immunocompromised children the current proceeding as well as possible alternatives are reviewed .

[ "In", "order", "to", "point", "out", "optimal", "strategies", "for", "treatment", "and", "prevention", "of", "varicella", "-", "zoster", "-", "infections", "in", "immunocompromised", "children", "the", "current", "proceeding", "as", "well", "as", "possible", "alternatives", "are", "reviewed", "." ]

[ "umlsterm" ]

Bcl10 is a Protein, Bcl10 is a Protein, beta - actin is a Protein

82_task0

Sentence: NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).

[ "NF", "-", "kappaB", "inhibition", "by", "PMA", "correlated", "to", "PKC", "-", "dependent", "Bcl10", "degradation", ".", "Levels", "of", "intracellular", "protein", "were", "assessed", "following", "24", "h", "stimulation", "with", "PMA", "(", "162", "nM", ")", "or", "HK", "E.", "coli", "(", "5", "x", "107", "CFU", "/", "ml", ")", ".", "(", "A", ")", "Phospho", "-", "PKC", "increased", "in", "response", "to", "PMA", "and", "HK", "E.", "coli", "stimulation", ".", "(", "B", ")", "IkappaB", "decreased", "following", "stimulation", "with", "HK", "E.", "coli", "indicating", "NF", "-", "kappaB", "activation", ".", "(", "C", ")", "Bcl10", "activation", "was", "inhibited", "following", "long", "-", "term", "stimulation", "with", "PMA", ",", "which", "explains", "the", "inhibitory", "effect", "of", "PMA", "on", "NF", "-", "kappaB", "activation", ".", "beta", "-", "actin", "was", "used", "as", "a", "loading", "control", ".", "(", "n", "=", "3", ")", "." ]

[ "Protein" ]

Bcl10 is a Protein, Bcl10 is a Protein, beta - actin is a Protein

82_task1

Sentence: NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3). Instructions: please typing these entity words according to sentence: Bcl10, Bcl10, beta - actin Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).

[ "NF", "-", "kappaB", "inhibition", "by", "PMA", "correlated", "to", "PKC", "-", "dependent", "Bcl10", "degradation", ".", "Levels", "of", "intracellular", "protein", "were", "assessed", "following", "24", "h", "stimulation", "with", "PMA", "(", "162", "nM", ")", "or", "HK", "E.", "coli", "(", "5", "x", "107", "CFU", "/", "ml", ")", ".", "(", "A", ")", "Phospho", "-", "PKC", "increased", "in", "response", "to", "PMA", "and", "HK", "E.", "coli", "stimulation", ".", "(", "B", ")", "IkappaB", "decreased", "following", "stimulation", "with", "HK", "E.", "coli", "indicating", "NF", "-", "kappaB", "activation", ".", "(", "C", ")", "Bcl10", "activation", "was", "inhibited", "following", "long", "-", "term", "stimulation", "with", "PMA", ",", "which", "explains", "the", "inhibitory", "effect", "of", "PMA", "on", "NF", "-", "kappaB", "activation", ".", "beta", "-", "actin", "was", "used", "as", "a", "loading", "control", ".", "(", "n", "=", "3", ")", "." ]

[ "Protein" ]

Bcl10, Bcl10, beta - actin

82_task2

Sentence: NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).

[ "NF", "-", "kappaB", "inhibition", "by", "PMA", "correlated", "to", "PKC", "-", "dependent", "Bcl10", "degradation", ".", "Levels", "of", "intracellular", "protein", "were", "assessed", "following", "24", "h", "stimulation", "with", "PMA", "(", "162", "nM", ")", "or", "HK", "E.", "coli", "(", "5", "x", "107", "CFU", "/", "ml", ")", ".", "(", "A", ")", "Phospho", "-", "PKC", "increased", "in", "response", "to", "PMA", "and", "HK", "E.", "coli", "stimulation", ".", "(", "B", ")", "IkappaB", "decreased", "following", "stimulation", "with", "HK", "E.", "coli", "indicating", "NF", "-", "kappaB", "activation", ".", "(", "C", ")", "Bcl10", "activation", "was", "inhibited", "following", "long", "-", "term", "stimulation", "with", "PMA", ",", "which", "explains", "the", "inhibitory", "effect", "of", "PMA", "on", "NF", "-", "kappaB", "activation", ".", "beta", "-", "actin", "was", "used", "as", "a", "loading", "control", ".", "(", "n", "=", "3", ")", "." ]

[ "Protein" ]

adherence is a Outcome_Mental, mometasone furoate is a Intervention_Pharmacological, MF - DPI is a Intervention_Pharmacological, > or=12 years old is a Participant_Age, mild - to - moderate persistent asthma is a Participant_Condition, MF - DPI 400 microg once - daily in the evening is a Intervention_Pharmacological, MF - DPI 200 microg twice - daily is a Intervention_Pharmacological, Adherence is a Outcome_Mental, actual administered doses is a Outcome_Mental, Health - related quality of life is a Outcome_Mental, healthcare resource utilization is a Outcome_Other, days missed from work or school is a Outcome_Mental, 1233 is a Participant_Sample-size, mean is a Outcome_Other, adherence rates is a Outcome_Mental, Mean is a Outcome_Other, Adherence rates is a Outcome_Mental, missed work / school is a Outcome_Mental

43767_task0

Sentence: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration .

[ "Improved", "adherence", "with", "once", "-", "daily", "versus", "twice", "-", "daily", "dosing", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", ":", "a", "randomized", "open", "-", "label", "study", ".", "BACKGROUND", "Poor", "adherence", "with", "prescribed", "asthma", "medication", "is", "a", "major", "barrier", "to", "positive", "treatment", "outcomes", ".", "This", "study", "was", "designed", "to", "determine", "the", "effect", "of", "a", "once", "-", "daily", "administration", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", "(", "MF", "-", "DPI", ")", "on", "treatment", "adherence", "compared", "with", "a", "twice", "-", "daily", "administration", ".", "METHODS", "This", "was", "a", "12-week", "open", "-", "label", "study", "designed", "to", "mimic", "an", "actual", "clinical", "setting", "in", "patients", ">", "or=12", "years", "old", "with", "mild", "-", "to", "-", "moderate", "persistent", "asthma", ".", "Patients", "were", "randomized", "to", "receive", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "or", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", ".", "Adherence", "was", "assessed", "primarily", "using", "the", "number", "of", "actual", "administered", "doses", "reported", "from", "the", "device", "counter", "divided", "by", "the", "number", "of", "scheduled", "doses", ".", "Self", "-", "reports", "were", "also", "used", "to", "determine", "adherence", ".", "Health", "-", "related", "quality", "of", "life", ",", "healthcare", "resource", "utilization", ",", "and", "days", "missed", "from", "work", "or", "school", "were", "also", "reported", ".", "RESULTS", "1233", "patients", "were", "randomized", ".", "The", "mean", "adherence", "rates", ",", "as", "measured", "by", "the", "automatic", "dose", "counter", ",", "were", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "(", "93.3", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "89.5", "%", ")", ".", "Mean", "adherence", "rates", "based", "on", "self", "-", "reports", "were", "also", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "QD", "PM", "(", "97.2", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "95.3", "%", ")", ".", "Adherence", "rates", "were", "lower", "in", "adolescents", "(", "12", "-", "17", "years", "old", ")", ".", "Health", "-", "related", "quality", "of", "life", "improved", "by", "20", "%", "in", "patients", "using", "MF", "-", "DPI", "once", "-", "daily", "in", "the", "evening", "and", "by", "14", "%", "in", "patients", "using", "MF", "-", "DPI", "twice", "-", "daily", ".", "Very", "few", "(", "<", "8", "%", ")", "patients", "missed", "work", "/", "school", ".", "CONCLUSION", "Mean", "adherence", "rates", "were", "greater", "with", "a", "once", "-", "daily", "dosing", "regimen", "of", "MF", "-", "DPI", "than", "with", "a", "twice", "-", "daily", "dosing", "regimen", ".", "This", "trial", "was", "completed", "prior", "to", "the", "ISMJE", "requirements", "for", "trial", "registration", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Age", "Participant_Sample-size" ]

adherence is a Outcome_Mental, mometasone furoate is a Intervention_Pharmacological, MF - DPI is a Intervention_Pharmacological, > or=12 years old is a Participant_Age, mild - to - moderate persistent asthma is a Participant_Condition, MF - DPI 400 microg once - daily in the evening is a Intervention_Pharmacological, MF - DPI 200 microg twice - daily is a Intervention_Pharmacological, Adherence is a Outcome_Mental, actual administered doses is a Outcome_Mental, Health - related quality of life is a Outcome_Mental, healthcare resource utilization is a Outcome_Other, days missed from work or school is a Outcome_Mental, 1233 is a Participant_Sample-size, mean is a Outcome_Other, adherence rates is a Outcome_Mental, Mean is a Outcome_Other, Adherence rates is a Outcome_Mental, missed work / school is a Outcome_Mental

43767_task1

Sentence: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration . Instructions: please typing these entity words according to sentence: adherence, mometasone furoate, MF - DPI, > or=12 years old, mild - to - moderate persistent asthma, MF - DPI 400 microg once - daily in the evening, MF - DPI 200 microg twice - daily, Adherence, actual administered doses, Health - related quality of life, healthcare resource utilization, days missed from work or school, 1233, mean, adherence rates, Mean, Adherence rates, missed work / school Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration .

[ "Improved", "adherence", "with", "once", "-", "daily", "versus", "twice", "-", "daily", "dosing", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", ":", "a", "randomized", "open", "-", "label", "study", ".", "BACKGROUND", "Poor", "adherence", "with", "prescribed", "asthma", "medication", "is", "a", "major", "barrier", "to", "positive", "treatment", "outcomes", ".", "This", "study", "was", "designed", "to", "determine", "the", "effect", "of", "a", "once", "-", "daily", "administration", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", "(", "MF", "-", "DPI", ")", "on", "treatment", "adherence", "compared", "with", "a", "twice", "-", "daily", "administration", ".", "METHODS", "This", "was", "a", "12-week", "open", "-", "label", "study", "designed", "to", "mimic", "an", "actual", "clinical", "setting", "in", "patients", ">", "or=12", "years", "old", "with", "mild", "-", "to", "-", "moderate", "persistent", "asthma", ".", "Patients", "were", "randomized", "to", "receive", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "or", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", ".", "Adherence", "was", "assessed", "primarily", "using", "the", "number", "of", "actual", "administered", "doses", "reported", "from", "the", "device", "counter", "divided", "by", "the", "number", "of", "scheduled", "doses", ".", "Self", "-", "reports", "were", "also", "used", "to", "determine", "adherence", ".", "Health", "-", "related", "quality", "of", "life", ",", "healthcare", "resource", "utilization", ",", "and", "days", "missed", "from", "work", "or", "school", "were", "also", "reported", ".", "RESULTS", "1233", "patients", "were", "randomized", ".", "The", "mean", "adherence", "rates", ",", "as", "measured", "by", "the", "automatic", "dose", "counter", ",", "were", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "(", "93.3", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "89.5", "%", ")", ".", "Mean", "adherence", "rates", "based", "on", "self", "-", "reports", "were", "also", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "QD", "PM", "(", "97.2", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "95.3", "%", ")", ".", "Adherence", "rates", "were", "lower", "in", "adolescents", "(", "12", "-", "17", "years", "old", ")", ".", "Health", "-", "related", "quality", "of", "life", "improved", "by", "20", "%", "in", "patients", "using", "MF", "-", "DPI", "once", "-", "daily", "in", "the", "evening", "and", "by", "14", "%", "in", "patients", "using", "MF", "-", "DPI", "twice", "-", "daily", ".", "Very", "few", "(", "<", "8", "%", ")", "patients", "missed", "work", "/", "school", ".", "CONCLUSION", "Mean", "adherence", "rates", "were", "greater", "with", "a", "once", "-", "daily", "dosing", "regimen", "of", "MF", "-", "DPI", "than", "with", "a", "twice", "-", "daily", "dosing", "regimen", ".", "This", "trial", "was", "completed", "prior", "to", "the", "ISMJE", "requirements", "for", "trial", "registration", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Age", "Participant_Sample-size" ]

adherence, mometasone furoate, MF - DPI, > or=12 years old, mild - to - moderate persistent asthma, MF - DPI 400 microg once - daily in the evening, MF - DPI 200 microg twice - daily, Adherence, actual administered doses, Health - related quality of life, healthcare resource utilization, days missed from work or school, 1233, mean, adherence rates, Mean, Adherence rates, missed work / school

43767_task2

Sentence: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study . BACKGROUND Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes . This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler ( MF-DPI ) on treatment adherence compared with a twice-daily administration . METHODS This was a 12-week open-label study designed to mimic an actual clinical setting in patients > or=12 years old with mild-to-moderate persistent asthma . Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily . Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses . Self-reports were also used to determine adherence . Health-related quality of life , healthcare resource utilization , and days missed from work or school were also reported . RESULTS 1233 patients were randomized . The mean adherence rates , as measured by the automatic dose counter , were significantly better ( P < 0.001 ) with MF-DPI 400 microg once-daily in the evening ( 93.3 % ) than with MF-DPI 200 microg twice-daily ( 89.5 % ) . Mean adherence rates based on self-reports were also significantly better ( P < 0.001 ) with MF-DPI 400 microg QD PM ( 97.2 % ) than with MF-DPI 200 microg twice-daily ( 95.3 % ) . Adherence rates were lower in adolescents ( 12-17 years old ) . Health-related quality of life improved by 20 % in patients using MF-DPI once-daily in the evening and by 14 % in patients using MF-DPI twice-daily . Very few ( < 8 % ) patients missed work/school . CONCLUSION Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration .

[ "Improved", "adherence", "with", "once", "-", "daily", "versus", "twice", "-", "daily", "dosing", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", ":", "a", "randomized", "open", "-", "label", "study", ".", "BACKGROUND", "Poor", "adherence", "with", "prescribed", "asthma", "medication", "is", "a", "major", "barrier", "to", "positive", "treatment", "outcomes", ".", "This", "study", "was", "designed", "to", "determine", "the", "effect", "of", "a", "once", "-", "daily", "administration", "of", "mometasone", "furoate", "administered", "via", "a", "dry", "powder", "inhaler", "(", "MF", "-", "DPI", ")", "on", "treatment", "adherence", "compared", "with", "a", "twice", "-", "daily", "administration", ".", "METHODS", "This", "was", "a", "12-week", "open", "-", "label", "study", "designed", "to", "mimic", "an", "actual", "clinical", "setting", "in", "patients", ">", "or=12", "years", "old", "with", "mild", "-", "to", "-", "moderate", "persistent", "asthma", ".", "Patients", "were", "randomized", "to", "receive", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "or", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", ".", "Adherence", "was", "assessed", "primarily", "using", "the", "number", "of", "actual", "administered", "doses", "reported", "from", "the", "device", "counter", "divided", "by", "the", "number", "of", "scheduled", "doses", ".", "Self", "-", "reports", "were", "also", "used", "to", "determine", "adherence", ".", "Health", "-", "related", "quality", "of", "life", ",", "healthcare", "resource", "utilization", ",", "and", "days", "missed", "from", "work", "or", "school", "were", "also", "reported", ".", "RESULTS", "1233", "patients", "were", "randomized", ".", "The", "mean", "adherence", "rates", ",", "as", "measured", "by", "the", "automatic", "dose", "counter", ",", "were", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "once", "-", "daily", "in", "the", "evening", "(", "93.3", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "89.5", "%", ")", ".", "Mean", "adherence", "rates", "based", "on", "self", "-", "reports", "were", "also", "significantly", "better", "(", "P", "<", "0.001", ")", "with", "MF", "-", "DPI", "400", "microg", "QD", "PM", "(", "97.2", "%", ")", "than", "with", "MF", "-", "DPI", "200", "microg", "twice", "-", "daily", "(", "95.3", "%", ")", ".", "Adherence", "rates", "were", "lower", "in", "adolescents", "(", "12", "-", "17", "years", "old", ")", ".", "Health", "-", "related", "quality", "of", "life", "improved", "by", "20", "%", "in", "patients", "using", "MF", "-", "DPI", "once", "-", "daily", "in", "the", "evening", "and", "by", "14", "%", "in", "patients", "using", "MF", "-", "DPI", "twice", "-", "daily", ".", "Very", "few", "(", "<", "8", "%", ")", "patients", "missed", "work", "/", "school", ".", "CONCLUSION", "Mean", "adherence", "rates", "were", "greater", "with", "a", "once", "-", "daily", "dosing", "regimen", "of", "MF", "-", "DPI", "than", "with", "a", "twice", "-", "daily", "dosing", "regimen", ".", "This", "trial", "was", "completed", "prior", "to", "the", "ISMJE", "requirements", "for", "trial", "registration", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Age", "Participant_Sample-size" ]

cystic fibrosis transmembrane conductance regulator is a Gene, CFTR is a Gene

421_task0

Sentence: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene.

[ "Mutations", "and", "sequence", "variations", "detected", "in", "the", "cystic", "fibrosis", "transmembrane", "conductance", "regulator", "(", "CFTR", ")", "gene", ":", "a", "report", "from", "the", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "Cystic", "fibrosis", "is", "the", "most", "common", "autosomal", "disorder", "in", "the", "Caucasian", "population", ".", "Since", "the", "description", "of", "the", "major", "mutation", "of", "this", "disease", "in", "1989", ",", "over", "150", "of", "additional", "mutations", "have", "been", "identified", "in", "the", "CFTR", "gene", ".", "This", "update", "summarizes", "the", "different", "mutations", "identified", "and", "reported", "before", "March", "15", "by", "members", "of", "the", "international", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "The", "report", "includes", "information", "on", "DNA", "sequence", "variations", "found", "in", "the", "gene", ".", "\n" ]

[ "Gene" ]

cystic fibrosis transmembrane conductance regulator is a Gene, CFTR is a Gene

421_task1

Sentence: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene. Instructions: please typing these entity words according to sentence: cystic fibrosis transmembrane conductance regulator, CFTR Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene.

[ "Mutations", "and", "sequence", "variations", "detected", "in", "the", "cystic", "fibrosis", "transmembrane", "conductance", "regulator", "(", "CFTR", ")", "gene", ":", "a", "report", "from", "the", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "Cystic", "fibrosis", "is", "the", "most", "common", "autosomal", "disorder", "in", "the", "Caucasian", "population", ".", "Since", "the", "description", "of", "the", "major", "mutation", "of", "this", "disease", "in", "1989", ",", "over", "150", "of", "additional", "mutations", "have", "been", "identified", "in", "the", "CFTR", "gene", ".", "This", "update", "summarizes", "the", "different", "mutations", "identified", "and", "reported", "before", "March", "15", "by", "members", "of", "the", "international", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "The", "report", "includes", "information", "on", "DNA", "sequence", "variations", "found", "in", "the", "gene", ".", "\n" ]

[ "Gene" ]

cystic fibrosis transmembrane conductance regulator, CFTR

421_task2

Sentence: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis is the most common autosomal disorder in the Caucasian population. Since the description of the major mutation of this disease in 1989, over 150 of additional mutations have been identified in the CFTR gene. This update summarizes the different mutations identified and reported before March 15 by members of the international Cystic Fibrosis Genetic Analysis Consortium. The report includes information on DNA sequence variations found in the gene.

[ "Mutations", "and", "sequence", "variations", "detected", "in", "the", "cystic", "fibrosis", "transmembrane", "conductance", "regulator", "(", "CFTR", ")", "gene", ":", "a", "report", "from", "the", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "Cystic", "fibrosis", "is", "the", "most", "common", "autosomal", "disorder", "in", "the", "Caucasian", "population", ".", "Since", "the", "description", "of", "the", "major", "mutation", "of", "this", "disease", "in", "1989", ",", "over", "150", "of", "additional", "mutations", "have", "been", "identified", "in", "the", "CFTR", "gene", ".", "This", "update", "summarizes", "the", "different", "mutations", "identified", "and", "reported", "before", "March", "15", "by", "members", "of", "the", "international", "Cystic", "Fibrosis", "Genetic", "Analysis", "Consortium", ".", "The", "report", "includes", "information", "on", "DNA", "sequence", "variations", "found", "in", "the", "gene", ".", "\n" ]

[ "Gene" ]

amiodarona is a NORMALIZABLES, dicumarínicos is a NORMALIZABLES, GGT is a PROTEINAS, FA is a PROTEINAS, O2 is a NORMALIZABLES, urea is a NORMALIZABLES, creatinina is a NORMALIZABLES, bilirrubina is a NORMALIZABLES, AST is a PROTEINAS, ALT is a PROTEINAS, GGT is a PROTEINAS, dopamina is a NORMALIZABLES, piperacilina / tazobactam is a NORMALIZABLES, vancomicina is a NORMALIZABLES, gentamicina is a NORMALIZABLES

178_task0

Sentence: Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico.

[ "Se", "trata", "de", "una", "señora", "de", "76", "años", ",", "que", "ingresa", "en", "el", "Servicio", "de", "Cirugía", "Vascular", "por", "un", "síndrome", "postflebítico", ".", "Durante", "su", "estancia", "en", "planta", "presenta", "deterioro", "clínico", ",", "motivo", "por", "el", "que", "se", "traslada", "a", "UCI", "el", "10/5/03", "en", "situación", "de", "sepsis", "grave", ".", "\n", "Como", "antecedentes", "de", "interés", "destaca", "HTA", ",", "obesidad", ",", "artrosis", "y", "resección", "de", "adenoma", "tubular", "de", "colón", ".", "En", "agosto", "de", "2000", "se", "intervino", "de", "colecistectomía", "por", "colecistitis", "litiásica", "con", "importante", "plastrón", "inflamatorio", "subhepático", "que", "obligó", "a", "una", "resección", "subtotal", "de", "la", "vesícula", ".", "En", "ese", "ingreso", "desarrolló", "TVP", "de", "EII", "con", "TEP", "posterior", "y", "fibrilación", "auricular", ",", "iniciando", "tratamiento", "con", "amiodarona", "y", "dicumarínicos", ".", "En", "estudio", "ambulatorio", "el", "último", "mes", "por", "clínica", "digestiva", "inespecífica", "observando", "en", "control", "analítico", "elevación", "de", "GGT", "y", "FA", ".", "\n", "A", "la", "exploración", "en", "UCI", "estaba", "estuporosa", ",", "ictérica", "y", "con", "hipotensión", "arterial", ".", "Saturación", "de", "O2", "conservada", "con", "mascarilla", ".", "Auscultación", "cardiaca", "rítmica", "a", "80", "lpm", ",", "sin", "soplos", ".", "Auscultación", "pulmonar", "normal", ".", "El", "abdomen", "era", "globuloso", ",", "doloroso", "a", "la", "palpación", "en", "hemiabdomen", "derecho", ",", "aunque", "sin", "signos", "de", "irritación", "peritoneal", "y", "la", "EII", "mostraba", "buena", "evolución", "de", "su", "trombosis", ".", "\n", "En", "analítica", "destacaba", "leucocitosis", "(", "37.000", "/", "mm3", ")", "con", "neutrofilia", ",", "urea", "1,83", "g", "/", "l", ",", "creatinina", "4,2", "mg", "/", "dl", "bilirrubina", "total", "8,6", "mg", "/", "dl", ",", "con", "fracción", "directa", "de", "5,7", "mg", "/", "dl", ",", "AST", "312", "U", "/", "l", ",", "ALT", "106", "U", "/", "l", ",", "GGT", "416", "U", "/", "l.", "Con", "el", "diagnóstico", "de", "sepsis", "de", "origen", "biliar", ",", "se", "inicia", "tratamiento", "con", "fluidoterapia", ",", "dopamina", "y", "antibiótico", "empírico", "con", "piperacilina", "/", "tazobactam", "obteniendo", "buena", "respuesta", "inicial", ".", "\n", "Pruebas", "complementarias", "realizadas", ":", "TAC", "-", "abdominal", "(", "11/5/03", ")", "que", "evidencia", "múltiples", "imágenes", "hipodensas", "en", "parénquima", "hepático", "que", "sugerían", "abscesos", ".", "Ecocardiograma", "transtorácico", "y", "transesofágico", ",", "que", "confirmó", "la", "existencia", "de", "endocarditis", "a", "nivel", "subvalvular", "mitral", "que", "condicionaba", "insuficiencia", "grado", "II", ".", "Tras", "este", "hallazgo", "se", "añadió", "vancomicina", "y", "gentamicina", "al", "tratamiento", "antibiótico", ".", "PAAF", "de", "una", "lesión", "hepática", ".", "ERCP", "que", "no", "observó", "dilatación", "de", "via", "biliar", ",", "aunque", "se", "realizó", "papilotomía", "para", "asegurar", "el", "drenaje", "biliar", ".", "La", "evolución", "posterior", "fue", "desfavorable", "con", "instauración", "de", "SDMO", "refractario", "y", "exitus", "a", "las", "96", "horas", "de", "su", "ingreso", "en", "UCI", ".", "\n", "Soliciamos", "necropsia", "que", "reveló", "colangiocarcinoma", "multicéntrico", ",", "con", "múltiples", "nódulos", "en", "todo", "el", "órgano", ",", "extensión", "local", "al", "lecho", "vesicular", "y", "a", "vías", "biliares", "extrahepáticas", ",", "metástasis", "regionales", "a", "ganglios", "linfáticos", "del", "hilio", "hepático", "y", "a", "distancia", ",", "manifestadas", "por", "focos", "microscópicos", "a", "nivel", "pulmonar", ".", "\n\n", "Asimismo", "se", "observaba", "extensa", "necrosis", "intratumoral", "con", "sobreinfección", "por", "Enterobacter", "cloacae", ",", "también", "aislado", "en", "sangre", "y", "muestra", "de", "PAAF", ",", "lo", "que", "nos", "hace", "suponer", "que", "fue", "el", "germen", "responsable", "del", "cuadro", "séptico", ".", "\n\n" ]

[ "NORMALIZABLES", "PROTEINAS" ]

amiodarona is a NORMALIZABLES, dicumarínicos is a NORMALIZABLES, GGT is a PROTEINAS, FA is a PROTEINAS, O2 is a NORMALIZABLES, urea is a NORMALIZABLES, creatinina is a NORMALIZABLES, bilirrubina is a NORMALIZABLES, AST is a PROTEINAS, ALT is a PROTEINAS, GGT is a PROTEINAS, dopamina is a NORMALIZABLES, piperacilina / tazobactam is a NORMALIZABLES, vancomicina is a NORMALIZABLES, gentamicina is a NORMALIZABLES

178_task1

Sentence: Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico. Instructions: please typing these entity words according to sentence: amiodarona, dicumarínicos, GGT, FA, O2, urea, creatinina, bilirrubina, AST, ALT, GGT, dopamina, piperacilina / tazobactam, vancomicina, gentamicina Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico.

[ "Se", "trata", "de", "una", "señora", "de", "76", "años", ",", "que", "ingresa", "en", "el", "Servicio", "de", "Cirugía", "Vascular", "por", "un", "síndrome", "postflebítico", ".", "Durante", "su", "estancia", "en", "planta", "presenta", "deterioro", "clínico", ",", "motivo", "por", "el", "que", "se", "traslada", "a", "UCI", "el", "10/5/03", "en", "situación", "de", "sepsis", "grave", ".", "\n", "Como", "antecedentes", "de", "interés", "destaca", "HTA", ",", "obesidad", ",", "artrosis", "y", "resección", "de", "adenoma", "tubular", "de", "colón", ".", "En", "agosto", "de", "2000", "se", "intervino", "de", "colecistectomía", "por", "colecistitis", "litiásica", "con", "importante", "plastrón", "inflamatorio", "subhepático", "que", "obligó", "a", "una", "resección", "subtotal", "de", "la", "vesícula", ".", "En", "ese", "ingreso", "desarrolló", "TVP", "de", "EII", "con", "TEP", "posterior", "y", "fibrilación", "auricular", ",", "iniciando", "tratamiento", "con", "amiodarona", "y", "dicumarínicos", ".", "En", "estudio", "ambulatorio", "el", "último", "mes", "por", "clínica", "digestiva", "inespecífica", "observando", "en", "control", "analítico", "elevación", "de", "GGT", "y", "FA", ".", "\n", "A", "la", "exploración", "en", "UCI", "estaba", "estuporosa", ",", "ictérica", "y", "con", "hipotensión", "arterial", ".", "Saturación", "de", "O2", "conservada", "con", "mascarilla", ".", "Auscultación", "cardiaca", "rítmica", "a", "80", "lpm", ",", "sin", "soplos", ".", "Auscultación", "pulmonar", "normal", ".", "El", "abdomen", "era", "globuloso", ",", "doloroso", "a", "la", "palpación", "en", "hemiabdomen", "derecho", ",", "aunque", "sin", "signos", "de", "irritación", "peritoneal", "y", "la", "EII", "mostraba", "buena", "evolución", "de", "su", "trombosis", ".", "\n", "En", "analítica", "destacaba", "leucocitosis", "(", "37.000", "/", "mm3", ")", "con", "neutrofilia", ",", "urea", "1,83", "g", "/", "l", ",", "creatinina", "4,2", "mg", "/", "dl", "bilirrubina", "total", "8,6", "mg", "/", "dl", ",", "con", "fracción", "directa", "de", "5,7", "mg", "/", "dl", ",", "AST", "312", "U", "/", "l", ",", "ALT", "106", "U", "/", "l", ",", "GGT", "416", "U", "/", "l.", "Con", "el", "diagnóstico", "de", "sepsis", "de", "origen", "biliar", ",", "se", "inicia", "tratamiento", "con", "fluidoterapia", ",", "dopamina", "y", "antibiótico", "empírico", "con", "piperacilina", "/", "tazobactam", "obteniendo", "buena", "respuesta", "inicial", ".", "\n", "Pruebas", "complementarias", "realizadas", ":", "TAC", "-", "abdominal", "(", "11/5/03", ")", "que", "evidencia", "múltiples", "imágenes", "hipodensas", "en", "parénquima", "hepático", "que", "sugerían", "abscesos", ".", "Ecocardiograma", "transtorácico", "y", "transesofágico", ",", "que", "confirmó", "la", "existencia", "de", "endocarditis", "a", "nivel", "subvalvular", "mitral", "que", "condicionaba", "insuficiencia", "grado", "II", ".", "Tras", "este", "hallazgo", "se", "añadió", "vancomicina", "y", "gentamicina", "al", "tratamiento", "antibiótico", ".", "PAAF", "de", "una", "lesión", "hepática", ".", "ERCP", "que", "no", "observó", "dilatación", "de", "via", "biliar", ",", "aunque", "se", "realizó", "papilotomía", "para", "asegurar", "el", "drenaje", "biliar", ".", "La", "evolución", "posterior", "fue", "desfavorable", "con", "instauración", "de", "SDMO", "refractario", "y", "exitus", "a", "las", "96", "horas", "de", "su", "ingreso", "en", "UCI", ".", "\n", "Soliciamos", "necropsia", "que", "reveló", "colangiocarcinoma", "multicéntrico", ",", "con", "múltiples", "nódulos", "en", "todo", "el", "órgano", ",", "extensión", "local", "al", "lecho", "vesicular", "y", "a", "vías", "biliares", "extrahepáticas", ",", "metástasis", "regionales", "a", "ganglios", "linfáticos", "del", "hilio", "hepático", "y", "a", "distancia", ",", "manifestadas", "por", "focos", "microscópicos", "a", "nivel", "pulmonar", ".", "\n\n", "Asimismo", "se", "observaba", "extensa", "necrosis", "intratumoral", "con", "sobreinfección", "por", "Enterobacter", "cloacae", ",", "también", "aislado", "en", "sangre", "y", "muestra", "de", "PAAF", ",", "lo", "que", "nos", "hace", "suponer", "que", "fue", "el", "germen", "responsable", "del", "cuadro", "séptico", ".", "\n\n" ]

[ "NORMALIZABLES", "PROTEINAS" ]

amiodarona, dicumarínicos, GGT, FA, O2, urea, creatinina, bilirrubina, AST, ALT, GGT, dopamina, piperacilina / tazobactam, vancomicina, gentamicina

178_task2

Sentence: Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Se trata de una señora de 76 años, que ingresa en el Servicio de Cirugía Vascular por un síndrome postflebítico. Durante su estancia en planta presenta deterioro clínico, motivo por el que se traslada a UCI el 10/5/03 en situación de sepsis grave. Como antecedentes de interés destaca HTA, obesidad, artrosis y resección de adenoma tubular de colón. En agosto de 2000 se intervino de colecistectomía por colecistitis litiásica con importante plastrón inflamatorio subhepático que obligó a una resección subtotal de la vesícula. En ese ingreso desarrolló TVP de EII con TEP posterior y fibrilación auricular, iniciando tratamiento con amiodarona y dicumarínicos. En estudio ambulatorio el último mes por clínica digestiva inespecífica observando en control analítico elevación de GGT y FA. A la exploración en UCI estaba estuporosa, ictérica y con hipotensión arterial. Saturación de O2 conservada con mascarilla. Auscultación cardiaca rítmica a 80 lpm, sin soplos. Auscultación pulmonar normal. El abdomen era globuloso, doloroso a la palpación en hemiabdomen derecho, aunque sin signos de irritación peritoneal y la EII mostraba buena evolución de su trombosis. En analítica destacaba leucocitosis (37.000/mm3) con neutrofilia, urea 1,83 g/l, creatinina 4,2 mg/dl bilirrubina total 8,6 mg/dl, con fracción directa de 5,7 mg/dl, AST 312 U/l, ALT 106 U/l, GGT 416 U/l. Con el diagnóstico de sepsis de origen biliar, se inicia tratamiento con fluidoterapia, dopamina y antibiótico empírico con piperacilina/tazobactam obteniendo buena respuesta inicial. Pruebas complementarias realizadas: TAC-abdominal (11/5/03) que evidencia múltiples imágenes hipodensas en parénquima hepático que sugerían abscesos. Ecocardiograma transtorácico y transesofágico, que confirmó la existencia de endocarditis a nivel subvalvular mitral que condicionaba insuficiencia grado II. Tras este hallazgo se añadió vancomicina y gentamicina al tratamiento antibiótico. PAAF de una lesión hepática. ERCP que no observó dilatación de via biliar, aunque se realizó papilotomía para asegurar el drenaje biliar. La evolución posterior fue desfavorable con instauración de SDMO refractario y exitus a las 96 horas de su ingreso en UCI. Soliciamos necropsia que reveló colangiocarcinoma multicéntrico, con múltiples nódulos en todo el órgano, extensión local al lecho vesicular y a vías biliares extrahepáticas, metástasis regionales a ganglios linfáticos del hilio hepático y a distancia, manifestadas por focos microscópicos a nivel pulmonar. Asimismo se observaba extensa necrosis intratumoral con sobreinfección por Enterobacter cloacae, también aislado en sangre y muestra de PAAF, lo que nos hace suponer que fue el germen responsable del cuadro séptico.

[ "Se", "trata", "de", "una", "señora", "de", "76", "años", ",", "que", "ingresa", "en", "el", "Servicio", "de", "Cirugía", "Vascular", "por", "un", "síndrome", "postflebítico", ".", "Durante", "su", "estancia", "en", "planta", "presenta", "deterioro", "clínico", ",", "motivo", "por", "el", "que", "se", "traslada", "a", "UCI", "el", "10/5/03", "en", "situación", "de", "sepsis", "grave", ".", "\n", "Como", "antecedentes", "de", "interés", "destaca", "HTA", ",", "obesidad", ",", "artrosis", "y", "resección", "de", "adenoma", "tubular", "de", "colón", ".", "En", "agosto", "de", "2000", "se", "intervino", "de", "colecistectomía", "por", "colecistitis", "litiásica", "con", "importante", "plastrón", "inflamatorio", "subhepático", "que", "obligó", "a", "una", "resección", "subtotal", "de", "la", "vesícula", ".", "En", "ese", "ingreso", "desarrolló", "TVP", "de", "EII", "con", "TEP", "posterior", "y", "fibrilación", "auricular", ",", "iniciando", "tratamiento", "con", "amiodarona", "y", "dicumarínicos", ".", "En", "estudio", "ambulatorio", "el", "último", "mes", "por", "clínica", "digestiva", "inespecífica", "observando", "en", "control", "analítico", "elevación", "de", "GGT", "y", "FA", ".", "\n", "A", "la", "exploración", "en", "UCI", "estaba", "estuporosa", ",", "ictérica", "y", "con", "hipotensión", "arterial", ".", "Saturación", "de", "O2", "conservada", "con", "mascarilla", ".", "Auscultación", "cardiaca", "rítmica", "a", "80", "lpm", ",", "sin", "soplos", ".", "Auscultación", "pulmonar", "normal", ".", "El", "abdomen", "era", "globuloso", ",", "doloroso", "a", "la", "palpación", "en", "hemiabdomen", "derecho", ",", "aunque", "sin", "signos", "de", "irritación", "peritoneal", "y", "la", "EII", "mostraba", "buena", "evolución", "de", "su", "trombosis", ".", "\n", "En", "analítica", "destacaba", "leucocitosis", "(", "37.000", "/", "mm3", ")", "con", "neutrofilia", ",", "urea", "1,83", "g", "/", "l", ",", "creatinina", "4,2", "mg", "/", "dl", "bilirrubina", "total", "8,6", "mg", "/", "dl", ",", "con", "fracción", "directa", "de", "5,7", "mg", "/", "dl", ",", "AST", "312", "U", "/", "l", ",", "ALT", "106", "U", "/", "l", ",", "GGT", "416", "U", "/", "l.", "Con", "el", "diagnóstico", "de", "sepsis", "de", "origen", "biliar", ",", "se", "inicia", "tratamiento", "con", "fluidoterapia", ",", "dopamina", "y", "antibiótico", "empírico", "con", "piperacilina", "/", "tazobactam", "obteniendo", "buena", "respuesta", "inicial", ".", "\n", "Pruebas", "complementarias", "realizadas", ":", "TAC", "-", "abdominal", "(", "11/5/03", ")", "que", "evidencia", "múltiples", "imágenes", "hipodensas", "en", "parénquima", "hepático", "que", "sugerían", "abscesos", ".", "Ecocardiograma", "transtorácico", "y", "transesofágico", ",", "que", "confirmó", "la", "existencia", "de", "endocarditis", "a", "nivel", "subvalvular", "mitral", "que", "condicionaba", "insuficiencia", "grado", "II", ".", "Tras", "este", "hallazgo", "se", "añadió", "vancomicina", "y", "gentamicina", "al", "tratamiento", "antibiótico", ".", "PAAF", "de", "una", "lesión", "hepática", ".", "ERCP", "que", "no", "observó", "dilatación", "de", "via", "biliar", ",", "aunque", "se", "realizó", "papilotomía", "para", "asegurar", "el", "drenaje", "biliar", ".", "La", "evolución", "posterior", "fue", "desfavorable", "con", "instauración", "de", "SDMO", "refractario", "y", "exitus", "a", "las", "96", "horas", "de", "su", "ingreso", "en", "UCI", ".", "\n", "Soliciamos", "necropsia", "que", "reveló", "colangiocarcinoma", "multicéntrico", ",", "con", "múltiples", "nódulos", "en", "todo", "el", "órgano", ",", "extensión", "local", "al", "lecho", "vesicular", "y", "a", "vías", "biliares", "extrahepáticas", ",", "metástasis", "regionales", "a", "ganglios", "linfáticos", "del", "hilio", "hepático", "y", "a", "distancia", ",", "manifestadas", "por", "focos", "microscópicos", "a", "nivel", "pulmonar", ".", "\n\n", "Asimismo", "se", "observaba", "extensa", "necrosis", "intratumoral", "con", "sobreinfección", "por", "Enterobacter", "cloacae", ",", "también", "aislado", "en", "sangre", "y", "muestra", "de", "PAAF", ",", "lo", "que", "nos", "hace", "suponer", "que", "fue", "el", "germen", "responsable", "del", "cuadro", "séptico", ".", "\n\n" ]

[ "NORMALIZABLES", "PROTEINAS" ]

iodine dose is a Intervention_Pharmacological, aortic and hepatic enhancement at multidetector CT : is a Participant_Condition, total body weight ( TBW ) is a Outcome_Physical, lean body weight ( LBW ) is a Outcome_Physical, estimated blood volume ( BV ) is a Outcome_Physical, One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen is a Participant_Condition, correlation coefficients is a Outcome_Physical, correlation of change in CT number per gram is a Outcome_Physical, Adjusted MHE is a Outcome_Physical

43456_task0

Sentence: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability .

[ "Body", "size", "indexes", "for", "optimizing", "iodine", "dose", "for", "aortic", "and", "hepatic", "enhancement", "at", "multidetector", "CT", ":", "comparison", "of", "total", "body", "weight", ",", "lean", "body", "weight", ",", "and", "blood", "volume", ".", "PURPOSE", "To", "evaluate", "and", "compare", "total", "body", "weight", "(", "TBW", ")", ",", "lean", "body", "weight", "(", "LBW", ")", ",", "and", "estimated", "blood", "volume", "(", "BV", ")", "for", "the", "adjustment", "of", "the", "iodine", "dose", "required", "for", "contrast", "material", "-", "enhanced", "multidetector", "computed", "tomography", "(", "CT", ")", "of", "the", "aorta", "and", "liver", ".", "MATERIALS", "AND", "METHODS", "Institutional", "review", "committee", "approval", "and", "written", "informed", "consent", "were", "obtained", ".", "One", "hundred", "twenty", "patients", "(", "54", "men", ",", "66", "women", ";", "mean", "age", ",", "64.1", "years", ";", "range", ",", "19", "-", "88", "years", ")", "who", "underwent", "multidetector", "CT", "of", "the", "upper", "abdomen", "were", "randomized", "into", "three", "groups", "of", "40", "patients", "each", ":", "(", "a", ")", "TBW", "group", "(", "0.6", "g", "of", "iodine", "per", "kilogram", "of", "TBW", ")", ",", "(", "b", ")", "LBW", "group", "(", "0.821", "g", "of", "iodine", "per", "kilogram", "of", "LBW", ")", ",", "and", "(", "c", ")", "BV", "group", "(", "men", ",", "8.6", "g", "of", "iodine", "per", "liter", "of", "BV", ";", "women", ",", "9.9", "g", "of", "iodine", "per", "liter", "of", "BV", ")", ".", "Change", "in", "CT", "number", "between", "unenhanced", "and", "contrast", "-", "enhanced", "images", "per", "gram", "of", "iodine", "and", "maximum", "hepatic", "enhancement", "(", "MHE", ")", "adjusted", "for", "iodine", "dose", "were", "examined", "for", "correlation", "with", "TBW", ",", "LBW", ",", "and", "BV", "by", "using", "linear", "regression", "analysis", ".", "RESULTS", "In", "the", "portal", "venous", "phase", ",", "correlation", "coefficients", "for", "the", "correlation", "of", "change", "in", "CT", "number", "per", "gram", "of", "iodine", "with", "TBW", "for", "the", "aorta", "and", "liver", "were", "-0.71", "and", "-0.79", ",", "respectively", ",", "in", "the", "TBW", "group", ";", "-0.80", "and", "-0.86", ",", "respectively", ",", "in", "the", "LBW", "group", ";", "and", "-0.68", "and", "-0.66", ",", "respectively", ",", "in", "the", "BV", "group", ".", "In", "the", "liver", ",", "they", "were", "marginally", "higher", "in", "the", "LBW", "group", "than", "in", "the", "BV", "group", "(", "P", "=", ".03", ")", ".", "Adjusted", "MHE", "remained", "constant", "at", "77.9", "HU", "+", "/-", "10.2", "(", "standard", "deviation", ")", "in", "the", "LBW", "group", "with", "respect", "to", "TBW", ",", "but", "it", "increased", "in", "the", "TBW", "(", "r", "=", "0.80", ",", "P", "<", ".001", ")", "and", "BV", "(", "r", "=", "0.70", ",", "P", "<", ".001", ")", "groups", "as", "TBW", "increased", ".", "CONCLUSION", "When", "LBW", ",", "rather", "than", "TBW", "or", "BV", ",", "is", "used", ",", "the", "iodine", "dose", "required", "to", "achieve", "consistent", "hepatic", "enhancement", "may", "be", "estimated", "more", "precisely", "and", "with", "reduced", "patient", "-", "to", "-", "patient", "variability", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological" ]

iodine dose is a Intervention_Pharmacological, aortic and hepatic enhancement at multidetector CT : is a Participant_Condition, total body weight ( TBW ) is a Outcome_Physical, lean body weight ( LBW ) is a Outcome_Physical, estimated blood volume ( BV ) is a Outcome_Physical, One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen is a Participant_Condition, correlation coefficients is a Outcome_Physical, correlation of change in CT number per gram is a Outcome_Physical, Adjusted MHE is a Outcome_Physical

43456_task1

Sentence: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability . Instructions: please typing these entity words according to sentence: iodine dose, aortic and hepatic enhancement at multidetector CT :, total body weight ( TBW ), lean body weight ( LBW ), estimated blood volume ( BV ), One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen, correlation coefficients, correlation of change in CT number per gram, Adjusted MHE Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability .

[ "Body", "size", "indexes", "for", "optimizing", "iodine", "dose", "for", "aortic", "and", "hepatic", "enhancement", "at", "multidetector", "CT", ":", "comparison", "of", "total", "body", "weight", ",", "lean", "body", "weight", ",", "and", "blood", "volume", ".", "PURPOSE", "To", "evaluate", "and", "compare", "total", "body", "weight", "(", "TBW", ")", ",", "lean", "body", "weight", "(", "LBW", ")", ",", "and", "estimated", "blood", "volume", "(", "BV", ")", "for", "the", "adjustment", "of", "the", "iodine", "dose", "required", "for", "contrast", "material", "-", "enhanced", "multidetector", "computed", "tomography", "(", "CT", ")", "of", "the", "aorta", "and", "liver", ".", "MATERIALS", "AND", "METHODS", "Institutional", "review", "committee", "approval", "and", "written", "informed", "consent", "were", "obtained", ".", "One", "hundred", "twenty", "patients", "(", "54", "men", ",", "66", "women", ";", "mean", "age", ",", "64.1", "years", ";", "range", ",", "19", "-", "88", "years", ")", "who", "underwent", "multidetector", "CT", "of", "the", "upper", "abdomen", "were", "randomized", "into", "three", "groups", "of", "40", "patients", "each", ":", "(", "a", ")", "TBW", "group", "(", "0.6", "g", "of", "iodine", "per", "kilogram", "of", "TBW", ")", ",", "(", "b", ")", "LBW", "group", "(", "0.821", "g", "of", "iodine", "per", "kilogram", "of", "LBW", ")", ",", "and", "(", "c", ")", "BV", "group", "(", "men", ",", "8.6", "g", "of", "iodine", "per", "liter", "of", "BV", ";", "women", ",", "9.9", "g", "of", "iodine", "per", "liter", "of", "BV", ")", ".", "Change", "in", "CT", "number", "between", "unenhanced", "and", "contrast", "-", "enhanced", "images", "per", "gram", "of", "iodine", "and", "maximum", "hepatic", "enhancement", "(", "MHE", ")", "adjusted", "for", "iodine", "dose", "were", "examined", "for", "correlation", "with", "TBW", ",", "LBW", ",", "and", "BV", "by", "using", "linear", "regression", "analysis", ".", "RESULTS", "In", "the", "portal", "venous", "phase", ",", "correlation", "coefficients", "for", "the", "correlation", "of", "change", "in", "CT", "number", "per", "gram", "of", "iodine", "with", "TBW", "for", "the", "aorta", "and", "liver", "were", "-0.71", "and", "-0.79", ",", "respectively", ",", "in", "the", "TBW", "group", ";", "-0.80", "and", "-0.86", ",", "respectively", ",", "in", "the", "LBW", "group", ";", "and", "-0.68", "and", "-0.66", ",", "respectively", ",", "in", "the", "BV", "group", ".", "In", "the", "liver", ",", "they", "were", "marginally", "higher", "in", "the", "LBW", "group", "than", "in", "the", "BV", "group", "(", "P", "=", ".03", ")", ".", "Adjusted", "MHE", "remained", "constant", "at", "77.9", "HU", "+", "/-", "10.2", "(", "standard", "deviation", ")", "in", "the", "LBW", "group", "with", "respect", "to", "TBW", ",", "but", "it", "increased", "in", "the", "TBW", "(", "r", "=", "0.80", ",", "P", "<", ".001", ")", "and", "BV", "(", "r", "=", "0.70", ",", "P", "<", ".001", ")", "groups", "as", "TBW", "increased", ".", "CONCLUSION", "When", "LBW", ",", "rather", "than", "TBW", "or", "BV", ",", "is", "used", ",", "the", "iodine", "dose", "required", "to", "achieve", "consistent", "hepatic", "enhancement", "may", "be", "estimated", "more", "precisely", "and", "with", "reduced", "patient", "-", "to", "-", "patient", "variability", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological" ]

iodine dose, aortic and hepatic enhancement at multidetector CT :, total body weight ( TBW ), lean body weight ( LBW ), estimated blood volume ( BV ), One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19 - 88 years ) who underwent multidetector CT of the upper abdomen, correlation coefficients, correlation of change in CT number per gram, Adjusted MHE

43456_task2

Sentence: Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT : comparison of total body weight , lean body weight , and blood volume . PURPOSE To evaluate and compare total body weight ( TBW ) , lean body weight ( LBW ) , and estimated blood volume ( BV ) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography ( CT ) of the aorta and liver . MATERIALS AND METHODS Institutional review committee approval and written informed consent were obtained . One hundred twenty patients ( 54 men , 66 women ; mean age , 64.1 years ; range , 19-88 years ) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each : ( a ) TBW group ( 0.6 g of iodine per kilogram of TBW ) , ( b ) LBW group ( 0.821 g of iodine per kilogram of LBW ) , and ( c ) BV group ( men , 8.6 g of iodine per liter of BV ; women , 9.9 g of iodine per liter of BV ) . Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement ( MHE ) adjusted for iodine dose were examined for correlation with TBW , LBW , and BV by using linear regression analysis . RESULTS In the portal venous phase , correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79 , respectively , in the TBW group ; -0.80 and -0.86 , respectively , in the LBW group ; and -0.68 and -0.66 , respectively , in the BV group . In the liver , they were marginally higher in the LBW group than in the BV group ( P = .03 ) . Adjusted MHE remained constant at 77.9 HU +/- 10.2 ( standard deviation ) in the LBW group with respect to TBW , but it increased in the TBW ( r = 0.80 , P < .001 ) and BV ( r = 0.70 , P < .001 ) groups as TBW increased . CONCLUSION When LBW , rather than TBW or BV , is used , the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability .

[ "Body", "size", "indexes", "for", "optimizing", "iodine", "dose", "for", "aortic", "and", "hepatic", "enhancement", "at", "multidetector", "CT", ":", "comparison", "of", "total", "body", "weight", ",", "lean", "body", "weight", ",", "and", "blood", "volume", ".", "PURPOSE", "To", "evaluate", "and", "compare", "total", "body", "weight", "(", "TBW", ")", ",", "lean", "body", "weight", "(", "LBW", ")", ",", "and", "estimated", "blood", "volume", "(", "BV", ")", "for", "the", "adjustment", "of", "the", "iodine", "dose", "required", "for", "contrast", "material", "-", "enhanced", "multidetector", "computed", "tomography", "(", "CT", ")", "of", "the", "aorta", "and", "liver", ".", "MATERIALS", "AND", "METHODS", "Institutional", "review", "committee", "approval", "and", "written", "informed", "consent", "were", "obtained", ".", "One", "hundred", "twenty", "patients", "(", "54", "men", ",", "66", "women", ";", "mean", "age", ",", "64.1", "years", ";", "range", ",", "19", "-", "88", "years", ")", "who", "underwent", "multidetector", "CT", "of", "the", "upper", "abdomen", "were", "randomized", "into", "three", "groups", "of", "40", "patients", "each", ":", "(", "a", ")", "TBW", "group", "(", "0.6", "g", "of", "iodine", "per", "kilogram", "of", "TBW", ")", ",", "(", "b", ")", "LBW", "group", "(", "0.821", "g", "of", "iodine", "per", "kilogram", "of", "LBW", ")", ",", "and", "(", "c", ")", "BV", "group", "(", "men", ",", "8.6", "g", "of", "iodine", "per", "liter", "of", "BV", ";", "women", ",", "9.9", "g", "of", "iodine", "per", "liter", "of", "BV", ")", ".", "Change", "in", "CT", "number", "between", "unenhanced", "and", "contrast", "-", "enhanced", "images", "per", "gram", "of", "iodine", "and", "maximum", "hepatic", "enhancement", "(", "MHE", ")", "adjusted", "for", "iodine", "dose", "were", "examined", "for", "correlation", "with", "TBW", ",", "LBW", ",", "and", "BV", "by", "using", "linear", "regression", "analysis", ".", "RESULTS", "In", "the", "portal", "venous", "phase", ",", "correlation", "coefficients", "for", "the", "correlation", "of", "change", "in", "CT", "number", "per", "gram", "of", "iodine", "with", "TBW", "for", "the", "aorta", "and", "liver", "were", "-0.71", "and", "-0.79", ",", "respectively", ",", "in", "the", "TBW", "group", ";", "-0.80", "and", "-0.86", ",", "respectively", ",", "in", "the", "LBW", "group", ";", "and", "-0.68", "and", "-0.66", ",", "respectively", ",", "in", "the", "BV", "group", ".", "In", "the", "liver", ",", "they", "were", "marginally", "higher", "in", "the", "LBW", "group", "than", "in", "the", "BV", "group", "(", "P", "=", ".03", ")", ".", "Adjusted", "MHE", "remained", "constant", "at", "77.9", "HU", "+", "/-", "10.2", "(", "standard", "deviation", ")", "in", "the", "LBW", "group", "with", "respect", "to", "TBW", ",", "but", "it", "increased", "in", "the", "TBW", "(", "r", "=", "0.80", ",", "P", "<", ".001", ")", "and", "BV", "(", "r", "=", "0.70", ",", "P", "<", ".001", ")", "groups", "as", "TBW", "increased", ".", "CONCLUSION", "When", "LBW", ",", "rather", "than", "TBW", "or", "BV", ",", "is", "used", ",", "the", "iodine", "dose", "required", "to", "achieve", "consistent", "hepatic", "enhancement", "may", "be", "estimated", "more", "precisely", "and", "with", "reduced", "patient", "-", "to", "-", "patient", "variability", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Intervention_Pharmacological" ]

mast cells is a Cell, rheumatoid synovial tissue is a Tissue, mast cell is a Cell, synovial tissue is a Tissue, Synovial tissue is a Tissue, mast cells is a Cell, synovial tissue is a Tissue, tissue is a Tissue, synovia is a Tissue, synovial mast cells is a Cell, Mast cell is a Cell, CD68 positive synovial macrophages is a Cell, Synovial mast cells is a Cell

PMID-17607547_task0

Sentence: Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Cell

[ "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA.

[ "Selective", "activation", "of", "mast", "cells", "in", "rheumatoid", "synovial", "tissue", "results", "in", "production", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", ".", "\n", "OBJECTIVES", "AND", "DESIGN", ":", "\n", "To", "study", "the", "consequences", "of", "mast", "cell", "activation", "in", "human", "synovial", "tissue", ".", "\n", "METHODS", ":", "\n", "Synovial", "tissue", "was", "obtained", "from", "18", "RA", "patients", "and", "mast", "cells", "was", "selectively", "activated", "in", "synovial", "tissue", "explant", "cultures", ".", "Expression", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", "were", "determined", "and", "tissue", "distribution", "of", "IL-1beta", "was", "studied", ".", "\n", "RESULTS", ":", "\n", "Compared", "to", "untreated", "synovia", ",", "selective", "activation", "of", "synovial", "mast", "cells", "increased", "significantly", "the", "production", "of", "TNF", "-", "alpha", "(", "0.49", "+", "/-", "0.88", "vs", ".", "4.56", "+", "/-", "3.18", "pg", "/", "mg", "wet", "tissue", ",", "p", "<", "0.001", ")", "and", "IL-1beta", "(", "0.058", "+", "/-", "0.032", "vs", ".", "2.55", "+", "/-", "1.98", "pg", "/", "mg", "wet", "tissue", ",", "p", "=", "0.013", ")", ".", "The", "expression", "of", "TNF", "-", "alpha", "and", "IL-1beta", "mRNA", "increased", "significantly", "(", "19-fold", "(", "p", "=", "0.009", ")", "and", "13-fold", "(", "p", "=", "0.031", ")", ",", "respectively", ")", ".", "Mast", "cell", "activation", "induced", "IL-1beta", "expression", "in", "particular", "in", "nearby", "CD68", "positive", "synovial", "macrophages", ".", "Secretion", "of", "IL-1Ra", "was", "also", "increased", "but", "to", "a", "lesser", "degree", "than", "that", "of", "IL-1beta", ".", "\n", "CONCLUSIONS", ":", "\n", "Synovial", "mast", "cells", "produce", "proinflammmatory", "cytokines", "and", "may", "thus", "contribute", "to", "the", "inflammation", "in", "RA", ".", "\n" ]

[ "Cell", "Tissue" ]

mast cells is a Cell, rheumatoid synovial tissue is a Tissue, mast cell is a Cell, synovial tissue is a Tissue, Synovial tissue is a Tissue, mast cells is a Cell, synovial tissue is a Tissue, tissue is a Tissue, synovia is a Tissue, synovial mast cells is a Cell, Mast cell is a Cell, CD68 positive synovial macrophages is a Cell, Synovial mast cells is a Cell

PMID-17607547_task1

Sentence: Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA. Instructions: please typing these entity words according to sentence: mast cells, rheumatoid synovial tissue, mast cell, synovial tissue, Synovial tissue, mast cells, synovial tissue, tissue, synovia, synovial mast cells, Mast cell, CD68 positive synovial macrophages, Synovial mast cells Options: Tissue, Cell

[ "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA.

[ "Selective", "activation", "of", "mast", "cells", "in", "rheumatoid", "synovial", "tissue", "results", "in", "production", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", ".", "\n", "OBJECTIVES", "AND", "DESIGN", ":", "\n", "To", "study", "the", "consequences", "of", "mast", "cell", "activation", "in", "human", "synovial", "tissue", ".", "\n", "METHODS", ":", "\n", "Synovial", "tissue", "was", "obtained", "from", "18", "RA", "patients", "and", "mast", "cells", "was", "selectively", "activated", "in", "synovial", "tissue", "explant", "cultures", ".", "Expression", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", "were", "determined", "and", "tissue", "distribution", "of", "IL-1beta", "was", "studied", ".", "\n", "RESULTS", ":", "\n", "Compared", "to", "untreated", "synovia", ",", "selective", "activation", "of", "synovial", "mast", "cells", "increased", "significantly", "the", "production", "of", "TNF", "-", "alpha", "(", "0.49", "+", "/-", "0.88", "vs", ".", "4.56", "+", "/-", "3.18", "pg", "/", "mg", "wet", "tissue", ",", "p", "<", "0.001", ")", "and", "IL-1beta", "(", "0.058", "+", "/-", "0.032", "vs", ".", "2.55", "+", "/-", "1.98", "pg", "/", "mg", "wet", "tissue", ",", "p", "=", "0.013", ")", ".", "The", "expression", "of", "TNF", "-", "alpha", "and", "IL-1beta", "mRNA", "increased", "significantly", "(", "19-fold", "(", "p", "=", "0.009", ")", "and", "13-fold", "(", "p", "=", "0.031", ")", ",", "respectively", ")", ".", "Mast", "cell", "activation", "induced", "IL-1beta", "expression", "in", "particular", "in", "nearby", "CD68", "positive", "synovial", "macrophages", ".", "Secretion", "of", "IL-1Ra", "was", "also", "increased", "but", "to", "a", "lesser", "degree", "than", "that", "of", "IL-1beta", ".", "\n", "CONCLUSIONS", ":", "\n", "Synovial", "mast", "cells", "produce", "proinflammmatory", "cytokines", "and", "may", "thus", "contribute", "to", "the", "inflammation", "in", "RA", ".", "\n" ]

[ "Cell", "Tissue" ]

mast cells, rheumatoid synovial tissue, mast cell, synovial tissue, Synovial tissue, mast cells, synovial tissue, tissue, synovia, synovial mast cells, Mast cell, CD68 positive synovial macrophages, Synovial mast cells

PMID-17607547_task2

Sentence: Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. OBJECTIVES AND DESIGN: To study the consequences of mast cell activation in human synovial tissue. METHODS: Synovial tissue was obtained from 18 RA patients and mast cells was selectively activated in synovial tissue explant cultures. Expression of TNF-alpha, IL-1beta and IL-1Ra were determined and tissue distribution of IL-1beta was studied. RESULTS: Compared to untreated synovia, selective activation of synovial mast cells increased significantly the production of TNF-alpha (0.49 +/- 0.88 vs. 4.56 +/- 3.18 pg/mg wet tissue, p < 0.001) and IL-1beta (0.058 +/- 0.032 vs. 2.55 +/- 1.98 pg/mg wet tissue, p = 0.013). The expression of TNF-alpha and IL-1beta mRNA increased significantly (19-fold (p = 0.009) and 13-fold (p = 0.031), respectively). Mast cell activation induced IL-1beta expression in particular in nearby CD68 positive synovial macrophages. Secretion of IL-1Ra was also increased but to a lesser degree than that of IL-1beta. CONCLUSIONS: Synovial mast cells produce proinflammmatory cytokines and may thus contribute to the inflammation in RA.

[ "Selective", "activation", "of", "mast", "cells", "in", "rheumatoid", "synovial", "tissue", "results", "in", "production", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", ".", "\n", "OBJECTIVES", "AND", "DESIGN", ":", "\n", "To", "study", "the", "consequences", "of", "mast", "cell", "activation", "in", "human", "synovial", "tissue", ".", "\n", "METHODS", ":", "\n", "Synovial", "tissue", "was", "obtained", "from", "18", "RA", "patients", "and", "mast", "cells", "was", "selectively", "activated", "in", "synovial", "tissue", "explant", "cultures", ".", "Expression", "of", "TNF", "-", "alpha", ",", "IL-1beta", "and", "IL-1Ra", "were", "determined", "and", "tissue", "distribution", "of", "IL-1beta", "was", "studied", ".", "\n", "RESULTS", ":", "\n", "Compared", "to", "untreated", "synovia", ",", "selective", "activation", "of", "synovial", "mast", "cells", "increased", "significantly", "the", "production", "of", "TNF", "-", "alpha", "(", "0.49", "+", "/-", "0.88", "vs", ".", "4.56", "+", "/-", "3.18", "pg", "/", "mg", "wet", "tissue", ",", "p", "<", "0.001", ")", "and", "IL-1beta", "(", "0.058", "+", "/-", "0.032", "vs", ".", "2.55", "+", "/-", "1.98", "pg", "/", "mg", "wet", "tissue", ",", "p", "=", "0.013", ")", ".", "The", "expression", "of", "TNF", "-", "alpha", "and", "IL-1beta", "mRNA", "increased", "significantly", "(", "19-fold", "(", "p", "=", "0.009", ")", "and", "13-fold", "(", "p", "=", "0.031", ")", ",", "respectively", ")", ".", "Mast", "cell", "activation", "induced", "IL-1beta", "expression", "in", "particular", "in", "nearby", "CD68", "positive", "synovial", "macrophages", ".", "Secretion", "of", "IL-1Ra", "was", "also", "increased", "but", "to", "a", "lesser", "degree", "than", "that", "of", "IL-1beta", ".", "\n", "CONCLUSIONS", ":", "\n", "Synovial", "mast", "cells", "produce", "proinflammmatory", "cytokines", "and", "may", "thus", "contribute", "to", "the", "inflammation", "in", "RA", ".", "\n" ]

[ "Cell", "Tissue" ]